var title_f13_50_14112="Trucut needle";
var content_f13_50_14112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trucut needle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 478px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trucut needle extending from the tip of the echoendoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD and Mauritis J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14112=[""].join("\n");
var outline_f13_50_14112=null;
var title_f13_50_14113="Tetrazepam: International drug information";
var content_f13_50_14113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetrazepam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Megavix (FR);",
"     </li>",
"     <li>",
"      MTW-Tetrazepam (DE);",
"     </li>",
"     <li>",
"      Musapam (DE);",
"     </li>",
"     <li>",
"      Musaril (AT, DE);",
"     </li>",
"     <li>",
"      Muskelat (DE);",
"     </li>",
"     <li>",
"      Myolastan (AT, BE, CZ, ES, FR, LU);",
"     </li>",
"     <li>",
"      Myospasmal (DE);",
"     </li>",
"     <li>",
"      Panos (FR);",
"     </li>",
"     <li>",
"      Rilex (DE);",
"     </li>",
"     <li>",
"      Tepam-BASF (DE);",
"     </li>",
"     <li>",
"      Tethexal (DE);",
"     </li>",
"     <li>",
"      Tetra Flam (DE);",
"     </li>",
"     <li>",
"      Tetra-saar (DE);",
"     </li>",
"     <li>",
"      Tetramdura (DE);",
"     </li>",
"     <li>",
"      Tetrarelax (DE);",
"     </li>",
"     <li>",
"      Tetrazep 1A Pharma (DE);",
"     </li>",
"     <li>",
"      Tetrazep AbZ (DE);",
"     </li>",
"     <li>",
"      tetrazep von ct (DE);",
"     </li>",
"     <li>",
"      Tetrazepam AL (DE);",
"     </li>",
"     <li>",
"      Tetrazepam beta (DE);",
"     </li>",
"     <li>",
"      Tetrazepam Heumann (DE);",
"     </li>",
"     <li>",
"      Tetrazepam Stada (DE);",
"     </li>",
"     <li>",
"      Tetrazepam-neuraxpharm (DE);",
"     </li>",
"     <li>",
"      Tetrazepam-ratiopharm (DE);",
"     </li>",
"     <li>",
"      Tetrazepam-Teva (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of painful muscular contractions",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 50 mg at bedtime; may be increased by 25 mg/day until the maximum dose of 150 mg is reached; may be taken 2-3 times/day with the larger dose given in the evening",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10438 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14113=[""].join("\n");
var outline_f13_50_14113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303304\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980327\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980330\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980326\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821155\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980329\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_50_14114="Eosinophilic cellulitis";
var content_f13_50_14114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F87394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F87394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Skin appearance in eosinophilic cellulitis (Wells syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eosinophilic cellulitis (Wells syndrome) is characterized by areas of single or multiple cellulitic plaques, often on the extremities, which typically resolve in two to eight weeks. Unlike bacterial cellulitis, the involved skin is not warm. Blood eosinophilia is found in approximately half of cases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14114=[""].join("\n");
var outline_f13_50_14114=null;
var title_f13_50_14115="Topical thrombin: Patient drug information";
var content_f13_50_14115=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Topical thrombin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     see \"Topical thrombin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/62/2020?source=see_link\">",
"     see \"Topical thrombin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Evithrom&reg;;",
"     </li>",
"     <li>",
"      Recothrom&reg;;",
"     </li>",
"     <li>",
"      Thrombi-Gel&reg;;",
"     </li>",
"     <li>",
"      Thrombi-Pad&reg;;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg;;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Epistaxis Kit;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Pump Spray Kit;",
"     </li>",
"     <li>",
"      Thrombin-JMI&reg; Syringe Spray Kit",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may rarely cause very bad bleeding or blood clots. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703025",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to thrombin (topical) or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to beef products, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will put on the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11919 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14115=[""].join("\n");
var outline_f13_50_14115=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227307\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015908\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015910\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015909\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015914\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015915\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015917\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015912\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015919\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=related_link\">",
"      Topical thrombin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/62/2020?source=related_link\">",
"      Topical thrombin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_50_14116="Cefprozil: Pediatric drug information";
var content_f13_50_14116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefprozil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/22/14693?source=see_link\">",
"    see \"Cefprozil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/19/18740?source=see_link\">",
"    see \"Cefprozil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F147858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefprozil&reg;;",
"     </li>",
"     <li>",
"      Auro-Cefprozil;",
"     </li>",
"     <li>",
"      Ava-Cefprozil;",
"     </li>",
"     <li>",
"      Cefzil&reg;;",
"     </li>",
"     <li>",
"      RAN&trade;-Cefprozil;",
"     </li>",
"     <li>",
"      Sandoz-Cefprozil",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Second Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/22/14693?source=see_link\">",
"      see \"Cefprozil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &gt;6 months and Children to 12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otitis media: 30 mg/kg/day divided every 12 hours; maximum dose: 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pharyngitis/tonsillitis: 15 mg/kg/day divided every 12 hours; maximum dose: 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skin and skin structure infection: 20 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 250-500 mg every 12 hours or 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Reduce dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (50 mL, 75 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with or without food; administer with food if stomach upset occurs; chilling improves flavor of suspension (do not freeze); shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate suspension after reconstitution; discard after 14 days",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infections caused by susceptible organisms including",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     ,",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ; treatment of infections involving the respiratory tract, skin and skin structure, and otitis media",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cefprozil may be confused with ceFAZolin, cefuroxime",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cefzil may be confused with Ceftin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F147888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Diaper rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Genital pruritus, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Superinfection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, arthralgia, BUN  increased, cholestatic jaundice, confusion, creatinine increased, eosinophilia, erythema multiforme, fever, headache, hyperactivity, insomnia, leukopenia, pseudomembranous colitis, rash, serum sickness, somnolence, Stevens-Johnson syndrome, thrombocytopenia, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, colitis, hemolytic anemia, hemorrhage, interstitial nephritis, pancytopenia, renal dysfunction, seizure, superinfection, toxic epidermal necrolysis, toxic nephropathy, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefprozil, any component, or cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function, history of colitis, or in penicillin-sensitive patients; modify dosage in patients with severe renal impairment; some products (eg, oral suspension) contain aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in superinfection; do not use in patients with immediate-type hypersensitivity reactions to penicillin",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use oral suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Total absorption is not affected by food",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5956626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate renal function before and during therapy; with prolonged therapy, monitor coagulation tests, CBC, and liver function tests periodically",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins resulting in disruption of cell wall synthesis and cell lysis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed (95%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Low excretion into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 35% to 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: 1.3 hours (normal renal function)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1.5 hours (fasting state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 61% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: &sim;55% is removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/19/18740?source=see_link\">",
"      see \"Cefprozil: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report persistent diarrhea to physician",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suspension also contains FD&amp;C red No. 3, glycine, carboxymethylcellulose, and sucrose",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arguedas AG, Zaleska M, Stutman HR, et al, &ldquo;Comparative Trial of Cefprozil vs Amoxicillin Clavulanate Potassium in the Treatment of Children With Acute Otitis Media With Effusion,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1991, 10(5):375-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14116/abstract-text/1906160 /pubmed\" id=\"1906160 \" target=\"_blank\">",
"        1906160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barriere SL, &ldquo;Review of",
"      <i>",
"       In Vitro",
"      </i>",
"      Activity, Pharmacokinetic Characteristics, Safety, and Clinical Efficacy of Cefprozil, a New Oral Cephalosporin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(9):1082-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14116/abstract-text/ 8219444 /pubmed\" id=\" 8219444 \" target=\"_blank\">",
"        8219444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14116/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lowery N, Kearns GL, Young RA, et al, &ldquo;Serum Sickness-Like Reactions Associated With Cefprozil Therapy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(2):325-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14116/abstract-text/8040786/pubmed\" id=\"8040786\" target=\"_blank\">",
"        8040786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13133 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14116=[""].join("\n");
var outline_f13_50_14116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147858\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046074\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046066\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147820\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046078\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046070\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046077\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147890\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147888\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046081\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046065\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046064\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298994\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147829\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046084\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147831\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5956626\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046073\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046063\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046080\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046072\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046082\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13133\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13133|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/22/14693?source=related_link\">",
"      Cefprozil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/19/18740?source=related_link\">",
"      Cefprozil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_50_14117="Contrast-enhanced CT of appendiceal mucocele";
var content_f13_50_14117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Contrast-enhanced computed tomography (CT) of appendiceal mucocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Low attenuation, encapsulated, elongated mass.",
"    <br>",
"     (B) Impingement of cecal lumen by mass.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Louis-Michel Wong Kee Song, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14117=[""].join("\n");
var outline_f13_50_14117=null;
var title_f13_50_14118="Colchicine: Pediatric drug information";
var content_f13_50_14118=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Colchicine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"    see \"Colchicine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"    see \"Colchicine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8108144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colcrys&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13869718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Jamp-Colchicine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antigout Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"      see \"Colchicine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prophylaxis of familial Mediterranean fever (FMF):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-6 years: 0.3-1.8 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: 0.9-1.8 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &gt;12 years and Adults: 1.2-2.4 mg/day  in 1-2 divided doses; titration: Increase or decrease dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum dose: 2.4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gout: Children &gt;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flare treatment: Initial: 1.2 mg at the first sign of flare, followed in 1 hour with a single dose of 0.6 mg (maximum dose: 1.8 mg over 1 hour);",
"     <b>",
"      Note:",
"     </b>",
"     Current FDA approved dose for gout flare is substantially lower than what has been used historically. Doses larger than the currently recommended dosage for gout flare have not been proven to be more effective.",
"     <b>",
"      Note:",
"     </b>",
"     Patients receiving prophylaxis treatment may receive treatment dosing; wait 12 hours before resuming prophylactic dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: 0.6 mg once or twice daily; maximum dose: 1.2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant therapy with CYP3A4 or P-gp inhibitors:",
"     </b>",
"     Dosage adjustment also required in patients receiving CYP3A4 or P-gp inhibitors up to 14 days prior to initiation of colchicine.",
"     <b>",
"      Note:",
"     </b>",
"     Treatment of gout flare with colchicine is not recommended in patients receiving prophylactic colchicine and CYP3A4 inhibitors.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage adjustments may also apply to patients 12-18 years of age with FMF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coadministration of",
"     <b>",
"      strong",
"     </b>",
"     CYP3A4 inhibitor (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FMF: Maximum dose: 0.6 mg/day",
"     <b>",
"      or",
"     </b>",
"     0.3 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gout prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gout flare treatment: Initial: 0.6 mg, followed in 1 hour by a single dose of 0.3 mg; wait at least 3 days to repeat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coadministration of",
"     <b>",
"      moderate",
"     </b>",
"     CYP3A4 inhibitor (eg, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FMF: Maximum dose: 1.2 mg/day",
"     <b>",
"      or",
"     </b>",
"     0.6 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gout prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     0.6 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If original dose is 0.6 mg once daily, adjust dose to 0.3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gout flare treatment: 1.2 mg as a single dose; wait at least 3 days to repeat days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coadministration of P-gp inhibitor (eg, cyclosporine, ranolazine):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FMF: Maximum dose: 0.6 mg/day",
"     <b>",
"      or",
"     </b>",
"     0.3 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gout prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gout flare treatment: Initial: 0.6 mg as a single dose; wait at least 3 days to repeat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is",
"     <b>",
"      contraindicated",
"     </b>",
"     in renal impairment. Treatment of gout flares is not recommended in patients with renal impairment receiving prophylatic colchicine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children (Kallinich, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute): Consider dose reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute): Reduce dose by 50% or consider discontinuation of therapy; maximum dose: 1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FMF:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Monitor closely for adverse effects; dose adjustment may be necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial dose: 0.3 mg/day; use caution if dose titrated; monitor for adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dialysis: Initial dose: 0.3 mg/day; dosing can be increased with close monitoring; monitor for adverse effects. Not removed by dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gout prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Dosage adjustment not required; monitor closely for adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial dose: 0.3 mg/day; use caution if dose titrated; monitor for adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dialysis: 0.3 mg twice weekly; monitor closely for adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gout flare treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: Dosage adjustment not required; monitor closely for adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Dosage adjustment may be considered; treatment course should not be repeated more frequently than every 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dialysis: 0.6 mg as a single dose; wait at least 14 days to repeat",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colcrys&reg;: 0.6 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8097684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176363.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176363.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer without regard to meals and maintain adequate fluid intake",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F9549891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of familial Mediterranean fever (FMF) (FDA approved in ages &ge;4 years and adults); prevention and treatment of acute gout flares (FDA approved in ages &gt;16 years and adults); has also been used for prophylaxis of pseudogout, management of Beh&ccedil;et&rsquo;s disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Colchicine may be confused with Cortrosyn&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal disorders including abdominal pain, cramping, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, ALT increased, aplastic anemia, AST increased, azoospermia, bone marrow suppression, CPK increased, dermatosis, granulocytopenia, hepatotoxicity, hypersensitivity reaction, lactose intolerance, leukopenia, maculopapular rash, muscle weakness, myalgia, myopathy, myotonia, neuropathy, oligospermia, pancytopenia, peripheral neuritis, purpura, rash, rhabdomyolysis, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to colchicine or any component; fatal toxicity has been reported with concomitant use of colchicine with a P-glycoprotein (P-gp) inhibitor (eg, cyclosporine, ranolazine) or strong CYP3A4 inhibitor (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin) in presence of renal or hepatic impairment; concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is contraindicated in renal or hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and consider dose modification if colchicine is given with a P-gp or strong CYP3A4 inhibitor in patients with normal renal and hepatic function.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Patients who become pregnant while receiving colchicine therapy may be at greater risk of producing trisomic offspring. Myelosuppression (eg, thrombocytopenia, leukopenia, granulocytopenia, pancytopenia) and aplastic anemia have been reported in patients receiving therapeutic doses. Myotoxicity (including rhabdomyolysis) has been reported in patients receiving therapeutic doses. Patients with renal dysfunction and elderly patients are at increased risk. Concomitant use of cyclosporine, diltiazem, verapamil, fibrates, and statins may increase the risk of myopathy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate), CYP2E1 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor like cobicistat.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanocobalamin: Colchicine may decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: May increase the serum concentration of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the myopathic (rhabdomyolysis) effect of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are receiving ritonavir-boosted fosamprenavir.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Colchicine may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, colchicine may decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with telaprevir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with telaprevir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May need low purine diet during acute gouty attack. Avoid grapefruit and grapefruit juice; may increase colchicine concentrations",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Colchicine crosses the human placenta. Use during pregnancy in the treatment of familial Mediterranean fever has not shown an increase in miscarriage, stillbirth, or teratogenic effects (limited data).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, urinalysis, and renal and hepatic  function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disrupts cytoskeletal functions by inhibiting &beta;-tubulin polymerization into microtubules, preventing activation, degranulation, and migration of neutrophils associated with mediating some gout symptoms; decreases phagocytosis in joints and lactic acid production, thereby reducing the deposition of urate crystals that perpetuates the inflammatory response; inhibits secretion of serum amyloid A protein. In FMF, may interfere with intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediate activation of interleukin-1&beta;.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1046570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Oral: Relief of pain and inflammation occurs after 18-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &lt;50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Concentrates in leukocytes, kidney, spleen, and liver; distributes into breast milk; crosses the placenta; does not distribute in heart, skeletal muscle, and brain; V",
"     <sub>",
"      d",
"     </sub>",
"     : 5-8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 39%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; three metabolites (2 primary, 1 minor); partially deacetylated and demethylated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: 27-31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-2 hours (range: 0.5-3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (40% to 65% as unchanged drug), enterohepatic recirculation and biliary excretion also possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"      see \"Colchicine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If taking for acute gouty attacks, discontinue if pain is relieved or if nausea, vomiting, or diarrhea occur; avoid alcohol. Report any signs of muscle pain or weakness or tingling or numbness in fingers or toes. This medication may cause bone marrow depression with agranulocytosis, aplastic anemia, and thrombocytopenia.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kallinich T, Haffner D, Niehues T, et al, \"Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119(2):e474-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14118/abstract-text/17242135/pubmed\" id=\"17242135\" target=\"_blank\">",
"        17242135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M, Spino M, and Read SE, &ldquo;Colchicine: A State-of-the-Art Review,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(3):196-211.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14118/abstract-text/1862011/pubmed\" id=\"1862011\" target=\"_blank\">",
"        1862011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Majeed HA, Carroll JE, Khuffash FA, et al, &ldquo;Long-term Colchicine Prophylaxis in Children With Familial Mediterranean Fever (Recurrent Hereditary Polyserositis),&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(6):997-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14118/abstract-text/2112191/pubmed\" id=\"2112191\" target=\"_blank\">",
"        2112191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terkeltaub RA, \"Colchicine Update: 2008,\"",
"      <i>",
"       Semin Arthritis Rheum",
"      </i>",
"      , 2009, 38(6):411-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14118/abstract-text/18973929/pubmed\" id=\"18973929\" target=\"_blank\">",
"        18973929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13179 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5CB361C86E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14118=[""].join("\n");
var outline_f13_50_14118=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8108144\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13869718\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046565\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046556\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154279\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154263\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097684\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046568\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9549891\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046567\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154346\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154343\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046572\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046555\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046554\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154332\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046574\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154275\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923644\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046564\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046553\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046570\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046571\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046562\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13179|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=related_link\">",
"      Colchicine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=related_link\">",
"      Colchicine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_50_14119="Poorly diff squamous CA Light";
var content_f13_50_14119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F63428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F63428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Poorly differentiated squamous cell carcinoma of the head and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEFAYgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDotXs9Th8LyWtjIbfVdW1BQ0vmAEAnLHkcgKOnpVPxEHsBfNCsxstJC3MNrakKbnoMY9N3JArobrVLSKyh1i8tpmihj89IPLJlR8chR68ke9ZMOv6dDc2+oanJdO1+VFlBcQbDajv06Z7546V6kXLsfUNa6GbY2sMb6ZJewG2S8u5pJLaziLRRmVF+SYnoTzzjFdTqFhLazQHTdHtr1EJASeTy9vpgdD9PaqV3role4trFlW4eIkJjHmH/AHjkCqFv4mH2Vor6KeyESZSWeZXDkey88GnaT1C3Q6LxFcpbWoia/h04XKMJXX5HLkYyp7YrmbrUBp1lbrLqN/cXtrGo86JQwuMnhCf6/rVa5N5qlzb/ANqXNnLZv9xo/vBTwe3WumnlOn6Ulvo9skk0QVN0hHyJ6nPU800uWyKS00M2/t01nVYpX0a8WW4i2P5ke3aPQkHOOKe+gR6dq/8Aatw0mmhF4AbKOSAAd3XA9x1qa6u7zS9XsIbhFIuV+dw3yqe/XtXQNqVizQafdlJp5kyoHzIw6ZzScpK1tgE8P6clpYzGSWV5Zf8Aloz7sg+/rWQ2hWAuEvrgzskEvmkMMEYPYA56/ga0BCdQvIgZZYbWJXCRhcb2HBI9fQU2PRmUvJNJIsauuTu2tgEEHj6AVKdne4d0GteI7PVNOu7DS1uLu5uYzGq2xCMoY8sN2ACvXHtUvhu1s7PTQ2pR+fsjME090ArSrnODnquDgZ6YqqLPVzpuqwxHSJRO6/Z2tYWidE3ZYMxJycenv2qfxK1lZWKedbvdR3EwwAckMB/9bpT0+FEJaWMrQ/8AhG1vpda0jzJ5bcNaLMd+xAPmEYB4O3scfjVPxPd22tww/wBoyyIJJCodYipUY5DVu+IbG9bRILe00iXVomljjCed5PljrvLHnA9B61p2ujLpiQ2Fmtw8bMX3z/vkDEdMtyB6YpqaT5uoXVzG0O0t7rTdR0Q6mDHcW+z9wCs0IxjKg8dO9R6Lqn2C2j07StK1i4t7JNskl6myRkHAZCfvnjp1A9qd4ovNQhjNvBp9hNfE/wCpa4MTsg/iVhyB659DVO/8N3Alht5i89rcIHjWabdNCxGCQ3oO1NWfxdQtqSXdtZXF1LcWcULyWTJex7yBKszAgiNWIGQvbPP4Vbsb/RdUtbi41GdbQxMsMgufk356AD1Pt6Vn3+kx6be21jfWs11p0zcXLzMXWQchs54P49PpVtNM07VvC17HZxWF5HC/l7jJvVWU9S/ZlPQg8dKbtYfzGa/De2TRaXZRwT20rFVgkRWwo69TuyP/ANVGrafeaXd2N2Luxs9FgGJYJ5AizA8lSzHGcgYB9KmuYrS70yztb60nN7ZhTHLbMWZWAHIbvx2NMk1vT9WvmsrW8Sa4RFaS0vYMFgM/MFYbW6Hp0IoTY3c2NE8SWN3aOb1RYbHCrG8ygPwD8jHhhyOmeormtW8bXt1q+i6TodstpPd34jmkuWXzkt05kYREcAYOTnPp7SeL5IruMpKunmS3Afe8RZ0Y9lGMEHjj86u+H7A63bpc6owmurZTCtzGqrlGwSowOmQOKXLFLmsRKHmS6uY47zWLuwsni1C5tmRLiVPKSWTACguBlmwOP8K2PB63lpoGnjWI0j1W2gjnu2UAbJPnLnjgnaOTRrF1q0SNDaWVvNaAEtI82ZdyjKssYHJBHTOajmi/4SCzvry5v44bbU7FLCRYW+WKQllYZOCCQ5XHXNQ9Y2M5u6tYu+MJri2ga4s7SfUo3e2mt7aB9oDCUFpC2em1g2OnHpUzxs3i2aAojSQ2cctnJJyoy37xSM8g7Vz6HFUvEcUU1hpkEFzv0rE2gX4t5Bvg3oEQkj7rqyqvP/PQVZ07T7qxv9Atoi1/Hb6eYJbmZsy5UAAt6lsfnUL4fv8A6/ruYQfu/f8Ah/wxK8rNr0dndW8ENvNGHsZF3GUSR5MsLk8ZHDLjqob0q34ifZaaerHazupWQ9FOQVb3Gf0Jq7qFvBdi3aT5v3wuImBzhgOCD9f61lajdW7abApaGfTbsBra5ByiM4wvPZXyR7GpXQVN3aGaRY2llf6i0NvNE8UzTlpeVdXwSVOfugj6jFaOs2Mep2l3BIHNvdwmJwTjj29we9V72ae11QW28DzY1eEMOCy/LJGfY5BB7En0qSS4Aa1srUlZAokAKnaIwQuCem7Pb2p6tpj1bUjKtG1Gwi1LTYl+0uNMkfT2kXGZVBAjb8dpHsasatpS61p2kjW9Khu5xEt9FBcErGLsxEAP16M7DkHG4HtWs8ZEoZtwCAtn1B71c89WW2aRspANjjruBBH+FTKTvdETfvcy/r+tDxHwb4S0/QtKdPGN/ZwJqkGy2sLmTy5LaOMljErEjcVYj5lGTtFVpNNt/D13Ffy6hqOpC8BS5u2iRkMI/wBVCsbDMjFQ3HJwOmK6y68F6bq+o6lNPotqblL7zI7i9meYOVIDAow+UZVW+XggnsTWfrV1Znw/4qsVv7y91bTbO4upbq4tjGFkjwP3JIx8oLYx2J7V1qpd7+psmkc/8OLSaHXZNVsPD6Ti6jEEkrXERSzcPtK/7MuPmKqOAwHevTL2NLDVJ102ON9VvtvO/wCRTjkEjoxUFgCB09a4f4WanPrka2Wp2MDaxLag3t0YdibkkZY1lAIy5QMdwwePpVbTPEvhzR/EfiSOO9gsV0y7CqpR2abYCp3O3YMzHd64GSMU6kXKbXYfNY6e0stF0bxPpnh2CCN7AK629uJmkdJMNLJ5pb+8c8HPbOOBXRahayXtl9l1G2+0i4w81rEAwHz5VT9AAfc8VW1rxHoOjaRo+o3IhW31G6TfdF1UQ71JWRj3HAB9N3NT65qD2dxaWWLyKG6IiW+t8FIZH+6Xz0U5HOMVg+Z2JjL8P6ucdrjaHaaRquu6ZeXlydRQthZA6WVzHH8vy43RuckEMe+AOao6F440sx6ZpFtIsn2nTobmO9jkDRxIuEYEYyXB3kqQKm8ZwyaRbvZT2dzrbauzI91IY1UNlfkkxg/KVDLjkNk57UniVfC3gXQ7g6Fa6pFd380EzWNmS6Xcu7ehOclM7SCFIyARzW6s0la9x3krWLOvaPIlzquuW2r6db33y2pEtxvja3A4UhfmRz8vA7+vBqDw54n+3XzWuqQ6M4tLcH7XGzFwx6RiQkhm7nv1zVjStP0vVnuZrjTtM+0yN/pkRdUaRVRncKNwA+YkZboFPsaj1TWp4hYaLpWs2NvazAGSWzlRvs8I5cKcnbtBXDYJOaEr+6zVPU0td0XRUWDVPJtpNSSJpbeSaSSFYV43u7Kw/dKCDhuMngDNT2beMzcvJqmsadcIDlYUWSMFfoOM+/SrMmmW76jpV5q2qw3mm28b2ytdAR+es6FGO9cZJyODxxkYPNVdM1DTtI8FWN7e31y9jFHmO6v0AnkjJO0lR/ERjA64xnmsru1lqJNOXvK5ythPpOga/d32oam2m3816/2z7Su5rhmChEREGX4YMpXI+Y55zXfXsui3ljfX96I72zXybfdbwAGaVuFVGON77igABGPauQt7dtQ8Vi5eztLKTyVX7ezlrm2BXMZVWXBkBc45x6jIrpptAupbLTDPrN4lglwiyb1V2Z1bCqzMPlB/vKM/nmnUtpcVRdb2MhJdMtdcstNutZtZbV0nkVbuIq94qNg/vWwjAE4wuWOPYmtzR2s3ll1PRod1raI6XCaSUO18A4MYOGYenUZrg/GHh57jxsuixy2VhcER3JXVczWl/iRcNGAPkIbarcrv6YODVzX7vUvDXh660+w+wxyaSFuIY9NsGVZJeW2feYOxy5IUAL3NDimlZ7/1/X9Innc24xd/8jasNc0Pw7rIS0tNUttVvojfX8F3GT5mQB5jHkl1BVQsf4jvRXI2dxHYPoXi241mLWtHgs5pGmliYXM9zIxDQuw+4M7cL6ggjvRTlQ59ot/15mapKWrTf3Gh8QWe30fzrm4ubVLgLEv2UATknkBM8ZIB5qrNqLA20d9qVh5aAKrXEZaULjo5A5PbNZqaJqWiy3F5dalNPFFeJcxXssxklkj2hWQx425bjDdsVdfXbC31S2FhpyTtdIkk8KzqHiUvjcVbjAPPrjmhJW01O3zZY/4Su2Yq9nZvPDtxAoQIWbOMZ6gda2dUsNPs9HkvddhkuJGdSPKhAaINjagUdccZJPJpkOmrNrkl893E0bEtCuO2MADoMVeu5tT8642yRxJ9yLOAOn3vr6VDauuUuxkapon9nXEeo21uJo02t5ODmMf3gO3Xmtyd4dW0+4hjk/eMgLI46qehB/Ssm5uNWv7Szhtb6HSbmKVd8rKkxuEzyACfkJ/+tVfxGt3Za/Jd6XDdjzUUMSuVAHbAp2b0b1C5flxez29vbT5H+ruVIyu3gHn1HtV3TLCC0A09rRt9rITFOxyG3eh9OnFUdM1HyrKa4dXtig+faPveuAatafrMK2n2i2S6khLYdpTjy/w9qGnsh9Tas720mtpfKYSywPsznHlsD6f5B61X1O6mubS/tNMmjg1AxMsZlHyhyvynPPfHODWPd6hpAh32QeG6ugZl2R7Q5xnLD6etGi60IrJrjVon+QhVdYufXBx7UuS2pOlmbem6Tc2GiQWkt08l2sYDzjjzHI+Yj2zRpUBgtpgw/i6MvQ+o/nWX4Tt2tb/xBqEt5FJY394JLR2umlcpj+IMcLgHAUenpiqJ8XTxa7bWvkXD2l1LJmdo8rbgDCBVx8xJ6+gxRyttpExk2jqtS1k2mnR3sDxzW6yjzWQFyUxyQB/Fn9K1NM1KDVLGG7sHD28w3KxByfw7GqOnWcVozrbW8EKFtzrHEEVj67RWd4g8VQaPcJY2Nh5txhSoP7qGMHOGZugHFRy82kUZSjroJ458MaVr6Jc6jNPaXEEUkMdzC21trjHPdsHke/saxNFs9Lj8RQ6mb29v9StbX7Gry5VNgxzt6BuMf0rUjmu9X06KW/NtNFcqTiBiMnoFU+1Z+h219baTqNxrGkDTpY5ysMKt5khi7FlUk5J7CtVdRs2aRjFWTE8TatcXGopZpDm1ClzEmDI4wecdzzjB9TTPDYJ0yGz0a1W2toQYp0lTY4k/vMv8WT371qCWTWLU3mlW4W4g+QXckQRHwBujLEEhec8c1j6QdU0q5mFppQNu7k+Zax5jY5PQs24gfWmtrFJq2hW+zy2erTX80kyzqQ4hjHykgY/KuiW5hK21xNqNuklw6xRwvIimRz0VWPJJ9BWRpdm+nyRpqFxearqAJcyvD5K8nIAVSQMdMZNaN1HYTwkavbQQ3UgZovLXEwHdgcZyPX2olqVqXksNMvL2KY+Wl1Ip2RrKMy46nGeec8+9YF3Y6ndeVPq0n9iSlWU6bFciYLg/KxK4AJ7jtQvh/R4zHHeXNxPM/wDqrp1QSRDrjpyDnOcVdu9M0WzjWD7Q11fRx747J7geZMMkgkHoMjr0oWmxF3cih0i81+xm0bW9sml7hLDPDOY5EkBHCtnLAjg/TtUv9k3fiKXVdIup4X02C+SYSW5aJwUHy/MR87blyT78k8VpWsEN3Y2lxNZi1ZRnyXYlkPpkd61DqUUiNFYTq13yEQ/dPsTxz9alyfQmcb6ouWENlC2t/YUh86Wdbq72ZyJwqjcy/wC0qjkDqvrmoNUheeTRry1lKtYX0YnVH+9E4KMrAem8HH0rnvF1pLd6/wCF7jTprqxluLhvOubO4x58caCQIQPlYMvmHnuvvWjpVvcWvivV1Izb3sSFivCNJGcAkepjKkEY4GDnArNRSV7/ANbHMo3Wn9dGWbWwa3N/4YivGW/s3a/012XJWNnLAH+8oYshHXawHvWjp8Vre+HEJsFS2ug/n2g58t2Ys4/773EY+vFZ3iiOfWW1FvDMkS+J9HVI4ZJCVxkq/ltjruQYz0zj3qay1VWuo50haJZLho5YuMwv1/InNKza8/6/MzinPbff5/8AB3RqG3inEW+TzVTG0nlkJ4DZ7545/wAaUyFUiicMS0nl8Do2G6/T196kuLGOLWLiWHzECwtE6KflYN86kj/ZO8D/AHvpUyxZm8xlO12wpJ5JA5NRe5POrGXp+oC58UyaRKCvn2RuIpC3IZHCsoH4g1Ygv4n1L7PKxE6qrle+0HH4g4NS6eVgv5ZwgLopCHHXI6Z/KqEqRLLGTxJjZuJ5PdsfjVWuzRQTk10sv6/Iy/iTr6+G9OtXs7A6hdxygRW4JDyZPzhR/EwUghRyfpXM3/h9/GmmaxpniG9lmdb5zbTWjbUNqyhoA4AG7ryD06ZyM13Gvwx6hqNsS4Wa2laeON2KrLH5XlyZPsr59643xp4st9H1Pw7cRR3C6bNe/ZLkoq+SFdWAGV6MhCgA4GDznrWtK9ko7hDRK/bUyfh3ZSHwJqOm+IgYrGc3a34GfNiZgFKkAfeXO4HByNp6V3EUMNt4SkhtooNa8qxWJhII2lu4gAoTdjkuOOeO1Zt8s19qlhd2Vnd28k1pIFvI5wwEpIGx4wMZ2hcMcg8jggV5LoHl6p4qu5PF9/Lb+JIEb7JDFbiELJvKMqgL+8BXDL6fN161pye1u2W1t/XU9MQWsOiRLYaS1xM1psiimkWWK22sBJH84KIUJAJIOMDrWTqPirWNMvzpstrLrNzqkA2ptSUwSFACrkYUpknLE7cc/wCzTI9ZTSLU2TTJY3UJaaZ94ZrW1HBmcKmFLsFAHLMSM9K09M1ZtWW8vdMmtNS0VIthlSXNxLKW27cMMIuectx6DFO1tWrotW6lvS/7X061ex1iex1nUWUNBZxwrbBWAy8e4ZXAzkMQDirWm+Hmglmnk03TDcMfMjWBnVkI5wrseTksCRjtwOa4nwxZJdNN/wAJKs3lXs2RKt1JKjGHOQk6fLncMYyMhcc97PiDxD40sbDV7+10S5tVt44hptrJslESAMsskpBzJkFWwc4IB9ckou9k/wBAu/snTabLBcQLFFo76Le2pmdZZYsxQSOpWRz0D/KSe4/CqPw50O20LSYrWCZ1mtmEkx2xlwrguse5RwOQxA745IqXQ9fu9VMV5dpY/wBlujnzbeUuwVkyqyJ0APzL3OQB3qtqOs3MVlCNPSPRItRvXVtQnY3EmcYHlxICdxVcHdgJx17Tyy1iO/U2fDviG38RXV40djci1t22f6VEVbzATng8Zx2+97VoG00/VLWESxfaIYpFaKN0+RWXo3PBwf1FRHR9NtdNFta2qTW9oWmjglO6XHJY7ic72OcvVHw5qs2sai9ro5iuPCC2iLBNFGY5LWULyCGGZd24EEdMc1m7O7iJyaDxvp0k0A1a2ub23k02N5Hgto1f7QD0J3cDnjPbJrjtXutM0jStVi8VTyf2tqVqCbZrxjcy7Dv8qCIZEUYMfDn5mYk/KABW5qo0jRvCuptF4kvbu4Yw2tze288clzFGZUVuORGvQE9t3ripvE9qNbvvCklvYzrp9tL5h3ou9MAiORm53dAdpJyGGR1rSLtZdPu8ybub5ex0HieO2j8Exk291dQ3n2YYkdfNgg3CTYXc8Y5G4nI6gkgVy3jL4laHbXsunaboGo31xp9uxtGt08u2QqnzYcH5gM8jBrkdXk8TzfE+PTPE2pNb6bqJQWTNHvt5ypXcwjGV80jI+bgBicdK7/UUXTpAlxaNdr5ubeaIhWzLlBzjB4YYIGCACealQUbX1vqRSpJOz3RxNjqEOn6Z4Wu/s7Lok8RlhtXT50uJGYm4zwJF2kjnkDBFFUPD9loNzpd3Y6lLfJa6TOIpbHU35WRVUBkUdEYAjAz0zxmiuhxjJ6pnXDmUUrmlFealpBNxq2ySzYcoZASf9nBq1YW1hrsUuo/2ZNp8IYLIEQETrnj5gMke1VvDesfb/GceitYLPZRo+2eb5XeROpVDyUycbsdc12LeIrI2RWxdWeTekQhiMirIgO5W29Dx0rnk2nZLUrmT2M3V7uHTrjT7T+yprgzkxwSbMxQOPu78cgZ71GZ/E1te2ov47S4tWt8TNZx5Pn56AMeB71r+EtXmv47I3du/CZupcbVDknaFHfsT2GcVS1vVLjSrsWmn3VvNdSStO8EiEvJHz8qD+9n17VKvflsF7nN6o8r+IbG8bwMs16UbDG4Cyhh93JBKAEZwT34rpFisNVuntJftWm3cOGCreqZXOMn5R/Poabf/AG7V9PN55k2lag9pLELby96oc/LITjPGMgVk6JBDJ4lsZ59RsJ9WgtEt55hjfMp9B25q73V+3qJX3J9e0kTXyS6ftuZy+2XzZSqZGOoH/wCqqHibVtWsdctLCNWhtpEBaWO23wr75I/HHavQbx403xW3lNd43bSmfxOKwf7etMPDrMc1u6zKLZJgUeXOfn2gEKCQcA8nFKE2+lymyOO2EBFxrEH2oQMpjnC+W35rwR9azNI1a70C1s7G5a71i/eJ5/Pht2MChpDwzE9ecY+lbPi26jvZP7IQSBgRvGdowcHBNLpl5eHXLfT9K0iVfDVvaOZdQnHlvJcBgBsU8lewBAzye1F/d1IlJL5la2s9Mu754rWwk863uBHdRtKYlgZgWyoA+c84wPXrWtY6fPFqRu725Q20IKxQKOB7k9vw/OqSvLc21xYXl2La5feqeQVMqA8biR369eas63F/oVvZQSNHuwo4J4XHU/560Nu9i0tNSn4pu7gxoiXYiillwhjkVA/HQsWXoewyTUWoaq9heWn2uS1uY5lKSW8s3lKg6EhGBZs+hPPaszQtGgv4NQGvWcuLC+8+CWd1+ZgD8yKpO3HAwSc8elal3BBeLdzRNOBGhkfn5lwAMoSPvY459avRaC3GeJNMkufD8dvbW8t0ZIGgxYSCBI0J3DbwSDx/PNU7PXtS0nw+n2rRZbKzhi8hZUvVmnywK7sjP7zHOSc5NaQubWLw+VsLm4luxsjleJi0ik8gsTjjtx170ngyzltzevpkNmY7hjNMB+7IcA8NnOO9F7R1E1fUp6R/YemaRb3Wkf6RpqmSxSaeRkSJSRuC565I5YA9Dk1Z0u8bSNRVJrjR40vmf7KGkkXzm/ubm+XJz079qu6te6b5E2palc/a0SMrZ6dIFSJCvORwfmJ5LHp6VjafqyaoLS2lsLZEnPnCa0TzYUl/hJYqcH1yB65xRq1doSuaPiaKa80SWbVpZtJjt1JbyrgIXb0yeregrK8Na/azabA8M14sQLRp5oMjTNn6Z64BGKuX13cJG1ukUtk4lLrdTRLcrOcfeHPB64NTaRqUtnaQXU0E0FxFmKIgLIzZPJ7Dv1FNfDYrVEOqaTe3N3NdRRJFqCOkVu07FV8raCx9d+7dn2xWRK8um+Kre41T7ZfXsK7Y/sFo8zyAjoxIAAHqTxWk8Dz3KLDcI8IiBHn3KvMuDkgLngn1+lXtP1i8EMSrC8MbI23PzhsdRkHJPTnpTTaQxviW+upry0Yva2sTRZuRJd/6UvGfLSFeCenJOOvTFZHhIy3mvJLapqcMCkNMCibcDPy7xxg8DHNauirZ3LXWmXN2l5dTPnEcQUx4OSC49DWlcTxabEmi+G/s4vs7szPhVyeTz19KV7LlSJ2JvCsdrplpeeGbBrqS50+3knhlulBWEOSFVXA564HtVrw+LjRdBMuqF57rBO8tklQPlGfYZGaXSbvUI3eS6ZCoAAAxnHf8Mjirkc4u7ybTIpYm2wMSo4KhvmRwD1B5B9DgVjJu7Mpw5bt7Gvp/2OTUbvUYhGs7lIppE4aQAfIT645rmbhYPBusarcaoXmttU1CAwPGmSjSkqoI6YU55HapPB1xqBubnSL+yW3+w2lsxukYkXDHcrgjpjGCMc881dgsbi10JrO8uheKkpVZnUOwjLblDA9x0/UVK912OaMbSa+Rb1jWPseqaLpc8U7PqEsiGREysYRc4c9QCcAe9T61q0GmWV9f3W8W9pGzME+Zvoo9faqEfnXvi0zhZPIt1GfcYOAPqeaj8L3FxfG7mvIWRhcupVxwMdMe1LlVhqmkrvp+ppJL5OnTzTDazky7Tn5VP3Rj1wB+dYfiO11K+vtKGi3v2SOyu0mvd6ZFxDgkwg9c9P8AIrVhv4NbS+ihDKLS5azkOOSyn+XNNku3/tL7O9nIsIUubokbFJbAXHUtjnjjFNXTHFXRzXxN0a88VaXYaLa2dw4uVuZo7xXEXlypHhFYkH925baR3FcV4L8KeI9K8K2tnqmnwLd3Fy1vNBeNuHkZ+Z2HO0g/ddQ33vTBHqep31zdRxeH7O2vZZJnKyXhXakUB+8A2c5KkqMdM57VlSataw3eo6X4XsLeSGxtY7axPnjyrhipBjRt2Sy9/b3rSnUko8qWn9f18iVdSs1/VxF0+CKSLSrBbuTS45/JYF920EFz82RtCkjIHzHI65NUdf0izWCPxDYala6atpIs8d5cRb7fiQBy24cDaWAIxyc5p3i/VrLw1aRXWpGSTXFwtpY2zyB5nYgZ2KOQOTkjHyjmsfxTa2cIvV1bUL3/AIRrXbKK2uLszGVbR4+jfNlQJAcE44K5ppN2f9M0eqsitrvh6Qa7bf2bpEVpDeSzB2nnF0Jwx81lKZA2D5mCN8u5uqk10mqfYLvxfb6dbeJptPvrWNd2iwgR+YnUMFPDDGOAPu8dK4D4eXMvh7XbjTtI1bRLnw5CXvftbzGa4ltQvzxRBcjcjclTgtniuj8ZavpN74S0/XbpLXUPE1qryaRc6TGZpWUH5X2nG6MZy6n7vPANXNNNLp/n6kuTWxYuNaEGpWQ8NQRDTrNmXUbfYY5X25IgihOAzHnH4c03xzq2sQWGnQeFlna91i7iNwl3AHEEbgDy5VwSq8YO30OTVvw9b6tqet303iOGwngiYSWjRKS0bHB+UH50x1IJyDTby4v7/wAY2GlvZyafBCCzXcEqgtkfKUzkOueCvBBINJWUl5GzXVlfWX1fRPH2k6bAsN1ops3xbw/6Pbwzbl+d3JIbYAW2gbgD35NTPrhvNfNhpktlDBEPNYwosxuQ5IZ0CHcuMYz65zU/jt9MuraytrnVLezltJ5GHzhd4dGhcs3ZhuOMHqMEVU8GtoVtqsCJYadayvG/kC2RTIigAFS+OXYckZOMe9Jaxu1qJJrVlPxzc6HrOnNZXdvq+mvYRGQ3dvGI5NoymFLfeB3H8Dk1qXg1LXfCU+k+EWfTilrG1tqlwC0Trt+4CDkNkZMnOPetXxdEs+k+XJbTSiYGFjb7N5UqTtBYHAYhQenTrXC2PimPSvDmpaHZxXdtrFzZta29jOMOzniMhuACNzF24X5RiiN5R93oElodnrejJrHgOzTSW0qK+vI7d5LlLb9zNtZTI5UAFk4bAPXt1ps9mNLmbV7bWbq706x0x4rixxueZ4/mEnBwjADAwORx71l2dhrWh6G/h+1nt7rU7nTmjQXk5miSRdm5uVyEActg5ycDpWzaaq2mXttYa5FcW8l5ttbK6W1CpeSRRBnkITIhRj0Df3SemcQ7q9noZaRtzMi0LT/7Ve+1DVdSkv2uoEFrps0YEdnGyg5UN8yyEZGcjIP5cJ428R3Hit9a0PQo7nTLTSJliuLqc+X5ZQjCRheuNpbr2UdCK3PF9ze+JtSgsfDN/rOnoyPBJdR2hhid2G47pGwThAwXaCMuDmq19pmpWPhK3sdG06Ozs7GSN/tF3MqG4KqRIJWJwNzHljkYHuMaQVmpP7uxolZ36HEXviefWbbWdVtpnR4pYgbOcYhGchWcY3EEK2cc5YZ4orsBoWpXnh+4k0fTbLTbuWZRNbtMLhUjAOSjj1//AFUV0RnDVbf16GzjfZkfhD+0rvWbPxBJIoUQ/ZY45VUsgUk539eTnI9TVzxFdzWUFxf+EVgdYWeee1XCJO5Pzc9tvJx3rMHiMXGmtJHCkGcmeNVxkj+IY6Gl0D+3LDS7uTRbCxureV98LTPgSEn5gwHQ49eK5nHXmZTRu6d4m0fxTpWpaeJLq3CqLe5LxlFVmwcIxHPPToe+Kk1nW9O8P6zpkb6dJd6zdgxwRQopmkA7gk9Ov45qKPQ7O5tpluFuLKW5lFzODJuAkx0Deg5H0rn9VttO8cXEkUS2Wp2MLeRJeiUpNbhT0jJXB9zkipUYt+QnfY7mDxJa64LiDR5jNNbzGGYOpXy5ADwfoRz2qnothYaIt1dXM9gl+0Y8yePCBfmJOc8YOfanao0drpbRWTx5ZAodcBnxwCT/ABHgdeawIPC7avaCHVoSvlss0M5UA7wem0cHgn7wPapilbeyKSsirdJPd+Iru4e+uYnuYxGFgQgRtx83PJ4HT3q94fMF9rFuhQtd2ESz5upC08kat98rnpnHJ4HatjxHpN3ef2fbJfG309A3nl13zXDYAQBj93HJyOvTGKveFLGO3s5pbi3iguy22Y7gzlVAwHbjPHboKuVRcoW6mVYnVb7Xbi8awis4ZJS8k8igsTnsDyfwwK17+7VYJ1tWmlu9hBkjUl+euP1qbTNStbnTpr17iP7OkrIJGbGMHnIPQDp71W1F4rnQrnyb17cXAKrNako6j+8revHWovd6orToclBerolqurC0nuoomaPyY+HZ26sxP0xXTx2lv4l0yA3rzwq43FQQpVj2z06YrIXUp1ittNksnuoSET7RcnfJLxwzk4BJ79Ks6nZQMLaOe/aC3aQQpBG/lB3HoOx9a0f4gb+n6baadY+RaohQ4UrkEnH0781Qvb2Ow1zTNFMMKw6lExWFY28zPOWDdCMDkZyOtZ2u2qaHOY0eeSOYOiyn5SM8ZBHQ88GsjTHhtGj0a6uNTZkxFHcFR5uW5ypx78464pRhfW9ydWkdd4fu9EJsYtH2S2935m2W2yVUoMkMTznkdaoXk0xivtTWzvLD7DPNG6SR4NysY5lVR99CMgeuKo6DNpGmWbW+j2N+radMS21QGlkfjeR6EDP0FaS3llFqaah9sunkRWjjn52R9BgqeB1yPpRazFdt3KGtyS+J9KsL3SZWtdPlj8wzlvKdzkbYjlSyDrkrjPrWxFd3z2MJs7XTo/PVjPJE3yQ4HPGPm9BUtxe3Md1bj97drcRgLEsQWL13E9/pVF9UtJI/Lt4H87az7MeUhYDO0E8Z460bq1h2XUi0C5FyytGnkWFtkSPPhQ7E9QD9056e1YOqxafZ6qv9namt7eiQySxyzYlypDFMEYC+y9q3PD8FvfaZDqB0pp7yVDIIZ5vkUg4UkdC2BnOO9S2dlqd9cwLq9hZNCCX3NIvmQnttPUjt1q7qLYNtmYIfD19cN/os9jcyKGecRtEinuMk49unNTXVk+i3SNp2mxPKuLZLi4nP3Tz8ka5OOuc4yau3NnFfzlZ9UhuJrUGRI0i8yWJ+gdAMkEA9hWV9o0y1ifUoNVNzplnObS5mIIkjuOmwqfmJLN27GhO4m0nqzZ03WrS4MNrApivLqOS4iSCBgHCAkgnGNxx0PrVa21m1fwumv3VuLOZEeRzcgkxopx25zzj1yaSytLy6+1aPKI7eONmdZrdMEbWHVhgN0IIqT/hIbaO0lnvpkgUOEVpoDK91tHzZjAODxzSsuiDmZm2KQhL67t9Yuobt9yeaq+Y1u5yQQCcHGOfatSwu3Hjawu72aD7BLaiygvLZSJZXJBJk4wnPIX6e9UZtT01Yk1DRryCO2vJgN86OiSueRhtvHXvjFa9pql6LqHT301d7vsuBDPHmL0k2nG5fXHI96cr9gklJHUast5Jpd2kD+VdwSBV5IBZH3Ln/AGWBK5+lXobZYZ9VJVj9qEchU9Mjjik0u6ttRikjMvnRq7W0jFslGHUH6f1rm9f1y+0nVmtIo2ljN1Dau8gLNGZwVjYBeqK6qeeo3DgiuZJv3Tiercev/DHVX7xWOlYuTtuJiFQKfmfHJPsAMkmqcsH2uCz8mdorNJFupWXIZwOVX2BYgn1xj1rM0q0eGSWKfUrm/uVuJJbmWRgcM5DGED+FF6ba6MBJLIpDhFXjLEAY7frSfuis4rXqUYrC3sLi4t7MbUadp5MdWkdssc/kPpWTrU9ykK3FuYowjt50kpwscYJJb8MDio/FHiL+yrdZ7awa7tBbS3IuUk2xB0KqqM2DyxYc57HitDVVtV0u4/tCSJITGomZ8YDN3wfViABiqSas2awfKtTz3w/4guPEmm3N3oesnRocYmuLgeZEGbKgKGwEXKn6+2auan8P7A+EW0q0MNo6xGdNanRMQSx5be5PZi2OOgyc1q6f4MsNO0fUrGxmkV7tywjmkMkbL3DIxKtk/eOOvTHFZ9pZW0zanBrtzbQ+JF09JzG8fmQ29rlgrxxN8jbWBUjHHA5zk7uav7jsgk9+lzB0vw9dPHdaPY3F5dXFvEkeqP8AaCsl7uCHzUldGdYj842ggHg+oPceH4His/7JXRNQgtmSWRri42NB8vXewIwSegC9u1Z8WsadpOseINSN3HLdTvambEUjEwpEgWMKmQhBZmx0zKAelSaFqXiXXbmU6lockLBd9ptmxD5TE4dznaxAGQBnGeeSKU3KS12JTaXYyNDhj0zxHEG0+TS9CllUfZRabI57pgQJEIG7y8gcuAW69MV2kXhuxlc6kLcQNZlsfZyYxGDyxVVwCeWJPcMR3rQ0bw7YRrDdsrRpbp5UYRyARzn5M45J7gnis/xa08HhzUJtMnjF1hRG1xGzp97ChwOnJHz9vSsZVOZ2iLnu2o7md4ZuvPuNRvV1rTbrQLpWaziFs0MwkB+dt38YySOBzkdMUuo65ow1iz0W2vrT+0Z7bzIY87ncY+8M9+CcdcCsTT7HWG8aWdzeeTqEckKia7XZH5CBPmS3AO/Zuz98DnqcVZWC60TXdU1W9trMJLEsNrBZQLI5cbvnDn5x8m0MOn3iPSrcVfcuN4u63M238MaralW1e+066X5vs1vDaqGFwx4cM3BJGc56YzR4j0GJdGTV7/UDZ6xYL8upz3D7YkLr5m0dFLKCOBxnFdFpZ1Cc6Hc6kLZ3kWZpGtNwiDYyu0nqAhVd2TuLHpVPxbB/a3hy5igtItXsrqZYGijwxRAcmU8/MQwwAOnJNVzvmRpzXVmT6YqXmowa7pmqifSJLbyjaZ3rI5YEMc9Dg1R1Dw1bz+MtR1O0ubqPUZrSN3jjcIH3ZwpYrlR8vOMHJ962PDeiWmj2tuIoE+1TRKJPJCoXxuIG3OBt6Y689TWZ8Q9cn8O6LJezxXBZv3ZkhUEQnO5FYjkKxbAIBGevapTfPaPoK95Fu1uLD+zLC6Oky2V55qxSpN8rROSQzZOdwPXdk7hiptQ1a4/t22trbVLUarLOJbiw5bzbYIQwB/h2htwPHOR3rz2TxLe3NrB4h07zNb0v7KYrvTg2y6gkSQAybDkMRuCkDrwc122naxJba29le2zW9pJZxTQ3kwwJGJ2vE8nQvnBAHbPbo5U7ak2TVkTR6xci/wBUhvtOvltLa4EcFzHHuWSMoGLYznhtwyBjGKxL/TNL1n7TpmpwwX2lzujOYpMqXJLASgMGQgEYIx9cEivR5riKVkVYo7aFV/eEkBUx1bP5cmvKPEHhmxg8Sxahp1rPHflFuZpIOUkjGfmYg9NuQMe2cipptS0ehUJc2j+4ztO8EaNpEc72n/EveN2iS6lTy5eWyCXJIIUDBAAyOCe9FbOl6tp/iO0W0viJnuoH2uqgxMM7TgdQRgjaaK2dRxdps25YrYz8rZWariKG+dSHjgUbHbHYkcVl3es6rpdjYWhgSGSZpXnublg9uijlY3YD5SRxkdM96v8AiDUNNsJNNTULa5E13mTGzIjKjPOP4vaqVwtt4p8MRJdJe6feM4naGI5YYJCbhjoRzg9KUeja0HLXREvhi8t9I8H3mpXV2NRSaTykgtQ0yiYthY42blgCQM0yGx8PQ6z9svlTTLi+jMUkHnFCxHUBR90ZXPBHvSyeHjH4ga40bdYh4iZ5xuYuQMkIucZJ+nNWtB0s60un39xaA+XO6TWt6AkjJghnVh6cHHf1obSvK4kmtyrrMSPawx2VxfRaZYRtK9pEgd7o9RtkPOOnAPNdpaol54ct1N3cWyyRhzIjbHAPJGccdaj1TUINO1Sz0/bbR2Do292l2eWV5XaMYPfipL+aPVdImOmXkUoaJlSSNwyFiO57Vm22kVGxiSata2wcf2o0u2JvJmnO5IiBgZyeT069Satrr9jNpUTWyR6q9xEq3bQEGEOBhl3A9fauKvtDg0/TZLa81JAb1gZ3R8uiBs4GB6jrXUaboFlaxJfafNcXcDLtVZMD5c5AIUKMj+8RnBrSUYpXJ1vYbqGn+Irm6ntrG10i10PZ8jTnKFQM/MFOQSepxxjrW3Yx2ifZNL2rKjQblEWXiZcdQ/fnODXL3V9qt7Les1zaLpssD20VhtJBbGG3Mpz3zkcitrSdSbR7S0tb1ra10sw7beIAjcwALCP1UZ79T70pJ2KUtSDWEsNKmiub2VktUcRrK0ufL5G3dk5PP1IGaLS/tNb1+7j17R5LS809/PWSYhopF4wwI49DjvWimnaRq9lq24NLbXZ3ul0MIrAdR3A/lVqHS9NFl5BTzLf/AJbP5m1W2/3vQD29qXMra7hr0HXI/tOK9kRnmUyLJGZuQvABA9j1xTNXuYraW3PkT/a1QBXiQjAHZTTbrUrMaaH02eCK1R9oaIblfnoDUOkaHc2WtTaodVu7y1uSGS3JIEOB0yTjH4CpWm4bJF9387SbdL8fZfOXDxTLg/iRx+VZNzqFnp2pXOnT6cY9HEYYXruGhnJAOwdyRzkdsVNrc+kz3s32jLwwhpmhiYFXYDOPUVzOoQ2F4mnT22omwlupfKSCXFx5rcEkR45AB56cYq4RT3E2+p1WjanD4hsEe1dLayjl/wBECk/vI143Educ8e1al9o0V/f215dWKzPaK6282T+7ZhnIA+XPTBINUWtDa2zWdhLb3OttA/2dblfLimYY+VmUcLjnH8qg0zT9R0iXy4IoPKdI2uFindovMwN4QMc7Qc4qXa+gtHoLp8l7HPbpqlzHcXVtA5fy5QjtHn5S8fTJwOcCls9dudV1GQWYtk0+KAgxsGNy02eqnO0oB9DnPWi1hsrZprG20u9tRdfK17LFkynJPXrjr+lcgunXllrUtlJaXM8G8LttpBE0in1YjPXHQjpVqKlcdnY6mxuZbTxJbW91asZrhXMc8cGQoHZm6g+xqzq6QLrTX19rNudMt1WabSpIIirOhz5hJ5LZwRnnI4NUdFu9YhuidTuGt7IPlBcQkuF7r5hYkjp1qDxdeW9xqFrFBHp8TSHy3u7iJ3fPoEXg5HGW96OW8hSV9y4PDciWE+l6Vf3mmxyT/aIrmGZnVTv3uoP+1u5Of65v6bKRol4WaDXr+1EkQRXEe+QDhCw+6SfWshG1a60821pILTS7e0EEOk7cKAvG8ycnpjGPp61Ep0zw5LDITqiX96IzNcRzbvlByEI7gnOc5OCaGm9GTZ22GalDFpXh+wsZxZeRZKr3dpLOZDA8jZwXxkjngj0rbsG8M3Uds08E0d8gxHHG23Yo6EH06U680fTr42t7rkm9FfMb8gBGH+rYdCpyevTPUVkahZQ6drkssYihtpOUCoS7rxgL2J6dTRdS06jS6HVNqCWEV5NCkYZ4zIFRN0juo67QMtwAMdeKy/7Ru57HSrvR7M3F2bryp7eeUh4I3UsUyOSoYBlPQZ+orm9VvJJb0jWVkgfh7ZwrRyJGcFRtGdzDH611Wj65e3DkXCx7Qu5SnDlfoe1Jw5VcUqak7xEg8P6ofF0t7DqEFnCLiOc28bk+aGGJUmH+7nBB4OKNYnu7bxBc2lgzX15PdQlLJCB5VuMeYzgkYUgbdwBGcDHOareJNXutNlS508wW9vEqxBPIEkmSQiKEByck9emOawdM/wCEo/4TEahqUEpCXaJPctEjNBCuR5UEYIIjbJ3N8xHBxQk37zZjKMlqd8La9bwfcw6SFtWlQ/Z4r6PfHknOJEHIxyCPyrnmnksru2TV72xkvL6EtNHHn7PJIrDy5F3HjkAYJ64x1rp47y9fWtSjhhtjYrgKY23yvKQM9OFx6Hmo9Pm0y8W702ze3YW7lZ4dysNzcnK59c81mm1e6Bae8+pa1CPNtb3keDPA42MvIkDEBl+hHOfoaztb1Yade6db3EKpBLI+b+ZUEMagEmNnPKFsAjjaSuOtU9SubnRb3w5Y6ba/6Bd3bQ3MYBby18olCo6IoYA/p3rZ1vStO1LwpeWWtM81g0DfaXlOX8sHO4HH3gRxgdRS0Vm9iZaHDeEtL8Yx+OfEdxpb29tpCai9wlne24jjuSVVS8b4LFcAHIOBtHrV+ZdZ8Panqs/h3SblbWGdFubFC0kF48g3NJaHPybcEMpAX5uvasH4k+MIV+H2jv4bOovfSTrFp0sDMu1kXcoO7JPyjaVPU/nXqGh3s1r4Qh1LVlNteJbA3jj5xFtTLlWAAYnGeB14q5uSXM15W/r+vwMWrMi0m6vb7SoG1Gzn067ZWY2sn8DdgOe9Nv7MXkNus8gVY334dikchwRhh3HP51zWjeOxq+nwaha+G9djtWnMTSPAN6RkZEoXJ3KehxlsnAyasNrei6ibPU4L+71211n/AEe2hRs21pFGN0s8mQNu3g/P82SABzxDjJPaxpz8uhyXhvUNHi8Wa3qd7YTadrFjF5AW6mKQbWO1YwRkHcQDnk/Nz0rqL5v7N8PzLeW8NrqGrxssVqZmmkuLwqRtTg/IML83YHFSeFfEmk3qw3empuF1I8sauhhEpHLH5hySvzcdcE1Hr1iniVpDZrcWWoWW4wNcK0bpuwcowyPLJA+YZ6dua0k7ytJW/r/M1d+bcu3FzqI8LzywsbqawniXyhbiJBEsirKsQB5wB19a57RtRfTtVsZbVbi80rUkke2lhjDNuBJZcDCoqqvU8nPJzVi11idri1sIEistR0+1hSe21GcqziSRlIDj5dxKggn73yrxkVUtUePxxNYanpE4snuje/alJFtGwiEYJzgFieNuAMncTxmhK10/6/rcI6Jo6Cwtb6OK9vrO8gvJ9QuVZXnuvs6WdsE+Ty8qwbnkjAySak1LT49T0K0TWb5GWUKhlik8hLiXsY8Hnkbh6VyWieJLbxNf6tPFrUtnJbxNZJo8xiUrKWUM525+7twOOpODzXUXGm3N1os1hqUNlf2QjRYI7uMuqyqOXYdMc8AY96mScXqEU7txOde1v9Mtre21GI3N3p10otryGF8ywY34k2cFtxwxIwcZx3rtLO+07Uoy1rcwS3MbFJYlkEm1gOlZXhu6KPrNmMfabe8YXckYzH5h5UAn7x2bM/WoLXwVpelLcTaak0V7dsDc3Ukxd3TO5kHZdxzwB3+lEmnpIpLsQrrthdeKL7TLpIFtZ4BbxvINyzzBjmLb3Ubh83TPHauimsIZtLlt5CyRyxm3JjOCFI7GsnUvD1rd+JtL1OSEvNb25iVf+WYUHIAA75/lWzLJEsDmWYRwhTh3O0D+8xPv0qJNWXKVqcrcW8fhu3vW0OBDfO0YCIR5l1kqOeQBwGGTgDqaKk1i5TSWNzLpz3iXSG13kqqQkISEyem8nGeecUVrG7V+W/r/AMOOTs7I5bWb4Dw8qXusWGnao/zzyXEfmD72xhjnB7Y610Gm2em22mf6BsRbdQrOmWLP755I54BrNOnaXpOuXEH2eytbO9kWSY3LbjPJ2OGzyOTj1p3hjUb/AFDUNRvLRDcaNKxFqeAR5Q2t9SxB/SpauroafVm/oPmyIY7uYyzI5Jdo/L/AVS11NLlvbu4upz5qxC2lQSEBATnHHQkVz1vda5q/jjS4vss9po9ujXctw6lUlYnhewLDpznr0rXbSrFLK6jgULY3EzycZ3M5PzSFz1JyeOnYUrWlqyt2YV7ayy6lYLHPDqGg7TEbVXU3CSHJMgZscKME+3arWh6rZadolraf2HLpMV7HPNBCZM+btbLZHXLLhsdh7Vf0nQbC3Ev2eeSczLsYnaCq9/oOlZejHWdJtWtJIkmjsd4trm8UAxpnj5jx04zxkVrpLQVupq2N3oN/aC7lt495OxXk6A+px0HvV5tTuptOtn8O20N7HIpIj3+Wcf3iCRgd+ecVzepXMdpaQDVLiy0y/J3HlEQg9Q2eOQam8O2mmeGtdngGvR3LX7JE0TxEhnKHaFfpt5wMfTtScVa4OVtC94N09dHuLDTLC2S5sZTNOtxHHuEKnkh5CTuYnK5HUYrpbbT2mtJbrV4FmnlkM0dm7hhAijCIh6AnuffmoFd9NiSy0tYjJFgLHJJtGM5PIHXknFZ2rS3WuXeqaFIJrNY4IJDdQnLSK+S6DIGOmM1DvJ3CUdTMvNPv9Z0hLfXtPu9OguLrd5MUxBkjXn5z029cgdgDxWdNNFBq1tY6dfQW2mSusUhZzwxBGwrj5cjgfzrY1jTU8J6ZNfQyXy+cAio0D3J3Nwu4DGBxyc1ak8OP9j05dPiWHVWdZbtrZz5czBTwd43FR1A7VopL5BfoXYdOtzDLp1tp62lnHkRSkBgH/vbe5qK51Q6CltBqMklzHL+7d4oAuSRgHj7v40avq13EzWSTQW1wrfPLIpCgegOTz9eK6DTN7aYklwu19ikEsCW96zemrKurHMaVoOjRWyXlq0UxR3EkiIS6vn7gxwMd+9N8QaPdWkcTaJFHahWLCUS+X87cH5sErkcZHrVLRo5IvEus2Xhe00+KJnjubnzllG5s/O23IwTjAIx610WtXstgUS4gVrdpsC4dCIo1J+RiOuOgJGcGrbalvcm/RlC0vtVtltZLvw/Eg8tot0d+ssyHOPlJHzZABz1qsj6jYeHCdJnvtRu5ZQsf2/ZvgycZds/dB7j0qKXTtYvX8jVYGRWkdVeE52pjIPGQDknj0AqK1sLGDUImttUcyCVIJojGeXcnBIPr0zzT0HYt2013dTXt1BaavBeWs7QiK9UIkmBkspHVT25/Gsu81bxDHpMl6LW4sJY7qAPPdQ5hnR2bfs552gDNdLq+p3OjERagiG3B8tXxygXoPYUusypeW1vbQXLW4lAmiZ1Bjf1AzxnFJPq1oFnbcj1WLTdSMOoxFpdLKdWfOACeQOpb2FNvLG01m3gu7ASvZKWEm5HhkTaOvzAN2+h96qXXh+aeytBNcpMyO0itJPgJjqVReXHI46DitK0u/Ot4obO6lmgigBKbcTOQxBJJ4C/Tp0o2WjF1tcy7aC+l1W3kglUWygBITJ+8jIPX/aXgnjrmr/iW1N/BcMsdlcCCTzldid0GTyMLzjrxUKabLqM8xjiexiyCgLnBxx07NjsOKIPscd9KkN3u1doA00AYkSxtkZwOoJU9CcHrTvrcbNPTpZ5NGgWKFA0ikbckrj1ycnBqvYyPYR/Y5o8m3zIGA4iBHQeoH9760seoLbwp5RRorRMlVb5lIADIwx1HNQ6TfTXMkmos3n6fNuVJV2gxj0Yenv05qbbgM1HULt3t5rWxhvbCQZlcbjIp7EDHp9e/pVzUpLqSO0bSUkRHUqk8tsZBuxwDnDKAcg8Cq1ld2thIY41LWkpUJMj/ADL6jHcg8YHP51S1u/naK31PTL7UjPcF40tEiMwkEZAbco/1eM8k45Ip212FKWpPbyOulxRa88EevkyyWsUcipOEXjcoBOVOCTjjHHUUav4huNHey8qymnmChrm827oLcFQecdyCMD3zVa6WS/02a7ntoU1+aJLSBioEqxKxPLgZA5PA6k1N5cNzaQ6brV3Ib66Rlla0+YRxjcR25faMYxzinZbsSv8AaL+r6JpGp3Xhqe4NxA6TTXVtHp9wsCq+N7Sv0L8KF4z948ck1o6a+ny6pdRW+jPaarBAFmlEBRXR33EJ2Y7xknrxXDzeJLW18NacdMtpDeJehdPi1Xak0sSj59gXGSAT8ueSMYJwK1Zvi1DZ2scOs6TdaTfOZE8ufmOEAfITIQv389OCOevdOnN6JHO9HojQWfXvt3iu81C5bTrCNBaaXbSurADzMC6I6rkngEcgHsBW7o13fJ4VtS91Y6lrMcMjqsMiqLnacAD8eC2OvpXB+HvEHhm/h1m8jjuTYNtt2Vh5jXG4YKxxJl5F7hhnGDnAGa1dMXSvC+h6t4o/4Rk6XdFwbhHcmQQs6hW25OwuNpKDnPXpSlDo12JsumupfmuJraK71PxPd2V2ySWSQaNFtlTS94KB8tyS+5vn46ED2ozeKdF1q7XRNOuJr6wYm4vyxxDZ2yAmSReOQWCqAe7ZANQeEhY6DbyW19La3GsX0avJ/Z8O+NI1BMcAB7IGB567j6VrvoWmXEunXFzq82oaNBGR9mljAhN6CZBcuc5YKNqrGAVUYxSdo7/ImzitEZ+ieKdJ1rwdc+INYtJbLTra7e7s8SnbdIoHlMTnmRSu3aeAw46Cl1sQ6d4VsfLto76HXb5XuV1KMTR2Rk+eMSRxBF25A64555JrH8XXGr6NL5WnxGXws09nDDbR2CSRt5rhZA4JHlr6cEsWUdMmu/guYrf7fFJdWj3kI3SW0GBIibcxq6ZJB2gdfyFDtG0kNKz5bmLqN9pktzaQPsMQ3+RcMhWCGUDaoDj7hJyuR2qlLoNvrmu6ZcarLOl5BposZbdGZAJd4mEiNkZKg89QSR6VmeNbYifTvEN3qd/Y6EsJtr6zWB2Vo5ADjCjKnPBzwOOneWO+svGupC50r7TbadZwGzja8jVIbvcFZ45C3zhAqxtlSP4u/FUk0rr/AIY1no9R/wAQtAsr6NJFkafXI4GCXkbIvkKFwFk7FCQoJO45YkYHTnPEVlr8MXhrT9UEEGhTiK3vjpcDfaJSXZhDu3HcpJyenUkE1HoWqaP4ca40yzDahvmNzdRPc7IEUqwC2yEZZCrE5xyB14Fd5Y+LLI+I7+yElrBaWFrHI4lnb7TFKApKGPbyig/fUkdB3q3zQskrr+vuDS1jN08MPEF9daTbaartqEhke1iVEvYz0kVyT86KCrqMHcCT1re1SK7ivzrT6k7aR5DxXVg3zq7AZRov7r5I3DoRjuKo3J0bTp7rXlmhVFt2udsACRHcMZIHUk4yx57dqxfFl1PJb+FtUsS9zqliVC6VbuGWZrhVyWI6qgyQR/8AXrNLma+7+v60H8KR1T3NjpNvPOkLwxF1muNkeSpIG92A54GM/StKx1O0vYWls5457N/lMkfIwPmz7UyGKeKVJbiJTGWKM4YMrdcHrkEYORXPWus6ct2mhQ3lul/c3k4twF8z7SgYu7Dp6sv/AAGs7cxUpR6mst1/afh1rm3S8jLxs8QUBJSAeB3xnFc/rl5eSeEbafULhrN5ZfLBZAuY2BXMg6A5OcjHX1rbt7+aLWriya2MenrEkkEyjgsxwyY9uuT603xPYjW9DvLWWziuQyP+4nOUcY4wR0PQj3FNOz20HZnDarFeW9xpmq6rqrQazptq0XladmVL0k52i3PLHaevHODnpgrSUaX4c0+DUPEEtwL+7aKyMvlkvKBwsS44UY5OMdMmitt+lxcj6HJxR3vii6u57W4spteixEiXH+qtwW5O09wOQcV1HhjXLe7jFjpkE0IMTuhClY90blH59zz+NVpNPk0OG0FtIJFtgsU8hi+adAMbyR3HWpvP8QzzX9lp1vHFZfdju5iAEzzwo5PWok1JeRaR0Mc0sN7a2YtjJC6MZpAcrHxx+dZ3ilms4LGCO2lltp7pYWZOWgBBIcjuoOM+1SNdW+kfZ7eSQCRAqt6nPT8Kq6yZtW1OG2VWFujZbAzuHtURWt+hp1L3g3RZbOO7N1dG8keUGIsmNgx0zVbxDpn221nhtGEjzSBnR5Sqnb0A9icU/WNZWxs7iEIR5f7kktgK+OFJ7GuSs/FourSztNQhls7mQpHPMpwYiemePTn8auMZyfOGiWpY8Xw2ep+IbK21O0SIfIplQHBCj7wDAhh198Vbt4PC0egWurWFvLfWskJigkfJ2COUsCqn7pDZqLRbXVbOOS5sLt3852S1eRck/wC8K2/EEUk2hw2+omGK5jXe8luMBZMH5gvpknIPBq27Wjchoj8LRWMusSX5vZ555FwYCpEUZJ+9jOckcdK3bvVra1W4unvI1jg+QM3Kqw4AJHbPGKpeFtI+xQxTXEduL+ZCkxhBRAM5ACk8cf8A1qz53Nj4pbw/Y20C2Mti92wlyWeTfjC8j5QOT3rJ2lJladR/heLVZEvlutSe9knV54JnYhC2OIwG57Dk+vAFVm1LWJo0hjR9La1lDS3NwAd6HOUAA6Hgj1HUjFJYadqOkaPqrT6gZ7raJE2RACIsfuKTyRjnk1taff2d9ZadDeeTfxuQrGJhJHvUbsORwOnfvVN633EkloZfiTw8NW0O5a0lWS7vLj7TCZwVjjUDCrwc4xnOOpPYV1CWUg8NrYO8dtJ9mETPFnEZ2/w5PAB55NGoarplrfwQXc9tDf3PyW0TcFs/wj8K5/xPqNpembS75HaFCpcRPtYHr6YI9u9SnKVkIr2ZvfC2m2TNIuqXzN5MkrrsdkZuBnOSvAxmpL7RtWsbK6ttGJuLi5uDJNLeyeZt3/fHou0DCqMD61nwXNno2tXl0uhme6fFvbyxTM5eJUUkyA5VWz6dhnjvpXGs/wBuaBcxWCzw3l5ILNJI1/iPPU9jjBPvWjve4abkw0S8guNJgs77zNPuYfIv4y7B3XbncjDntwQeM9xVOKzm8MahbWXhSze+jm3G4u7ifzZLYg5WM9wMZxmreoXGp2XiGWaw+yTaFaW4tldRukR1XaVz1LZx+ANc74PspbN5LOC2j095TuZPm8yTHdiTk5A/D86au1dv+vMmKvqdlrt3CLJF1FGa4ljOY05ycc89K5uG6kmsoTNLbLYStvhinGwxkHBG0cgDB7cGmv4nmtNYSxa0d2gdt07RkkkjDEZGAoGQDT0h0zxej3DNLZSuzIwWUSK6cYcHsSB+FEY8q12NHsbFt4ftYvEtvq7qkdzHbtFEzltkiEHkc7RwT27Zqvrmy9jmEIVoo24js38uS5k7Izt8qrjPJ4FZ8v8Ab+mRwWulhbx7hvs0EpHmR2wAPl748ZwcBc5AGcmr/iIf6BYpq6mHUZY0a5MQ3osoX5lX2yDSs7p3JvrY2/D7TPokKzWk9q5jLG1lvFuTCQflHmD7w4ByB3xWRBZ6RbaPNItmbBI7o3G6IEtHKcZZe4Ht05NZNlq1tGbu4t7CU6qgWGESSkRzyNwMjgADqT0FaWtX0sNkLC73XMwZN8seU54BbHpnt6cUcrTGl0G6fHpFoJxpd65N/L56hssBuJ3Bcjuc8GtZk02F7G1nMunjyRHEqIRGQMjaecH6fjVW78P6bPZ2bNm1mVg6mRjux6kfWqmpWtldX15Hbfarq8j+ZoXnYq4OMmNGOA3HtyKNJdWJ6jCtlpV/q2nWNwd3lrK1tcFQXbJ+aMkYJI/PNTWko0+QpELh9VlleVbdoyH8uQ8CRBwuMEDPBK9ao2nn+IV1LTvEOjW8mlAGK3kgXdIYumxgwyjjAOcjnpUuoxaTceIIrfyXmNlZhY7y1ZopogASIy2RuPy5GcjJ+tV5MnqXV1m3e5lE14POGIrko4LWjgH5WQcjcBxx3PpVdLC9tLqW6sdMh1uyKqbdLe7EFxE5yHdS3BABGBkYOelUNRj0zXbl7XzI7e4vLZPtGqI8a3TLuB8mTA+blRk9QR7V0WnPaabYXUQaCRIjwXkABJHAz7cAk896l6LQEnLRnlniv4f+FbCG6QSa7damlush0lnWSZFJyNsgBG4YDEZ5DcY4FTal4YtrPwtqlxcWUq7EFjcRW+pxShX3xkiVn8wQsBgEk8ZyQM16ppEGsW+lXU9wtneSkBVG7KsmehPUgdgT1qlpStP4P1lNbsbHSYbkSXU72kKxIyseS6jrJgck9cfSq9s+uvzMXCzPMvCfhrR9T8a6RqWhWuo+H0iX7WbNXLxCBP3QZJ3BDO8hJG0FduTnPFei+INI0nW4tY1TWtVFzDa2k7xqpzFFI8bRlnxy5QHKH73JOc4rkr7x7Ja32laJo2jAXaQtbXdtJcCa6t4oiBG0jD5Q5RnJBJCk445qz4X8Prr/AIZ1C91i9n1Z7e9mWKGNtscP3WVQq9CCAcdABjp1ck37zdl+JEIxasii1na+FdE07W/EdpFP4h0N/sVjKLgnzogQEkdRgllJPyHGB97Ir0vUNKPiQ6HpeL2KIRDUry7gUxgFZEHlbhwGYGQ7QOijpXAzeHrV/HNvaazc3FnOb2x1OacYZb1guwxBucEyY4ONwJJ6Cu+13UZ9Gv31O+mt4vDFuZ5dTiMZ8yMABYgiqe4OD/8AXqKj2tuKUdGloclqXj+LxFotzrS6tL4btra8D2FtaQrNcXLpvULIhGCzHbhTwAAeetZ2iXc40CHV9OTb4j19xp95qFkHWWFgRueQN8olx1YBRhvarth4bvE02PUdf1QfbJHXVbTTmdUhgwpaOI9pAFwTgDmuhdG8N+ENYufEusanePcyiTOnW4EkYkZcxQpyBx/F15J6im3CKtEfLHlv0NfVDqS3J0S0v4oLyWwadb9EyfMQorSKo4BOScZ4J9q4rUfD9kLjX9Cv/Ed3PPdzz3MNoHwsSSrvIb1ctuPzEcdq3ND0mPRdT16ZL+XUr+5QSKt7egSxKQGEXJwMZOTjqPauWvPDV/c6dqOn2Hh9IHkLMur3V0LmS4VRmMyFeQclh3wABz1qYWT3NY9Dei1CeOeeRZ4r9oBtfTHtVDSYijMckcoXIZWDLgnbhzjBAqTX7nV7DSrH+yLWz1DU0u4bW8vkU3H2YkAuGHDEL06jg0zwz4plv9Ktle1nnvLc+RfSCEpmVPlIHuzDbx6e1Z9xrj+GPED6fpulp9klkXa1xceVGWdiZ5DK2QzA4G3qe1HK72sVyJK6NeyjXV7H7TqEFwmqQk4u5bY2kIUNl0UE8gjj5s5o8Rv9i8PWF/p/2bytLvI7mCWWRkht4futKyjBYqrHCjuc89DL4ovhZxxSadpcV3K2EgnmlzHnPGV5z/nmp5Xk1rwI8Go3hSaaGUzG3jE7lM5dI1A+Y7QVHUAnvUtvSXQJL3bHnqwXmr6l/avhu0v0ntdTZP7VF0q2N1HHgeaYerl4mIIUdec9RXcXdvb32pfY7fQxBLZPILTU4+ls0kY3FR/C+DwDxxWDoeq63frY/aNKh0zT75RHZWVlbEG0RMFpHH3FQt8ozg4NdfaW8cumXdhq006XWogfaA5Ks/B+4QeMZ4IOcVVRtb/1/X3EqN43Zvx7EeUOZGeZFj+0TKN2QOpGMDJ64FZ9pqdnqOqy2FpeRvNCWSZIxynT5gfx47HPtXGaD4otIfFV9o+labey2MUMa21xFctOTITg/LK7HZ/tjgFcGp9NXX9O8P3AigsZ9UeV2L3khiCIOVB2qd2Mtx9Kz9nbccVdadDf+Ilx9j8O3IhtmlnjiaOBIk8xlZsrvweBjcTRUHhnVhLbXbXF48ksZVGdojuJK/MSrAYXOQDzkUVdObpXXLcXI5bHG+F1XT9Yv450uHnul3SzH5oRjkhR70rXD6kbLVNWml0+1srhjHag583HAP04zn61P4XsbqDSfJvpoi8SlQsfO0d8mnw3iQPLplvZ397MiK++5twLds8hEkJ+YgUN6s6GktDM1iFdema/j8+NBKpLz/KuBnAXHODnrWtqC2dzbp4dubu7hubqHzUltnKNgejjoeKItCvDeG6ubyJZrmNUit5FC/KvJwvTIz1FWL3TCt5YX1xAkVzaBokMQyHVhyKTktFcLXLHiNYbDwO8CEvJtVYx95mII5J7nA5NcNpXhTUr0GORRbTSKZEaXnn1zk5wMDmuj16x1CSxRrXzJ4VG4W6lVMjKcgFjyBnGQPSrFvquq22mW1u8cDai/H3gip6KSTyelVBuMfdF6mzolhNYQ2dtdM0pi4WXPXI9PwpniW0sL5HhvpXQyRlZIYZtryJ1IPoPX61Nqd5fWos1isWunAV5XTkDJ5C+/WsZ9P0rWvFEOouDJdabPLETHMI28xRxjHBHKk+hBFZxvfmY29B2nW+rwaXrU9hqLSSTlfs0dwhK2vIGFz224wKWwsbGLxFd398st1rIgWT7VOuERQuGSP8Au+p4year6fcar4ekk0ya4k1a5hjkvJrrUHEQ/eHEEIfOCS4OSegB/Cyk1lfeLYLXUL6ObxHpNqsd2IEKJPkYcgY5UbgB3IAJ61eupnzK6Nm8u2ewaCzhR5HXLRPzuU8HI7n64rOtYodB0+0iu49M0mydy0kcZ2iR+wGec8g/XHNHhHQby1uL+efUTfW5b/R5DnKJ6Mx6nPasrV/Emn36SCTTU1WJJGCAAsGVG2sWU9Oc/lSS15VqjS52DyWN9Ba3KQJctC21JpFBkjPPQnkGsfxLoL6lJFJHqTWXnAmWNAv788YHP0ArTt9o1RI7GSGO38geZbKoyp65GOhwQPwpZ9CgutXhv53YiMYSM9M8dfyqIy5XdBpY5vRdWlvfEyWMcEmm32ws1oR8syg4ZuxB7/lXQ3czW+s2skECrGp3OxfBXHrk8DrzVGw8O3mjtpkUF88qwCZ557hd8s3mHceeoHsPQVUm0mO1vzMt01xFcBnBPPbqT6Aen6Vo3GT0FbQpXrWkul6pBBebLC3ne9E8wH+kszHcirnO1Rgbh3ya0Yri1g06XU7MPMjbF81cg7exbPHGSMj1qjpsC3utlGtprkw2ztFdXCbopHB4xnqvPQ+lR/YL3w3oqCXU5L6a/wBQjidpThDuDO+1T2wMVbtsJe6Syg+I5JPsGpvPIsr7V8lxEFGBtD4wMfUg4q1baRBp0N1Pqk0X2S3/AH07eZhIwoyS2B0wOg/Cs62tNdmEZhknSaYGRXY7Y1XJxuOD2wAK0tMsbm31q8OpSSSJLHvBVD5fGMA579eg7UPTRMrWxLINRljj1nQpns1EOF0zUrRUDrnOQwbehbIPzZ7ZArNvoLu/thqUesW58ycb5IsyuiDqsWAQXJAHYAA0XNjAdOv7/UrwR20SSECSXCOdpUsw75BwB71Nqupx6D4cgXS10mOS5tlkEIkG50I+Xyo1wXJBzhe5GaF5Gb03DxHrFuJtNglt4G06UEv+7AkY5xhcd/X61parNaW+m/are3juIosRlHB3HHbPXPtRY3EZt/sd/ZJDb21v5ryTQhUjyOMZycjiqy7r+SG0lWWKG3AP2qOD93M55OG6EY4JA65qf0L8hk9zdDSI9Qv4i9yRw8eMhcjAJPf6ccZ6UaJfH+0p4byC1MpYrbyxxmLcTyBnJ/w71f1/SontFkluI4jCW8tmOVIJztP+NRWMMUixlhFZ6nLEyWl1FPFJK2ANxRWzuwOMnOKLpxDYgh1HUm1Y3FvpMvlq2J7dZl8xh03f/Wx0qXWdOk1Lw/LZmxiRLsSLc3MDNbeQMjy0UMSS3fd0znjtWZqGvRpp0VnrEuqWj71WC/mQLcTyZ6lUAHGcYHYdzUt35MX2L+0jPqNpK/lvfEAtanDNuZWUkphc5B4PFOz0ZD11ZlaFY6VIkem6Zc30d/pcX2G8lkUSmUMxKlyQudpB2sOmSM4raOl293ow+3XYupNPmZmksUBMo2sMMh4LA4OT6VJpV3qGtada3ehQ2tzYOzIk+8jO3GM5AK4zyuOOxNXL6zutNtZ7jw9Z2T6vNzOC5ZXPH3OxPXjuaJSd7DVtkVLWz1W+0J5fDmsT22pp8jPfr+7Yqc8w8hUYZU7enBHena14i26HZafc3Vims6mhjntbZhNlDgPtweRyQOcitXw5d6nNb3D3sEFtM7psdGACg5GM89Cec964rx9pWtaJqcWsaTuuNMtbr7b/AGbZDyZWZUUHzXwdwK7hkf3R+CjZzszOSsyF/B9ts1vwveWlta2txPby2UrMVa9RiGldJCCwbOMpyAwHAByX+MrltC0ddR0vVILeOS6MVy9nEovLiRm8sGFCANygBCp4K5PXBrL1vxYNb8U2+jXDB7MQ+ak3n4+zXJiKSIXQYLfOyem7bgjmt3TtDtfP0+fXW0e60nRdKeW1hkYh1K7TJJKgJBKgAFh3PritHeNnMmycTP8AGOl3d7baNatqlhJ4guNbjEwa5zuiER2iQDhSu0nA6E+tetapaQ32nX9sjIRdRsksj4O0shVfrjOcEe9cPe6clpp9xqMOqDUtK1a6ga5i1ArcAW0oYSrbOgUoGUjaRjG0c55qXwffG31WRX8M2tjcS2scsz6dqQnllcs6RpKDyHCLncxI4Pfisp3ktOhF2mZfxB8MDUZdF1KHV3FhZWkVheO0qoG2EHfuIOw/KpJAyQcDHNSX2va3dePfC48NoZ7C4he0l1HdiCRWPzNG5zlkK7unUDqDWrHC9tpV9F4bs7Ga/uJ4bi7sJ7jci2hY7zHGVH3uR83XnbxxRoMlpbeO9U0yE36w6fZo6h1JgtPNO9kQ4CxgAA478jtgNS011tf+vxHZWcUMtNK0PXoDLqOhXttBpdw8Vu0pVjeAEsWQ5PmZI6tj5m+tbMV1qFr4YubyKxlt7yWApFahS/lkngEjgt7dOwqaHUlm1ezSGWCa0mRlgWOIIWwp+ZufmDHdg4ArI8MpF4u1LTvEkFxfIunTXKJaykx4yiq6SqeyEE4HU85NZttr3tv6/Mt6LUyH1LVtN07XROYZ9cKj7PBCNiDJC7gDjPJLNjIHrzWvd6dpBs7e21K2F8LeHlEkJkUYzkgHkHnrTfGetnT9Omnjs4b6eNNu52BcbhwhABbLNs+UcHv0q74bFk1tDcWVnYi42kXJtAMo+3LKT97uevpVNvl5rWN720ILC5S4so1+yPBaNE7O8WGVBjIA467Txx3qobFl8FxuNbfRrNLaUSSGNUeOBsN1J+VwB17gsOOtT3WoXdjr2l2dvFGtlLG/mbR8/wAo+Xb+XSs7xPDF4g8J2ia8llAizwXe65VXDSAgEBDxg7sHPuKNdLdSaibRUt/EWo+JbjR00+FtLjjC3zWVxMFa8tJUPlurJkJjAIVsdfauqsdGstMi1BrWa5Vr2X7RcTz3RmLPtAyS3Ygcj37cY5641eTU9X1mzEur2Y+yrNDO9vHB5DL8vlQhuXRiAc9BnA603Q/s9zYSanE6/YrSze3ubYw7XuZ3/eOsiY+XYcAAc5Y54xRJaaaf1/X/AAxnHZN6si8SS/2KdJa7h0/Q7+zuF8q6WFmt0iYECIuo3IjEqGONuWBNGk634gttMvr7xDpsQs2P2gNaTq0yEHcyhOjITkgg8o3qKb4n03VfE2k6GI45NNZz5BjiTa0No8YUhyckMFGMDPKjpW7ctc22qw2Mgiu7OZzsOVzAQpVS6jt1Gce3tTura7jjF3TZJqeq6e7aRfXOopbRTurIhOBMCCQg7t95eB0ornpvEWo6fNpY1vQbSwRvOWFiBMkbRr+IUt/DjAPcCiodO6Wn4lKxh6jqzWFzJp3nqtzMWdWPAWM9APUDH161NPbX1zpumRLHP5fnEpcBjmJBtwxB7HBOOKt3FhplxqP22WaCVrVwiiPBZOxXI/kap6trenm4XS4tUjXVIJBI1rKp+cMMgA9M45/GtE9rFuRuajp1nqXjLSrlZp5S9vJJDNDP8sEiADIXoQwJ/Ee9dDNDIiRSXN0X2gpk4VTnufesHw1/Zd48cdnHNKLPOyVoiqpuPKg8buayPHjw67rVhpFxHqUUUMnmSy28pjQgdUkHTHv1HbrWdm5cvYNtUdCbrSdUsPNt75ZE3mNZEyGDdxz2qk/hnT21231G5u3XyY+MvgBh/ECeAe/rWdq/h67C2y+G2iSKIAvGHwpOeoz14696v6mJL3ZYSW2JigM6sjNFJx0B9sVS0+Fla2Og8PWgsdMWCO6a6gMjPFI3UI/zAZ74Oea5m30b+zdX1fV9RuEdoiGs02hI2Rgf3RwB827ByOcZzWjp5ng1e3ht03iUKphj5CAA5XHbAGcVlX9pLqGrS2/iC9/s2Ayn7A0PJY4KlwemQCp5568cUR3eu5MnoRam1hY3bPqplbTdXkijv8yMYkmzkPH12NwBnpx0qx4v0nWtTWS0fTLOzh+1jTxfRsBc31vsyAH5PYHdkehFYtnAbLxXp/hT7TcajpUts1jBPCoZ7aYgk3EmQcMCcg5+VenIrtbddEtvsttpV5GbHSf+JXZ2rsySPeMTuLFhyWGSPz6VTlytNGGjkjO1jVIvDy2Vis40zQ9PaOO0soXzNfHjdjPJVc5JPJOelXLO60u1mg0eDTPJtpF+0RoCNvzZbOPr1z1zXN61rkurW9wunaWq65ppaCWOSDzXgjkUhnQ9DkAg81o6TambxK/iKRZDp13GqwCWPyzbqi4ywbG3JHHb86OVKOptHRm2Y7OwvkvvMEUwgb/RCw3yNnH3evemaPPqLeIY0vdQgZDE3m2KMCyHPGRj0I6fjUUg04eKGe5hjF4sAkEzyY+vfGNvP4VI3kxNd6zptrp0LtCxk1Mx/OUA5znpnuR1qBu9iXxNqN5Jd6YLM5heYI0kbfw52lcfQ5/Cq9xZ2EN9Lpkl1IZLhHSPdyRnvxxn0FZej6lpen6bqTWjE3cEkbXMDKRHDK53YUtwcglhgnipvETaPCHvb/V0srtwot5HyXhkbocY5A65PSqStoHMuhpwW8lva/2M2pC3vpseXIYyygDspz97GfpVPxBYXE9zbvGgnFk21I5CDtbBDOT3JB5z7VDd6fLaWdlFDew2tyjtiS5kMzO7dXLdyeDx6496tC5i8PLb219tubiQNMJd3+sPHX1POTQu6Gt9S9LejT/D9rLe3sqxQCOO6SO1Mzsx567htx+n6VZ8cpcw2MQhV51eRd3lcF4278c+nFZf9qCbxPaySXN01tNZCIWRUGDeCW80knrjC4AGcc1pDX4JoY5Zg8UYyqEnHTPX0/HtU2aadiUnc56fRYoNPns9VuTBZySfNGzhftA2n5B2P1NZunwaJc6XFanTY3EzLLaz6mqyGzVgqeUp+8uNoGAeuK3fFM5ewg1G6s5W06C5VHeKQ7wjNt3hADuGcHFUPGM8w1Gzj0GN5tdjQvBEYlaNUI+ZXLcKHwPy5IrWLctxSSZa0xINXiNhYXE02lowQzRNvd9uCVzjgevpnj1qLWZdP1HSLiKeG/gtWb7FGoD/ALrbgqwGeBnkn1zmqV5otzp1pYaXpWnzGwVlkkSylEa+ccMf3mcgA9OucVNYajqltqTz6/a3slvIHLLs3ohPG3HUjvk0W6pjT1Ni5jGl6bp1tq16LoTbIVnkiLRGXIULx8wJyMbsirUPh62jvIbuNUTULaFoYXY7lQEknAPQ9gT059SaoeIy8Vqr2GrrYO6A24346diDx+dS6FrN5baTFLrFv5lwSoD2oU+YDnlR3OBn8ah83LdD8iXRP7Tke+h13SlTcVlQeckqN2OBjjPB9jmqPijUJdL0+aKK1/sm0YxLJPHmRYd5I/ebR8gwCcjIyQO9aV5FOLa2vGeC41PjyjGoiSdj90YZuoHJHfBxVu/vpbPRsXs8D3ZUKVAwGJOPu+ntzST1uK1zktBKeHIBcJrhmtpUEMYW3aQIx6GQDkckngdK6K5sIL2OGz1SJ5HeQygqeYGGNuD33c4NINItn0yOWJ2srjAeOVBu8uTBxgHqAexptpcQWul3P2rVrnVF3YmubkrEUyApVdoUIo9u5zTlLmd1uO2tjVm1KK2WeNC19dkBTbow3uehXd645/CuW8Oa7eWc2paZ4gmutNAnaxgl1O3KRiRkJjYAnEiHaRgHJyMdqgn0rwzaaqkWlSxnVpYmEEYlcKjBDteUqcsuRw3c9+DVD4la5r0fhhYtWl0641K1WGdPNCyrOisBLsUjlie+Og4IOKain7q6mNRt7bf1sZnhzwvB4w8HWWs6hMLW1t2nlXT7GDyPLYSsrEP95h8uRnOM7QeK9A1uXTI/D9/az3ENo0QCxXktqtyYGfH7zymxuGMZ7E44JGK0dNuEs76Kza11G3N1E10kVzCBHChxuhDDIUjOQp9/SuMvtGupvHWq2+oWCXWg3FmYlkn/AHZLYDIsZzgktkZwSNvbuufnfvPRaiWsbCXNzo+m/DZLiK4097nSsWtpE7MY5r0YKhkRucsS4XoAccAVp29tqml+KLOx0TRrWJ7iAz399FIwtYZ9xWcBcfPIGZWCsenYdaqRXFl4c1CwvL3wfJDc3ciG4FuVnihu4xmFtpwNxBOJBjB3Z6ZqvqytrU/hy4tPEKf2NEptibKRpbt7o7zLEzKdjgggbsnlR2JJe/o/66GbbvY3IG0/wr4j1HWVFzBPHFaQX108ZMU6MpzKirn7oVsqBy3A6Vp+HNafXLV57jSrrTFl/fQi72gXCMN29ecn5cEhgCucVxU6eMLbSvC1jAyWl1dSPBdW+n3bRhYFKyPK8nKpwpB9mYDNb1tYPqOgadpPiRbeS9uI5Io5dMmkwE+Y7hJ6eWU55BJOeKmUVa7Kh8Wg/W/Emnmz03VtLEV3FcPtS6hgaRFiXh5HxghRjrnrV5tcuG0yyljW6EuqSKkQigLPawMSBKwAxgEqSD1z7GuLstHTQ/Ds2n6tBYSq+qtNaJHM6fKqhQXU4yMDGANvTOa6LSYdabw9p8673u7OcXEsCn57qFFP7tW6AElSR328U3GKRq78tzAstE/s3w1dLYXTatq91cSObgOVBkYFct3wFycnjr6CukfUYtEs0itZI5QsDRtbWibHnfA5I7DGCGz0IpugXGleMvDL32mFYWlV7eb7O2Sj/wAW8HHsceh96xPFvh650vS9Eu9OlN3Dp9u4vDHJsaSEKSrY/iOc/KBnpyAKd1KVp7l8yexqm8+3XH9k69HHD9rtWnEkUgJtGIxsL9QduTu6Z4rEn06STXItOSax1BrSEQPGigy2kBAw5zwpBAIwCSQKs+BvEMb6beXuqXsUcMNshYyRECKMHBy55KnIAXB56V1FpdXVybx2057O2Hy200jBHuPl5yv3lK+h7EdOlDbptqwXWzOb0rwn4Wm1fV5bWSaaS5CrdRGVg6yqxYSqSdwbJxkHHWtaCx1HUtYhuodRurK2shHELeZUlF9GEyzFuzZJ+YHjA4qLxa01o+gvasLeS8lDSSRIAZguAELdhkkke341ea6a116WOcNa2kdm1x5nASU8tLt75VRk/UVDk2r3E1Hcmu2l1G0vrG7intInhMf2mG4AY7uPlxyCPXGOa4bxfAnhzSfDstjJG1rp9w63ly8zF0PAV2xyxVWc4Pc5was6h4mt4vEmhyDUIUt50wJCm4Sk5DEYbgcgZIwCDV3WNdtLfWZ9Jbw/e3ccqsZYUs12ySEqN+WwHVhgZGSCuDVRjKLWgTSejMi71XXF8VXcdvJdT6NcI140+p2peBbUqCqbkzkcEhzg4ODycUVveEoTZ+Bra28y6m05mdLQXGEmjgY4jQ4POBxyRj8AKKfMtrbEwukYVqtm2kTTLYIkgOLox/KWfu3ucjNQzO8VxFe3Ngb/AEp7c+Y3khp49qk5UgA+mOfapdJ8Pxz6nDfTXr3Gk20I+wWpJXyifv7z/HnrVq9vpoZtQkTT55YLeFw1sucTIy8bMd88Urq9kabq7RQs9Rn1DSdQuNE1CJDAFeBfN8kCNgCNxIO3jrxknjjrTfEt/qGsrBDbqIyFAcQgszsQASc9R1qpZTajHNcW+yAW11NHNPYzRAXFjEwwEdkHzNwpGecdepFbmqaC92jQLcvZWoBWZ7dfLaRev3jz+AFO6TuKOurOit7+G009VEUrNHhNhADcDqQayW8Red4htbC3065mZk813icYhUnGX7D6VDo+laS+j/2dayKlsAwET3G+QhuC277wyM1W8Ny6Np5OlWU0sCxs4nmvMRGONRjfI7YDp0wQccioUVroU5aGnNr+jwy3ttd/bHuoI3vIoApWaUICQ6bc/Lx1OMjnpXE+F9R0zR7SPV5dQvNQsLnEdtazruaG4eUsJM9Bt+YZHJBP0rctDpdjd6l9glkJbTQ9zeiUFkiZvlEeOqkZ6cVZ022jiA143fnab5AKWskWAHVvlbbg4wfStFaKaMt22ypoK/ZtWvddFvcQ37TGzuLe1bzsMzYWTbnhduCcjjitrX7NdKuNPlF2dS1LTIp7qEXLgmSdwB5rAnAVFyB2H1rH0fS7h/GlnBElqLG6JmmmEjG4WRQSRjONh9B/9atORzP47N1LZRrcW6PFHLyxePaSAR0XknBpSd5fIfLco+G7zVoodJt0eELPPuvJbmRXXc6PI0K7eQCWQrnkD2q9o3hu7vbmG88SQLHLGsipZpcGSEKeCD2I4U85NP1SwbVEnttGhis7lD/aEOo7w0cl0Ww6sgGTlR1P0rP1HWdVudOvb/SbeSWd7ZPIiTAOXkClm5+XjJ9qLt/DoUlZ6nVXtrYX9+ILqNd8UWAWbBIYHgduAM0XVnF9jSzWeVUSNlYKcq6sOcj6VX1G3XVontp7nyJ3idXa34kCMvRSQQDyexrI/tqG3t00vSA8j2yCN3cYO1cA5Y8njJNRFN7FXNK3v9PjsNP0+FILiyaUWpL4YYCk4YfXjmptYsLZrq0unSA/Z12eU6KwKduD2HNYWmadaWF/5s9vJGWdXDFg0c5PQgdiOmKveM4pba7kvrYo+oRxApbecA8659/u56jI5xjNO3vaCbVhk11Dr1+LHUoiIxKGj8tsMPl5/D6dK0ltLDVIPMgnkKwt5CsU2kEZ45HGOnFVNMmuZoLTVBoU1re3MqRtauAGCEcsQM7PbOM+narX2PSbya1vJ5M3Onlgpt7rbGnOcOoOCOByRmhu2w79iK3a6GpRQA21va2EMwlZY8ypnHlGPt3JJ55HvRDJp9rplrEk8IsXWQStKTl2JzvI9dxJPNRmd7i+1iKe9YXixsltbbFjk2lRwMct6g85FTWeiz3em6XE0hhjt+Lm3lQEXPpknkHjofUnrQ7dReg7QdVkka7sZ5mkmgffBGFVXaPGVPy+vUA84xmsnwvLK0+rT61byW0N8WCxMf3sYGcg9CR/kVBq8+kXFrNaafeWaajOpEogbdOVQ4x2246ZyD9avaUIootNt9QF2/7oiG7u5t0xXqY3OATyOD1xV2snpuJGyum6de6ZJZ2LiOMjemHLNG3rya5vV4ZIdTs9Nvnmn09vLgD4IkUkn5iAMMuep7Ve0wQaTM2sa29jFcKzRrBY5bZC5ATd0J5GdxH1NUtY1PVbGS6lSxmlhuoTIlxFcbTCq4zgEfM33vlXt37AjdPQptGj9m0S60i1dNTkuLNU+S4kU4dckADIU9jzgZpUj0vTtOtrXTLf7SrsGeKQNuPpz2OO1WtM1WG/0qG6DJLMVzFI4wJMd8fX2qsLqCfxFcCaC7WS3hSS54LRAPkqFPfOCePpxU66piWiIPGSW0Onk6qTc29uiS/ZYYQ86KTwyf3eV5YHPFX1bSbvwvp9xffb4BMgjha7UtOC2SrSHnpjOT6c02aeDVtamSeykH2aISRTzRlCFPb1xxn8ak1iO6aAoyRQabIY1EgyzL6k45P+c0X0SYWvqihMkl1pttYSXaT3kknnRKmQoUckZPtz/Kn6fZ21lpjLYH7fNdowjtrxgplVT85Vcc4U8fzoiuprGx1MwJZwtZbRDfMxUlGJHzEg7cYBz05qnqlnb+IprK80qaBtXsAJ7BfP2Qyoz7S7qOSm7cQRgPjHSq126CbsVbePTNFvLa90a21GO4sYJLJljRXK7yWDSM3I2knHTqeSK1/DWo2lvr+lalrSmO5ubZtLjuCD5McgO9VY9FZt3Q8llBGaqQ6a8vjS9YXO+G5jBKxQ7UR1wG57qenrk+lNumbRdJhiFpdXdjNcfY5dNnk3JKXferK2Mh0K5Q8ntnngdpadWTOLcXY7fTrVdLsbHS59Qe61BEYJJM4aacBifm5OcBgMnrj3rmdet5fFpu7W21VLX7DdMIQtr5vlyYX/AFgY/MM8jAGOccgVDD4p0W2TXtU1CG9GqaMCbhDBvltwQFIjc4Lr93qcDkiqcX2fXLHXdR0BbtLk6uiXEkM7RyNGxh3sBnB2B8gHjANZxTTuyItbE0UviWx0x08WWem3Wg3M0g1T5zGYINowqKHI2kgk5OcN0FLYaG8eiWd9evDe6dDDJDpNroFux8uJ8sXyzH98du3K5APGTk427y4FxHqMKvINTslhUv5LbZ1I3yFlwRtKxgFiMAnGecVBoUAg8YXc5upLXTVsxBZ6am1IFiZjJ5ygHgg5XGO/XHAOZ2uS4+9p0K0mq22vaFbxW+j63Jps9k015dXMflJBC2VkQvyxkAJyqj6VSis9O1TT/D2oWhlisCYltLKOViiwglI5cggq4Azg9Rw3NdZFq0rreaWbrTftsSl4ovNI85thYbscqvAyeeh9qxvAN5qd3pljeX1xZ3VvcQusctqMxyESt84IAwoxjHXgZwaE2k2hq97N3KeraVqTtJqniBNMlht4GjV4SxYIr/IQSerY3EYIJwOMVWkvLa/26BDfT6XrUbW86xSzNmSIDcrowGDlSQcdDXQX0Vyumy2+oXMeoXCx+Z5EcSwrLyQBt5CrnPPPSnXmj6Tqt1u1CxWV9KibZvYiNQyjuOo4wB7dqan3NNkQx6paaNdG00HQgsEaLLcxWUa+bjbhW28bjwuWyfyqaW6+1aZHbanLPZalfpLtSAf6kgEklwMLtHGT1biuQ1vUnub7SLvUpdSEMLy8aSzFVPymMOFOAcZ4PBGe/Wu0+oar4lf+1NAsb61uZBBA/wDaW3yLU9SUXP3hyQeTnHSn7O+ovhdkbmnWwn1s2GnanBLbWcUS3zhGeaZiGBj3fdQ4AO4EkHOKk0rTHt/EF7LK80trEGjtLQOzLAjBVLMzHcxO3liSSTW7Hd/aV1KwsUEBsZBBHhgUZtu4bQOoAxkdR0rzefxBq0+srcSS2x123k+xwaVDmN7li+Gy7cBCjA59u2aI8027f1/X4DVt2bU0OqXZ/tBdPaLX7ZjH5AnBjkRWIVwWGCShyCMc8GpdUtIvFOhX+kalbvp1zNNAjXV6qxNK5HDQ8nLEJjb6VQOp2+racmoXMeu2d7FdFTcylQ1mA5GwKSAFO0AgZPI55q9pV/p15Z2Nvdpc6jc2Nx5jPdQsrNKCcODk/MC3T34wOKbTWvYe5di0uCHwtaRalZLaGJVgkSQpKVVflBLqMEYO7A6E57VW02CeJGtEm1K4sVRTbXN7iS4hmUkMWC8AggEYOCCKjttdc6FD9uVr0teCyaONcs5ZtqMfpj5iPrRKJIte1O5sNSt5LWziUR2qxl3RsAkdQDk4+mKWuqY1ui34SvdSlsI9M12yvrwrJIst9cW6xxOu4sGcFuo6YA7ZorNXxJqUjaXcyyxWtvI7R3CTw8S5OOoJKYB6c5oqZxne6/ATVjC8NeNItQ14Whsrq1ty7Q7ZIiArDON2fXFbsmsyxXqu88A0+aQCOSMk+Wqj593HB5GPaufml1Ga9j1CPU7i40/yVuFs5rfzGXCnG3HOT/OtDwrHFc253z/Z76dt72swUPH6ZUdPpnPrVSUdxpvZklxr2t22py2b6Yiy3c4SO58vMWwDiZmX73GMZ6YrP1fV7rVNQszo1pJrF7ZNNCkW8RjLrt8303AA4zwN2a2tQj1TT9UtPs7z3aSMqeTGgjhiUfeZz1JPYZwKz9YQWvir7VLLJLLsIJUbIbccjBX+I4/iojboga6FXTNL0my8YTKslxZXiWpkvY5APIZCvzBmGQSCeo71P/wj+meGtDneRxqFvEjMI7pldfK+8MhhjAPTj9atWHim28R6Jd2mmtKk8kckBkkhwF6jzAO/Y4OKrW6w3l61k+oRzfYrdRd291ZBY5TgAMd2RsGMj196d5dQsupTtvFGix38CT20Nr51gscU2wCKWBidsQx0G76Ywc4om1bzzeab9obTrG2iDWt7j5XmBGV54xkkD0xWjpktlfyaeLDTLW/sYVZobiGLatvOvRWT+EFSxBIxk1V1S3TWk1iZPDNnK1ioltZHmKrNIxGY2TIOevTg47VSaT2JvZG/dpfWYW5t/KbUP3SqDiJJJyVYrnsDgj6Nml1u81MPHbrYyafcS2wuLv7QpHkMV3FN390EMD+FQC0j8U20QusWV5b7JLmFSGMLjBC59Oord1Ceytf7Nh8RXy2mlOHtzHcHKzBuQfMPKkDI9MVlezXcbdnc5OzSVdJiFhcsIvs7+a8KsxMp+4gUc4+bP/6qntNRfUb2ytrppI44A1xLNLEYs4H3QD6HBzWvFLfaZrNrFrbLBpbt9ktbXTx5qTA9HaQgFeD931qaz8H3WkeHdUtkvrWSO6uZjbSQSPLGkbEFThuQ2M5ALDI4NU5rr1DnV7C3kMUGqyajNdbZrrEFvCTgM5GBtHcnBOPYms7wjaMNUlu95iibfcT3I4VlU7RGXwcLkEkDnpVWS8tLvw5HeC7WXMsE9rMyE/MCUDY6jB3Aj/arU0rUbTSFS38lVgaRTKkfCYY/MfxPb3paqNinqnY1742ey2m1CS3doxvMsQPltg44/wA9qz9T07w+NTuNa124+yz3nkxtOZiokVRhFXP3RwOB6VB4o02+bUJI4lW5s7ht1vageXGYgwDLu/vAEk/SnahpmqSy2Fhb2ej3enxSMHW+CTfal3AKiEjcgUHczdegFSraO5DeiuNl1DUIdOSGXTYbOaeYiwW0ufOW4xgje33ufoOnaotHtbCfT5Le0Wwuba4E0d4loD5fAKtHu69T+uR61a1CaDU9P02bRJbhPsdy0kQEO51dC0WNvXaGVsevFQ7LSHQwNOk8qzs5WIJYA/aFlJYMw4+9nOapPQqN73I9N1TTtPi0+aXTIILWwtRbJP5fmPCq8Bdx+bGOOtbmh6rc6tb3FzJplzbxKD5RuCg8w+i7Sflxg7uOuOa4/wAXNcWVtpsuvvDFcR3ge3nEgQSMWy0LHpsPBI4qwUm8q6vohcNe20RhWyjLRs4LDBwv3h2zge5puCauNO2iILg6lNe/Z5dOjVp2MtzqZhEMNqueF3kZdmIHH0rpopBpVtp8Ekkt9DNIwEipvWM/XsBnisjUL231HVb60v8ATrt2isoVCSzbbWRySXwoGd69NwPr04qPWF1y0+wR6bEkejbo4ztU+ZGB3K+nqc0371k9BJvU1tet7XSdZOtWCxRzzAR3rs5bIOANoPC9B25xVWSCHUdWuNSka5shEkbLcbiu1lPy4ByDkEg/QVZ0yPdNeTT3MN3aXEii3L4BMQXkHPB5z+VW7uG8VJABAbSIEpEsY4GOw/WpvbQtRG309nbyWkxfZBM37somUJHPGPukg45qkt0l99sisoLjTrq4Ikjurm3EsGeCSOfb2plnFb3LQXNzcsrwRPALTYRH8/d1wfYgj9MYrQvNPN1olzDczSwTeXtdkOSx/hCDPOegHWjRCXcjsrQx2lw9vcy3V2o8l52KmMORlsAHoMDr6jriptRj1L+xFh0+BLyf7xUyiNiB6Hp69a57TntLHSfs8c8unXFywSO58lwZdvZ1bODyRxn1rZ/euYbfUJI1uIkAjvF+VWfHDbOmPxzmm007i2RkSXTTXElsWnia2VTNLaTKrJxl1lB4AXOOav6gNEmZLqdElSfyVnvopNnnGPiNTt4JUnOOBUOk6LqMLu2pwJIAmY7kH94X/wB49QeeDxRq1kPFVpFZxXYjjVTDd2aOEw3HOO44/wAKbavuDV9Tas7JNOee8WY3GoEFmnbC7x2HHA6AZ/E1zDaxdSzzrqWnXtpol3lIpGRTPbSo331HIIBGQec8EHtUVt4k0qKUwefdPp0CtZ3dzcSeS1u+flHlYJJbAKt0/Wl1A6ymn20OmS21rAjLJEb1POjuVPRCy8qehJHtQo2eor32KH9qahYeJp/DfijXZNTtTpsiQNFE3mTmZjnIBw8ig7QGUAYAA9e68GzWq6bZWltZXFjEQFMU64JUD5AxH8QAGc8/lXHxaN4y/sS7uWj0y6nXzYXtJYzEwjccBWGMqG5HOcMeasy6lceGHR/EFnpchmCpFJG+xxJgAfK33oweGccrwTwQSTSkrLczguXY6y08PtL4wu/EV1eJbwW8KRwqJgoPy4k8wH1yMdq5K81lL3WYtfn0e707TrOxiisrwHfHcxyPtfdjr+8OQeCoxkc4rstUdm8K3k2u6PLeTiIvLp2mO0pkKncq7sAjkAE4IHvWbcavY+HPDk/iK20eWC6lhiuZ7Oyi8qSRpSFVHAABYFhnIJ4z1rOMn116ES1k32MeTxdo+reLW0/w/KLaXyo5W1EwAtMuOOSBtHZecEsD6Vl+DfFn2/xN9msbKPTIYdKWW6t7RfNt47iSTdH5SAD5yjZc8gkHj5cnW0G2u1u4b2cpcareXmy/uZoAJJLbYxSMgYUYKgdB29KXX/M09IShEbzXCxrKwJZ5X6KAvOADnpz0rS0b8qNFTb1vsatjoclvr0Wq6jfyTyyxSLEHx8ys27bnPCrtyFxwSeeai1uzhgk1OQyX0yX6B51WUt5UaqExEoxgAEt3OSSc1l69fRaXolyPts8UlqhW71CzjEstsARgBfck5z0psXiO0gv7DU7/AFK5gs5bVB5d1CABkBVf5eQXJPy45+nSbSepeiDTrEaPYNDZsYdPZBIqM2Ng4Zt/vjOc0ukaYH1FLjQ9XgstOkl+0G1tYf3kkwIz5jH7yYBwOO3UCrFpGTqqGykWWwnIZDGP3bx4yDnp3IzWJJdQaULqK/W5tAZz+/t0ARImOPMx3UEDI6/Nmr1fqU0mtS94nb+3HvBqFrLDoNluaLUraVDN54xymM7EONpPXimeJNZ0c2ulafqmn339pNAiJdLHlwndvM43Z4OfXFaNxGsVlZapesJoERd/kqzFgRhGBTqDkZByMZrmb+71LVpVTWkiso3IXTTlQEkC58ptpz0G7OCB04oik7dkJrW5ra9cWl74DtrrULO4EFlcQwtHeTGOWMblTcXOMtznnrzTLBbm+tLnTfDkP2BbG6e1jklYu4ULnzCTzzzjPbHrWrHoM88kk+tXX7iaHbdWUpDWzxberZOFYHncDx0rm7awurvS7mw07WbqW3eZpIbi3ZQiAceTu65AyBnIxSTVmk/8g3NXw5qs2p3tioSwtdMVCxuIJdzXQ2jIB2gKQWUE9N2QCelR614fvRquq6jaajbwPeIlvZoYTwAuQr9eecFuhx2qp4DgOjyy+FLls3ktsbudliLKQ33XY9AeRhQcfQ102l3TpokcPia4t/7RsAEkeJD5e3ko6d/uck+uaUpcsvdIjvc5XR/Et8Jb7TNV0x45IHFvFeTweQl0TnO1SOg7c5IweDxRUD2MfiHU/EEEWordWVyskEcbu8mZ1VGUcjAA3dMjB6E80VolD7TsPmktFqZU9/qS+FNV1OCBBfO6jYRnMSsBux9M8ityza6jl09dEs7WATwi5lmKgMo6hW5ySeefasCfUb/wxoMC6vfQX2qzO0flLHvEUYA2s/TK5FPaxhXVovEX9t3L6dceWJAGESkquWOB1UsCNoxgGp3BO+x02m6hqR1u4N4ZHtpX/dKIyAg7f596j8aSabf2DLeRzNdQzhEiSbyftDAD5S393B5zWNPc60I5rzTdSkvLKZ1WKy2hRAgPXcMk9/TrzWn4mt7OTQ8SXdlaawB9rjeePe6hfvMo+nBqbJSTHd2NDwxrGl3miSHzYLWaKQR3OJNsQkH/ACzWRjyBwM5rkYIdI13UHvrsalpVpDcb5JnchbhgSNgPfHt0HNaNjZ6XqUunxahdpcWl0hLRbNsVw4G7IC8qTzxnmsnXbHSbm9v7G+ubm2gaOOWSF3xHH3Hlk9OBjoauKSbtcWuxpTG20C/ljsrC5sZJ7lH+1IfN3xbh9/cenzHkVtL/AGZ4St9Q1C5hu7pppgwCkMrEnG4Fjy2BwBzx0NV9LfyLyK0gtkuNOSziV5J4w4Tef3e0scsOOc+2Kk8OzWOreIGt1t457m1ikEOspDlrWUNgqqNwCOqn+VTJ3Wone2ha8L3fnX0rp/ZTNd7WD2lw0okHJCSnHyvjnGB780/V/tdjPqyazpdrd6CqRvagrkiTI4bPBAOMnjArQvobfQdEuI7G6kkvXx5lzLgzTN3kfHVulVNZ1u80fSbGPS7f+0roO6zeY4QA9cNzxknH4VCfM7ocZXVi/Y3scM1hLqOkTQTXxDvNHMxKOy5ZWB49cfhiovDIs9LhvbLS5nlzO0zRjIIGMhlQ/dzzkDjPNWbrzb20u0aUp5ttuBQ5CSYypU9+ePwrmkutQj0gS6IbefWFkTzjfx7Q68713DnHp/jSSumN2Rb1fToNP8UyaeYC1nP/AKRAsOFUnPmM4/4EeR05HSmTrMoWa4EMkNqZFmtbfJeQ5AG4j7oA+b14q3q9+sni9BcwRrHJp62Mc4YBxI7FiDnkYVc/l3NZFnp15pekXcdpeHULy7lLxSuuArDja3ryTk1pF6K4R1R1Z0WC4+FVxYLqGrWjadP9qtruEiS5Ub8nb03gqxGPoT0qLVItK8TaHBHY36yXtoqmO4Z41usnhgJFGFc4JwOpGCKh0TV5fDlhFpyW5vBb3EGnlXl2+ZkDfITznGS2PQVneKfD9hbeJb7wv4Q02OzuLWJL+KZWIVixIPzHPOTxk8dBWcV72r8zFWjNpddR882p+FxYzLqlvc2mnzvZ6jOI8yhBkxy4ByZFBGQByee9WYljt7BJtOuo9TsopFkFpaWoVQ7Pu38cl85OPc5qstvqM3iPT9Rv47y9sLqA2VzYmPMVjIgyJG7/ADkEbsDnPPIpHsRZTXVrYabq9vBes0Fy9vBvhw4yJXbOUAJ6845q9PmXHzNTxNe2Jt4Uura3urWSTEkc7bs/0zgmqNxLJaRMdTinS2tm823uIQVZVYYGT0YY/Htiq3hrwpf2NlcreNaGOQ4it1B2RqD1yeT9feqmsW97Do97JYD7RcgqPvbwYw3zMsQPIA74498U4qN+VM0b0NTSL23vL7Ura31aa9FuqyG2kjAeIOMjbIMEjnoRwaztDfWtA8N3Vnb6e97p1uxkguEnWVpAz5KNEOV2jn3waXS9RgtYLT7BpNrM0iATXkJKF/X5mAzzxg9Kr+IrqfSfElo8k8lpb3SeaszBgQpwAo298kA+vPQVVru39aehN7K5Ru7i51q1tL+DbBZRSlDapbuTGx6GRyeM9cBQPU10msand6fdWFxb38AjlQwNHc79sQAHzjbwW5HB69qzp7r+0J2sGDG9tyBFJJlFJPIDKD1z3qxM9rcm4sLiyuL4JFkEsADMD8wVcbg2enXIpvpoV10NZtbsh4lsrTbdSI0O1WWPbASepAxyT161dvrKyl077HrTxyJdT740EhRt4OVKsDkEe3SqNzbtcaLY2Fk0umzW8okaIF3YKM/3eT1zzVDRrjTYdRuLO4h1OeO0xLbG8cmVzk5wowFA49SfWs7LddAvbRmlq6Xlja2io6apbLkvJcKGdcE7dpzjdjgnjOKof2vps96r6nZ3kaQFAMlxA2/7pQjG7kcjtVyGYTaXHYwLdNBO7wy3SkE2+B8rFuMc9TiobTStWju7VXn+3WUZUhZH80AZ+Yg/3sdCc4pq3UW42D/hJF1D7HJf6a5ZlnjjikwQm7A+Q8+vB9eK3Vl0NTeanFdQJeRMEujA+9UPQGReoI757Vk79PXxZNc2iJ/aLcTOU2qEVvlXLccZxxz9atT3Ehu9RS306GdQkgmW12sTIFJCtjqxUAc+tQ9fL8B7mJr0Nz4kki0/W4lktjJ5lvJFLs478joOK0LyxVNW0vT9OYSQwxhWgDjCgdh/9esPw1c3kel2R10G2tpXwtv5amRgM4UbsFRjBJ71peFtB1S38VnVprm2UDessIClmTGUXJ4Tkgk/e4xnk1pL3dL7CbOs067lbRpDZStfzWros8zkRrPyQ69gCAOeMflVbUPCl62q3cp1SEw6jp4tbmweISLG7IASh6gE9fXjrxjWtL2XULfWNNukX+z2iWaxvYh8rxSBlIz08xHDZGeQynHWsrwwnimwv7qfxDLZXNrbWq/ZY7AFn2xg5DBhl3K+ndeOtc6k1drQ5lJ6/wBehmG71vwtZ6JJqOop5FpPuvbhwAY4lQqkAAH7wsxUBup4yOtX7yDWbOWOGZ7i40y4jlnZhIMwkn5YDk5IxnjH1PFVde1XT9Xgs7Sw1CKFtRZLixnNoZYZMMGVGXHfBB5yOTxitG/Or6v4PAlSDT9bnXavmIXijl6MDjkEjkEZA461Tb0bRppdMrQa3My6cZNPmSCVjayyXDeW0JyNgyCRuJxgelN1a506CaaH7Uba6DeUkswJMcrL95cdMDn8BWFpPhHUNN8TxSSag19pQt40uba/33DLKBy6E/Ko3knOM4JrV8RaXY3OrQvdNMNkeDGjfe4GSfQ/Lx9aq0L6M0hc5bT/ACdAhFvpNk93Y3jq9w8qEeYQfmZzztAHbuetdPfW0dzfmW3021vJJ0Ow3D/I5AyOPbAG4dKwLs3p8HarLqsTKs9xJcLDY7X8mBcBY8Ejd3JPYmrFy+navb3Giw3Oo2t1bRRW7SvEQULfvAQ3Rs9Djj9Kt66lJ6GtFILfUojBcrbWEKC3k0wRokaErvHlkYJYNxjoQaytB1C6uYpYNTgEF7PG0rWjH5o+vy4bsAOn9K3LjSYby4srq6uJz5Sqqom1UzjljxnJx6+lZGr2c90mo6hMbe7uLR/PsIYQN6FcFhzjcxXrmpTT0G9NjQ8OTFrcRWqFogSDI24BT3H+eK5nxBJdNPKFsbea6EksSAyNGrW+S2VOOJSDj3xTtTuJ4LmD+yr2CFbu2At7JQ5YkgM0s5AO3B4BGM9OmTTJdWh0bWrqbxRMotvLjliMkbyFJwRuKsoI2HkgHpirS1uS2Saab270mSwSWDU7O7m2KHUlVj2gbeOx6nPTNaFrfvpFrc3c2j73ilW2eKCTdiMDG8cDGPT3qxBDPAb26dVW3dWlSO3kwrlsH5ccc8HPWqmma3b3emzTG3jhvAMrDKxAmfHTJ69ORSbvfQYyy168/ta7+02sl1BEFjsfs8J3qrDJ80k4wexHpVq7sr/UdTsL/UpdP012UwXFsYyXl+fKqx9Co5HQH61U2yapYz2mqWFva29whMyKpCsijcQxHbJyMHr0qfSbm2sLZkhjkNu+Tbi4fcQxPZ2yQuOh54J5pPTbcTM/VtP02Hxa9nLfW9lagJdCFSyPIf4V3Dgd/WisnxwiaVq73qWd3f6jtElmwuUKrkgGNF+8SDuPTkdD6FWoucU0xe05dg0Wx1K5lW/8Q3ZeS/h2LZmMI0EYb5SwzgEjAIH481hR65YR+Jv7PvxJPpxYW8UAgAjTDEEkg4Zc5zVvVL+eHTNNuNUsYzcpuW4IlDSQx7iFJx6Ag496ij0QW1lPH4g05D4Zi3Xcd15p8z5sEqVU5xkZ9sd80KyV2G0bIfZ21zaz6podlPFaXJne4UwyeYsSKR1U8gNnOPpW8ssWs2ST3U9j/aNisscjSqAhJU+vIzjJH1o0DS9OiS9Ghy3FtBdwxSxySfvVETKQjKrcg8EY9h7ViXOiSXljFc+LookexleSWSHKK6Dnc4A5DYyQOePc0rpsFfoXvDUc9hoN7rcVsusXcSxv9hsJNrI5G3qBwNmCAATzU/iLQUudJt4oLj7MN6zXE10EkKhudrc4G08dR0rG+F1nZPeX11YanJPfOHZsF49qYO3YDk46DcfoK6Xw3Ml74XvXtNzak4CXMUg4WRRgDphsAYJok2pNijcstYLqltrV/ot9byteWaWSSRgrFHJHwGHoACOg65qO1e70e8svC+mwRun2FpprzcBLM+cZAz7EnParfhWRIdBW2tIoVjO9iyNlC+fmAJ4Azx+dVfCuoJqGu2+q3mjzWEptiHvpAPKkUEjZnP7vtx1OajXXsitLFbTb7Q5PF62ceoA3MJSaaXyt63L7eFR8/dUE9QBnOM1sXVre6fKbLRrKKaLMlxPPJcfvFklyfukfNyOPSqclnaaFp8S61eaettJdhLKSzs1QqjZO19vYHo3ual1GWTS/EKRwazbm51OVPssU0Tsw28z4YAgA8bc4AywFDd3oTe1rlTUYZ7jSbDRNRuyl5e8748AwlSDgjueOnoa2Lu0vrPxDNciaS7Roo4Ps8hAwh4LEDqeKqOPD8euSfYoUv9UWR7wRRkkmTYM89Afu+2afBLrkGp2rnR7O1s2wsy3E4NwpZudu0fwjn5utDZWnUz/Flpd6nqqaboGmW4lt3S8vtQuiVAZV2wqhz93Gflxz1NdW+lXbmB7LWzDPArK0ckIkjZieTj+EnoPQGtDULqztWiaVVfzh5LOeh77azfD+paffSyHT5cnzyshzjnbkD8qjnbjotgUd2QePZrfStAku5J2tY7SdJZntYxJIjSYAyO2c9+w96h15n1Hxd4QtbXUxDPJM67IVY+fsUsyuF6AZH3v73Tii5tbMS+I76+0sfY5wm64SVpjcAKdzGHlflIGBjOao+BY9N0q7a2sL0z/bXk23LB/MmUDBZS2DjB+8px6ZxVJWV+3+RnLmN2xn03xPqMy2Ny0GuaRdfMIz/rCOHiBPDq2GBHfHHNXlnfVbKRBdxI1vdeXcpDJuV8KQYJV7jkcHpgVzmk6dcHXYLOCaO3kMwnkkjUMH28AFsZGAAMnj8arxz6adU1G/kkjkTxJqJtrMab5m10iG9pZW4AcnnI/lmk4q+gNpOzNW4vNT0u6FpBazXlncq0cUzSDfFJ6sWIJXHUc4GOtZl3prtf27adN5mr2z7w5TYpXA3IvfOORn0PrVq41W28QeEItW0NRqstjdKZIxIyyjDfN0/iAGQDkEetLqf9sWl5eXEVvG9szCSP7OokmMWRkqpPLDJ79jjpVRdvJmi1MN5NQ1TSLpLeRbKe0J8/ZFksrMScION5IwT75q3aahB4mtm0+aJ0uok3RiXlxjAJP14PHetyO7Jt7q8hdYkYFY7hI8v6Zcd8Zqpour2cVlqWp6/cWVnNb7FkuY1G2QEkLwOck44685qubS9inZHLrpphvmmvjDDIsgDG6jZt4HIbjrnArutUi0yNl1csyzDHKllDOeFyBk496h8WWem2MUE+qXMkTXTCCJY1Mh3H+EKO/c/nVbXS2ly2Fw1jJNZwxqrZAOeeNynoQcEfSk5c9mJW6F2+tRCmdOu7S1vyWczOzGPO394DnrjOffA+lZ8WvRyvagKl1YyRGOTWlkEZhn52w7SASW46dN3PSpU1Cxi1CG1tkN5cTjz4omXKtuGQiOQdoHJ5B54qvPZ2NhCRb2bxT3Tl0t5WEiRPJzK6ADg9Mt7cYpJdGJ3exMt5PPaQ3WrKsejtDNb3NkycyMMMshOc5+Urj8c1o+GdRlM6RvZTQ2cyGeNmkLs6nkMxGcA9B6CsTUb+zs9Ajt7ieWKcyGSNwRnAyM4bgk88c0aTo9pqqypd3MtvFCpmHk3LRx/Nj5UZTwMduiknHWm0uV3ERvFfXlqLzW3MGvXkb2ZsxIHihfzAI5goJCnYDnPXAPeq18L8wPOknkNbylZFUsr3KkYUMR90qRkHnINPvf7K8NywXulxEWcM6G4QMPMYHI3F24KA9Qo3HjBxmtmz1i5vtEgvtPtoNWlnfbhmESqMZPPYA8ZPT3p3a1S0BK2hJp+j3FzdsdbisZ45H3QtErAxqE/jJOS5bPTgAU3w3ocNymrWl7c2uq6ddJtaGKPZCpB9Scs3I+btWZC1jp1m0N7qF1cySloklE3mEA9QSMcjJ5HX0rp5T9kl8M2dgLlEmut5CRgqsaIAyEehyOeME1Em1oE9Eauj6baWOkjS4BINLMTIsLtkhWByPqMnmotD0dPD1glla38s8dqjywyXEgYhN27aW64ABwfbmoNNvLoHUDqsKx2yX8kNoyne/lDaAxx1LMW7cDH1rWtniS5xGqvBJHtPRtrgkED8Q3HTOawbepm1bVHKLp93p1/YNodrFeaZcF/tMRlVPszOS0dxH2OCzDg5wx+o6qGRmtl+1xmMg7W2yAtHwPn49cHkU0rsMkSOoK/NGCmA3TgemMdPalLPJaMbKRUuwC0eRkbgO49Mjp9aHLm3KcVuR6fALG/mgYuUVGUBm3BwR39c5B/CuV8T3lxba1p8VrbReZdTRQ+ew/eZIcfIO+Nuc9AM1peJdbaDV9PstPdZL6VfPltYW2skW0gtgjhd4AGSKjazZr46gilHubYRsrqd6YBBVcfdY5OauOnvSKg29TmNU02+tBdacgg1C+EIRrSRvLV1bhl3djt5B9RWoJtPs5rfTZJkfULKHfFBNKQ2zuR2PHcc8Vgx3N5qusvceRcWt/YsBLYywbmuVEeAA2dpUk8kEkY+lRWmnm00i5uLq9jh1y4AS2ljthOYwMlkXrx2OMDHAre11q/wCv8i7l/VJZLPRZbeK6na/vJGu2ZECKisR8oJ4CqOPU1HpFg17EdXs9SY3lsHjKsoHlgj5mKdckDAJ44qzpk2r6hfwoYbeWwjhCSW7xeXIcj5m3HgBcD5e5NSyWNvbvNLpN8ov5B5KoxDBcDhCo6Zx3/rQ3bTqBiRNdeJfDt62jXUP2q4DxXd6YvLUBTkoy8kMVzzx2PvVm31LUbieNbSOH7OuYvJuoNyEYxw38J9+Qe4qdba51bSs+b9lZSVlhgcCN+nzY9R05qWW11eKe3tRZRfYZZwrSLdb9sOMqxUgEH6E4JHpTbWwrE0P2q3sbWC7eO1fJjVY3B35B/wBXj05P0rKuLG2t7eAWlteag1ldJIiM4B3A8lj3FWtQsxrlvZyQ281vcWMsieTJNxE/Aycfe4wQff3qybe+KST206qy/LKqqR5h9V9SemD+dSnYqxzut6nJaZkvkndjK1u8EJzuTOXfHdUyATxzxmrFjpS3WmXmn2l5FeOiqY42/eGMsNyhs9Mg9jTbbT9YbS/sdtaHT9MtctFbS3ANzcqSxK+Y2duzIHTB9Rikl07RdW067sbC7bT7mQrO0j7hLEyA4bcDy2e5q7pKyI1tcit1vpJ1u7+O2msoZ4ooJFQIbeNMiQsCdxJO7HXgfSirFx4hgW8+w3tok9vffuZLqAFU89QBIoBHqdwIPO4e9FJq+6Azbx7KGbUY0tbqG9tMsJHX90WbhQrfxE9hj1rcFhLqtpZXbahPbSLBtKxJsCjrnHp35FcjY6SP7BmkOnT6YZNsUwmlMsrfJtyuTkYycVvw2Vzo9lp1jY3hFjGpjnuJR+9YEHkdgQTxnsKiXkwSdtR9zJa+H7DT7e3nuzJEvmCe4w814oyWBzz0PA7DGKyru3gn8DoNIuZ57UztKcOzuiPyVOecex7Vm6Zpgvo4dKur+VtctHle2kS6BLoTyxIzjAAODjkYrd8ORW3hwT6apkbWbkGSWeY7vMY9CxPAPt+dVZR23FHSyQ7OoWGgyvZ2rG6jijI2kRs7Hj529F646dadqWoC38L30WnwfZb+SRY2AYOsr7AzeWRyVydp4rW06zm1LTLefxJBBDeTMVhB4DjnkDue9Y3hjSI4E1S4ttIkuLuJzHFLqbiNMAnhBztjHXceW56VKkuo2tSO40CZdHdpbuZXYRmC3hQHy2HYZ4HJOTil1HSLPSrrSdb1ayv3kOAbKAeZao33cyM2FB5BJ6k9K3xq0kGjxmU219qRADR2f+rkfqAp9MYqlrukHWbbTkmuZYfIlE9zcSueMc4QE7c54zjjApqbb97YHHQfc6Es3iy1lhSRImspHD7j5CSKQEbZ03fMcD8QKfZlboapJZ+JZrsLM2yKBwzWikYZW6HaSCRnpj8aXX/FdrDoUGoaZm4N3PFBbxlju3u2Bn3wG57nFYN1aaTc2BFvbbLwTNu8pjExkyQxz3HXrSim9xbs7GCC0P2e4lu55Xto43mlJSMXGAcOzADdj1zjgVjan4kKMj+H9PszGjESiEqHVP7zYyzZJ6sasWrSTaI9uLVTb24VI0ZSwZRyRgd8j9azZ7D7fFb28t1HaXRmLywCIoJ4yP8AVSrlSwODwOeRiiKV9S7W1sbtjcXl+FkmWI2ciboSyj5CBwD68965/RYtVtNWeUW0GmaZG22Ms6qsrHOSATyf8a0NPaK60/8AsvTbZIIYPkWK7JCsuccd/Xuc880/VNNs9Tkha9jVk0yNhbG3IbyycA8d+RwTkjFNO10F9LHU6JLdfZpxOsUcmN0SQgHjsT2ya4bxNdQXF4kuo2NzfW+mwi5ivrRBGYZBIAY3UdOOcHqeg5NaeiQX+i6qWkY3OniNMuflWFQMgqOS3ce/NTeM7ewszFq+rNfwadGBNLPE+I2YthFKr8zE5Hb6mlG0ZES7mx4VuYbnVbG8S6jeOCQJdK5KkMc7Nwx0O7oax9W8MaroGsa7J4auLCOS4WOLTNOmulDXJD5kCxsQN+wn1zj3qr4yk07S9Ik07WNRuNNfVHWY3dtCxMRGMSSAc7iPlJ7Z5xW4dGs1utBfUjFqdzYyLJBJKuC04XCvkc54VvqBmp2d11Mpp3bix/hzW/Dlo0wtrezh1B0m3pZxuEnkQDezRgffUcnbyOc1DoUpuLO0PhKW2uNLklu7q+D5aTznCtHtB5RcgjaP72SD1rP0ywgv9c1iaSHR7eSOOZ4GV2ae3ll4DyIeWy4YkDA7fWVPD+qTNf2Woag8iT/6ZFqun/uTFPu4jEOMso64PUZ5HFDUV1HbU29MuPtkg8+1mglXcjwSRkqwPckDB/GltfDFpGgRraF1H3RMocKT3UMCARjjrXLnW9VvtCt7S4Nnq+sAs93bwSNbYIZghjYjGcAZyNpzxyK6zTrZzZW9mJLzS5o8PIEnRpdpyfLZzkgZ9MHjGaUk4+RpzNou+Ra2txp1nIbmaSaR/wB5JHv2OF3cnHyggHnqTxWL4ouLV5bfS7qWeOXWJJltg0YJRYgPvZ45xn6GtrUbGK/vLWa581zbP5y7e0g5BJPGe1R6VpoNq9xNp00F1M++eOS7EpI7c8CojJLUnWNmcjawRahCttqGlQSXmmSh4gfMRXI5BBVg3B7EkGtLxDe3Fxb2pubiGzvbl2HmIuxm4PyocEjOQTzWzp9rfXFhG2p2drBqTqyTLaS70AJIGxjySBj8c44rmdE8Pan4UsrqG9v77VjcEeVNcKZBFjpwSSDjr/KtVJNlJpu6L2nG30+GysPEbfaWvGYQCcB33IoLDJBAPfOarXstxb3mo2suhj7BKn/HwkgQyeg46H6Drik0i8uNR0eebxdZJaNAWmjZmUjaq53gjGASO9Jc6ymp6Vb21jcPFeMgdQ0BmKKT91gOCOuCDxTs7l2K2s2WjyaZaxzXVzpMdzGLaI+eu/bjHykg8kZG73yOas3Uc2l6PeaRZzGzPkbIbmOPbsJGF5bJZj1Y9epzzRrjtavazl9PjezjXziYGMgG7+BecDJ69RnrS+HtRsdVC21vDdSwjMsU7uZihYnOWbkcYwM+xo1tfoK2pHYXelPc6TZ3So155e4GFf3ZYDnn0z/Wty8u9RlSXUo763tNCtrSaOZ1XzWiuRKCjmMDlQoA/GsbwTYy3Ws/a9Q09SSDCkqgAKORyBwMD860INDaHw7e6dp+pwz3Md5J9qntpNxyrAFT/ddQQcevsaU+W9iKmrSNbff6joQhu7qGDUyFYXVvGwQYIKnaeQCOoPril0uxbT73UQ11LJFdXnnQjAVIcAZAx1yxYn247Va1Fb57K5+wSwrqEsJ8uWRcxiT+EsB2z1xWZq+uR+H7Own1FP8ARJXP2x1ZttuViLtIoGSQNp4HXIx1rHV6IPdSNXw/ex67p8d5ZhMpI42PxnY5VgR2yR39araVA+lvdSy6nPeiWUyqZ8bonP8ACuMfL2A9qZoltb2+nxTaVGyWUwFxGFUqW3jcWKnkE5B555xip9ds01bRLiATvb3D8R3MLYkhkGcMB3wfQ/zpOybXQLK5la3pDaxr8Umpsy6GlsYxFE2DNK7DcSRyoVRx9T0pNOXWoNVltLmSxutNRDidw6zqgGAMg7WGBu3n1PNZLRalcaZcwWOs6tNqenLDb3JaNY47ox4LtFvHys2D8xzwSMc1lTadH4m0nUZ4dPdtP1K+W4uYZJ5IpU2gEBSP4cc7SGHPGMAjZJ2s2Sk+iNLXNNunvzcpqK28k+IHMoU7IAM7Ih1AZuWPU8c4qPVtXs/CdlAbj7OlsiBQWYKOuMJ1JPOTSajLaa7Y2euWC3GJ1BjU4GFBIOR+HUVWu9UtLiGBrOK3vJcLiWeINGsi5BKgjIYAGrSbsmbX00NjQra4spZbpZNySsssfJ5Ujrg+vpVDS7W3bXLzVdO0/SpbZ/Mb7TBM/neZkDZsPHXPI44B9K1rvN9aiSLb9ogHLy8KmV5b1+6ePTNcnYxJ/wAJdZ3i3L2lvFCyzRBMrIZHIUlgdqnKg59MUlrdieyE03WZtWnnjOiXdhDOivOk8ZDheV44H8Wee+B06V0+mwS2Ph6WLT2W6ls4JRGr5y8gUsqsCRjJxxnHpWX4k1W8udW0+0sbm5heK5R5ixKhkIxtU9GHOT+FWr5L+/u7WPSoJZIPtBW/n81IzEV+6+043rkZIHPAxRLVLoD03K0WtvLeadFcQG31B7NLm5t+qxl1A25Hv6+ntTNNt4YtesLnUL26/tC5jkitrIy7IpEz1YAcn5s8nriptCk1Ce41CfVY0SWR3jjkjGP3IOEP0Jz9etY+r6Y980kGqXEDXtvN5ltLMGPltwNoPHXH0/Kmkr2B9mWtc1eK3kfWohqF8ImW1W3igJkyrsrLg/dAIJJPYr6iqOo6gIH40qKylvFIR5VZt0mPlzgdM49q2r/VU0i1tre9umj1Kc+VbjDSncwwNzY4BxjJrI0LxH59mdT1qe2tY45JLUBuPPkX5t0W5d+3BAweRzRHa9hJ26jLuLVItIsm8Q3EM08N4k8aWyGNXdcFEPHHJ646ZoqzqFsniTTkuLmSexZw0cbJ8zwOzAEgdsqOvain7r+L9f0CV1tqY2p6zcT+Go78Xi2O1POO2APtYNyDu5IPTt1rZguP7aisZd1vd2xiVp327NhIzn6/yrm9RsZ9EE9zDqMzrFbFVWWJSkA5JkAOd5yehH9KgszqUvhU3mia1LPdTMIYDfGO22ANmTA6MSe5+lJxVroG2mT+Ibae7vki07T1uxbSQXEVwzrCjBSfkJ4Lkn3HStKT+1tRSK91S1hiuIZnnR0/5d1GAkcicFjnJz6VX8V2eqvY2UE13YT6YhjS/jYeWUOfndXIHTOR3HvTE06fSLBLTQ5BDYnmXV7q4V43Ug4QLjnB7CmmmkK+pXMOt6TqGk3Gopc+Jb8NLJBJC7LFZhv9YmMYzzx0x6dMaup3MeuWrtNemxsYwFuAS3yxkqWD84ySAACOmak8HXNmmn3mnaLc6ZHelvPaO0MnlKDgFvm6HpwOlNh8OG5E8MTQ6raSS+bcrK7LvYZIHyjG0enfvSuk9dGhxhZWRc1DU08KxaPp2lW0k9q1vII2SPe3bbkjrnJ6dcCpL7WYYra5tNa067W2WHzRcmLckwwN5Cj7uN3QntVqbVdMsYwwt5JLmCJC1vAoeYR5AwB2A4z7Uy5/tk22refc22oWNwgNpGVGEUKdyMOOc4685qVZ2uh+hiaPYWepQT6XDYXTYxcQ3EqFYpVB+UKSOOvGOntirtvb6lLpn2mKyt7U7pAY4Fyz4PPPvz9aonxdqNz4buLS3tp7PWbeDfbJNC7LMgOCFIHBxn5etQeDb3WbQwWl1FHDa7S8zSMWZW6kFs8Zz9c/jWjUrNii0nY6PwtrgvLGa0gSC1vlBQRz4YkjOGxweuc+vrWNqV4LzXIra+0kzOow0kSvmNf94cZz+XrW1fs0YjnTTYNRnkbCSBFDJzwd+O1JPc3mlzSf2bYrIsh+0TSyM7rH6hQoJOSfugZNSrXukaWe50UduWs8X0bKqYKsw29OhzWLbaJp1i16sczxrcyhhBvIAb0XHIBqpa+Ho4/D15DdpdtHdMt5Ih3LvcAkBVblOTkg85/KsrQLvUG8Um3msJ0sJ5D+4aQPGGxkOv8AEmcZwOn6UlF2dmTc7Tw1HJc6xbWd3DbpNe7htDM4aNcYIzwAB1/CuV8M+Jhq3ibWNTaC8udIeF7W2uFjLKrKwUfL90njcDnPQ8dK7OxigtRPIhf7ZcWrWNuyAyLDuPzenb+I1TuZtO8M6JDFOdkIfbuVRhjj0HAzz1qE1dqxm03J32M3R9Mi8PWNhYtfPc6lA01xDLI3zOkjYcHqDjuO+Ca19ZsVmguJLGSW1uPKdo7mE52kjh19D/Ss/UzdXOmWM+kyWsFk0eXcxZbYQTgYUkDn861jfW9ppMcuqSWUSyBY2LygA59MkcEfzobe42czoVna3Ot3VpeXcN5rFlDGJ5GiKSPFJGrgMcbXAdVPUkfnVuCN7bUbe6hvdVuFsx+9s7MiRHDnAZ09FB4wT2ptzo2naH4igaNtRjn1qb7O6W8hWJ2UBlZ88qcAjjgjt1NZurXkKeNdH0fzNRtb6FmkthYSiNI1QA8jo4IXbyOBmrvzEK6R1t/aZ1L+1ZNYuBC0zTSQzMJY0JUDYhPzRLkbivqT0qrDZ2kct1J4dWLT7+aJgtwcvCCTkt5WQGYn6Vn3jWPhG98S6lqd0h0HUr03IiKFm8yQAlVxyBuzjpjg8VpaJGiWok0kWxtZlWaMzbmZlYcZB5HHWo2QRWlkjK8HWer6hdWlzr2o30d3pUpUgXiSR3SkMcSxIf3bjIIJJJBwelWdf/4SHUisdi9hbxyXHl25vJSoULlmlEY5lYjG1W+UdweCLGoSwQ+Iba2srZrWO7eO/wBQv1hYxMA23buXgSEqCR0257mqt3pc2tXnmajJBJCkVy6W1xKHltt67EkhZMfu2HZt2CoxTvd8zCyeiKmtXtlcxaTc6vDpc2+WfbDPAJJIEjAZhtU58zAyfLOOg61saDZSeJPCsq+ILux1ezuWN5a39gGgXYDlcdCkincDn6HPOWzaPY2OtaPaXdml2zSxut0rhHt50Q5cr1ZWI5APUjIPFc8NbbWjeab4fnj0x3vDJbSuzItzcZJddvXYyhwRjg4PWn8S90SWt0dt9itL1LmC5kQWMkUYTA4MZXAZ3JO8EqeT39a4nVfCkeh3sbW9zeG2uXWRpJYmaFSMgBnjO5V+q4966mS6ttN8J6hDFcrfPZKbO4ERDsjZG7IHdd6k+5q18NjeQ+FLZdZtzHf28xtVZsqZIUOQ59MjGfyFJTcE2ti3KyM+48IvfWiQzZfzV8t5Y5C6urehbp2qvJo934E0PUL1ppb+MAYhyI1VN4DO3+6pJ9W4rttTU3NhLBG0sRlG3IJUrkj5h6HGT71hWXhr7NoEmmLe3N6J7qOWRruUSlURg5Q/XbjFSqra956EuT5TTOlQ6dqVtfpNd8brWOGMKsW1gCVYAZONu4E8jJ7cVFqMOmp4i01p0lg1Fp55UliXCzlYtrNLgYb5NuCepAq1qVkmvNYSRXsqR6ddCd0t5cLNKmQ0chH3gDjI9sU2/gW+hWNlfz1EhifGWVipTcD9Ccis0+5EfeLGmXMr2M01iLeWYA7UmzsUbiDyPT278Vha7pzauwt2aFoI5BFNG3KOrDDZXsMD8cmrWkCTTdMsbByGuozHB8jbtuQ3zMOv3j19qpx6Trmn6h4gFnNpv2uS2iGmG5O3dOANzTN1PPQdPwzTXuttFOSi2zmNJGoWXjqfVtJiGp6Hro82a9B2+QY8qCVzjHTJxz7Y57xPnW4j3rEXXavAIUnHI+v9a5vUdZXSdOtLbVG02fUxD9qvrWGUeYkDKTNIinAZVKM20ZOD0p+s6gg07SrO0+1WqaxD5FhqMFt5iRSsB5asoGQCMnPYAntVyvKxUZRSbNh9Re31ES3hjhR3EcJ3LtfCjAx1B3buvXNZXh/Rk0zWdctbd2EN7ItwF3ZWLKn5Dj7udwOOoHIqK90mx8R6VZPrE32d4ly8tvOPKZwBuG5hgqSDyQDyadDZXukTtNpga5Mtq0zW8tyGM8gbClfT5Mrk9wAaFa1k9Sr9jn7DULjXfAVheWNqlhNbk272tuPlTy2KhVz2xg4JzQ0ZWWCe1skvJp5PLu2LCIWo/vhepYnj2wc9a1Ybuwi8dPaywXr3V/YR3E1psxBCmdwZscCQtkFs9eOprOY2lrqVzZ63eeXeXc3lRLDEY1UkcBXySWYY5OOeBWql29Qi7qxUYWh1W9hutOnZZzEUnDFvMaIM2WIICAZPykAN7kVc062tJobnRnWa7BjYyXXQYx94kYHPtSW91pFmbxbzUmRrULaTebuVl3KNpLHg8Hh84z6VNqUN80MNnot3axaYLfaoMJuFyDxhgw7fr0ob6FR8iDTrrSLC5sNPgla+vMFodx3EoOS3ptAyPWnaVf32mTPaarJ9vvpLp5EmgOyONCBtTJAzjB6jjOM1V8PXUj3t3GlqDNEmUJPDPj5lHcA/U1Rns7u3F/4m1+ab7LabZo7O0YRq3zAHeDnfwRgdOtNpXswd9zZ0m9utcmvbWaFrK3gnMSRyOFeYKfvDpuT5uG9fWn6sDYTXc9xai5Xbj5Bu+QEZ5ALcEdF649Kzo9Oi8RWc2o/YtU0zz5jiK5Co7KAArLn7ikfwnj09ak8MrJFZw29l4gg1CzjDMhcgPsBI6Y4UYIz/AEpaLUlMWe/P2LW5tPuZ7m4IE9xpyDDguuQSxHHyqeOfTisXQ5hq2oyz6xpEmmWMcOzyrhW8sK6jBRumXHX+Lk810dnaufET6pY3paCeHy7hSqlSgzsKsB2Ofrgc4zTr6eyvLltDv7+W4eK5iukgCiPZ8u5UJX7/AN0kluRkUKSWw3ckvbf7HeA2iQpHIoFyN2GdANoCjsdvrj86K4G81Bf+EouZReA299OsIPmKquisAAAcsFHPIHJzRT5Gkrjep2FzaS3cAkkiBZotsiSLw3se2K5W4sbnSZHv7yaw1C8g/d29vdOsMcKE8qgyF3e/tWrcadbarbQLqUzNLKuJljZl3nZtwAPTryKwdcFmdEuLO9NpYWMASC2uLjbLLKq/KWVT0fjG7HGamHYJuyudDqiJfPJqmvTHTYzD5SW8U4aNQAQH9Cecgc80/wAOafZ6bo0FlB5t+JW8xJrkF9xPPmbTwMf561leHtbkv/Ptr3TI4NJs48Fp134VAApJP3j3/HiugvNZsp9CmnW9lt7EptNzH8iIM42jI+9ntik01oGiQrT2+lZS2tLF3kQLdyJGEc84C7h06dKrQpMfFDizuLgWFlHGywBgkTTOCQZGJG4BQOOapaBfWjavPpml2cC6esayvMJBI0sj/Mp2nO0YBOT3xWje6RfRwXV5awLcXrSH7OJDvGWPUBuBxRotGK6Zm22m3vn3Wp39tHNqMUO6x1CwHlBi/V2Ucl8DnPGOBmrFgL6w/wCQZbrZ6e935g2pkSwugYsAc/MGyO36VXv/ABDfaRPZWlqsVxJIzJIibTiXIyrA8gYIIYcflRYanexW+qPq9ld4ilAxFIrvMuSd456Dj86uze4k10OtOoJDqEcRmvQtxkxGWNfK465GdwPvimQPd3+q3en32hxQ6dt3Q3aSf6z0OPfNZnhjTtPttO+0xzanex3ILN/acmWjBB42446ev0pms22uXtl9i0i9WCymG15EkBfy+jL7EjvWfKr2Hd2ubVhFPpttObl7KKASEArKHTbgYyR0b271UudUt9Y0jVIWg1OxsoQFkkQMjupP8JHP1AJ4PNUf+Ef0Kw0+1hTSbUNY5NqLtiAZTjJ3E4Yk9z04wBWhp/iG5vL/APsvUWNvqSbspDJ5gA/vANyBStfUE3szX0rTo7e3t4NOubxolRVjgM5ZSB7Nk9+T71Rm1C2sdXt7ZdGae/u5vLZ49p2ADBkZx0AB/IVlXV/e3V9e6RFZ4nkt3WPUXi8xChHzK2MEE88Z9Kdo4i0q0jkJhKxhQ9w7sNx6fdx8vpjmmo9w8lsdHc6xpOmri5uWtAxGFdOGGcDGCTz6YrF8TapNPPNoVtp9tdaswW5tbS8TEU6DOTknBYYJwSMVRlW41i4nOsaJI6XQKwXsi7rcIpyFjKdH/wBo4PHbpS6Zqfh1L9rRV1Ga6tjhJLoPKIuMERk5Kq2MkdDimoJa7sm7epXtvFGra1pmn3Ph8WiTzSpHdCZMkKAAxUdlzk/yrQ1TSNQ1nxBanUo9Kh0axtWmfUJlXzEk5OFHpwCcjHXnPFal9YullKbLUJNHxs8q4tQi7B33Z4IPTHfNMJ8RNfJaSy6fLoksbGWRYRHKWAwEZf4gen4/mcy3joKSfQa00+oeGrW58Jz6NqckMxPm3CuUWUA/MvGdxyeeKt2cUlzJdxT/ANnDUIwIPPjlSSVOAXBj+/GRwSDkdKj1Ntdk8PWsekWlnZ3SON8VoqrGOg4HT1zxWG1yJPGOlXt3pMKX8l7IqGxjDTQxhCGe6dcKS7BGBycKGznpUpNoltrcv6ZpWoNrrWeqXenRaVYostvOLxWvpFLffaMZ2puyOcdAAeaj8KX93diwuo7qW70m7WSIxSrgQvGx3SIf9rPI9SfStjWbBrXxHfu1vpMRn09Ybe9ecPLdc7tnljpGDjOcHIHXtn6RqsSW8WlzhIJo0ETCFQIo26bVxjj3AxTT5lfccE5at6F57hLcXYuLqNbWJAzLvVFDPkRE54+bB68EjFZOg3cFg9xZ3NraX/iXS7F5bgafGHYo8m1YeOkh6lBkD9Ks61LCmt6eEFncLIBFfGVVk3RDLRbkPXDg4bt83Bq5p17c41G4+1QmP7QhjtriRIUXJ/ePGQnmMx4xvJXLUtbCfMrWMLxSNR8QaJor2v8AZthrM8pi/wCJlI9tJujbKqqFizEsoBwDnrgCtFoodONzqcelNd3SESi2t4wGiuHISWWInHBBOQcEgA8Vq6z4d02/v7WfUIkkmtpRLbTxMVcezEcqDjlQQeOtEF551lPeTRy22zesglG3btOCR6jI4xRz6WWxcFdlbT9ItoPHU17b3UFpHeoFNnBw08oJd5H9j8pPrtHtWzNG13qOi6ha381pYwxSo1mqgi5Y/ddgehGCfxHvnn9O1gyWkWr2ljczmdkjT7NFhtgOCZHbG1FySWPA2ntVzw8dC1DxLNe6Zcme4miNw6DeAVcqokGRhV/dnA6kEnvUyvu+hM+VM6h5DGUeSRw5+fLfNknjBP0701lUNGd69AhY+oOB+v6ViePNZOmeHLm6tTbSXkk0MMMMzhVd5Gxg+gxuPHPFVjrHmtb3Cqq2l1FJPLcTHYsUSgYOB7DP05PWoUG1catYfoWp6fpeiXlxEkthYXt5PftLqEoVg7zCP5U6iNmGQT/e4zV3V47u6uodPYQJpsqTR6iCWE43IdjRMD8uHCg+xrm/GutaFpt/aeIr21bUNG1G0Szju4XWYsyMrxKI2I5LqxB7Y5q1bjVBDqmr3sW5rVZrpLR5FAkIjOxWbO1QGOSfqewq+XTmM4pcrMrQtBaz1zTLvX/E14PEOoBYLWeJgH8z5neMAqQ8PQYYcccjIp9tCli9z4j8Z31xcf2cZE3XKDkAkBY0zkk8AZzVzSPFWj3cNpc3DRQXOnfOxugN9uZIwrKjEZ5zgY5IPTpVm5uNQku7kW9xArRQSzM0hx5EmP3ZxjkLk9+tW3K9mPl1dhNWistah0+dNPtknvLfeovYA0kNu4BkTPJUkN07ZPTNZ93Z2Wk3lpql74huo3s7z7RawxTGEGNSQLbZzvTb8pwOB16mk02O30qaWdbgTwW2n7S88m0b+GdizHqWPJPpUXhO81r+2kk1myszDFbtOZwm4qzn5Y1foflBLY4IIp2stNhuKaszLstPuftOqeF9UlF1YatayHRrERFN4G4hDNtxvHH97HB46Hs/Cq+bomnSPbG3vbe1S2lVwT5TKBlVZj8wyv3snPPNebT6DbWGs39xfavdvolu63stxcq6NBI4KqYJEOcdAp4HHIrpbBxe6Va+MtL0/UpdQt9Pa1isJJ8G6gDc5xkFmyXDDjk8E4omroE2nqafjWRTpggtbr7Nq12CunojlWnnQhxDuPG1sY2kjO4d6i1zSB4x0S1nnT+ytRuIhvhmJIibskh/2T0PB6dKv+INKsNT0u6t9Rt5IluIzJcNDEryowjxuXcDlgBjjk9BXFyDXNTbQdPs7nS9PsY7Yyz/AGZ5JYLi2QooI8wbxIu3ODgcjkc0odLPYcm1Iua0dVt5IrWOxga/uolgki1H96jSKcPEWxg7gCwYnnOfpp6YksG1LSxNjYwFgtsjYXqdzYPU+/txWlP4g0qbTdIdbh737fI9rbXCLuOUBJkPfAAwTjr7Vm6akc4ne2dXZ1wWd8oyng568Y96fM2tUaRaZLpms2+rXl4lmAFgVSWTAKlvu8D2BNUmjlj1n7Pb3kkdsYxIULCNEByAhBHOTk8VFDBead4i0+JBYpp1zE6bIlCMWRflI2jkYx17VT1mezvdXubXS2VL1QIXmk5UzsCAEBGGdVG49vyqklfTYbloY9uvicaprGlDV7C5uJYkna51AsIrZXbHl/dKtuQg7QMAYPqK2ZrL+z5dVm8RLHHpYEVjY3CAb2Lgs4jwOIiARg+3vWW11dWl1bi6h1K+tVi+w3VsJMpFGu0eYQvG452n1GemKl1LUbR31u8v7wa0tlm4htkXbJJJKyqkaqBjYsaZB6dTVu9zLZ6staDoMNrJbzTwmWysbxpdNmgkZHWNlw3mg9QcAYIB4ParGqXCW+uRzxaVa/ZLuBg+qLjzfMJx5frjb3xzVHSdUi/4S9dRFtPZxX8cKeVdMFRNkYGyPPB9frn61pWdtpkLTaZJdxteW7/bGhyWZULfKcHoPXr1HrUS3vItL5HG6rp1zFrKzTqscSqyorR7XwOVOcfMPTmirl/Y5XUpbnUnutQjuF8wmIhI5T+8KKWPPQKB05OM0V0Rd1uF0il4b1eTxVoOrwwJ/Zk9oqZuIm3vIhzlSTjB461ynnQWt1NGtlbSK7Ry5lXe3oRk5znr9aKKiktWiKbcops7611RvE11qmi3ESw2YkYHYfmKrg7SfeqZ0e31D+2ooVS3tbWOG1jt9u5Mb97MRkZYkde1FFQ/dbS8glsUvDd4ms+PpJIoTpzpaeRGbRgmBGADuwMNuHGMcYHpXf8AjK+vLPwh5unXLWtw7xASqASvzAcZ9qKKVSKVRR9B2SjZGBLo9nfwnUdNhSwvNRf99KR5zDI3Hbu4X04AqKDQ4dPvopJZ7i7kkfH7xsAH1wOtFFCk9jSOkTZhcpqV5I5aSFP3QhY/L1608TWumXxjt9PtwWC4kG7cM89yf6UUUra2BapCa9p0WvwQJLNdW7ecHUwzHCtg/MFOR3/lWhZpb22rzWMUCrOcRy3ShVeTCgg8AY/OiipvpYmWj0IrPVZ0tNTM4Se5tdyrOVCsRvIGcccVz+p3sdtoMl61sty2oXgSaO4cug7HaOMZ4NFFaRS5vmNai6HdXl7ruv6LPMn2FLOMwqke0wtuUqy4PUZP19q6rWbv+y/DE4mhjvJo7bJeUEeZ2w2OSPxoopTS5kvQlI5/RoGvvEZt9ZuLi5SO3jnCwyGFHY5J8xed3XAAxgDHNdJ4dv77xTaanHZva6dNBPFawStCZ/K3g5cKWALAYAzwPfsUUqvV9rET0g2Himy1S3nh0221mSMWfko83lAvOc7WZjnv6dKw/F2uSaCuoPLH9rWW8t7aHBEbQ743JOQDu+70469aKKml7yV/62C7UbnImea3ji1GSV5ry6YgSOTmMKM498/hXb+HtVutQmjilcfvXAyQCUGO2aKK6KiXLc1RVsrmPUvFMsk1uoS0DWsSqxGFZvmOe5JUVe16xsk12ysxDIPLOQwlIzlS2CO4yKKKyektOwupS0uxi0u61Xw7pj3ENpdoLhg8zSKrhshlBOQwIxnd04OetdjLKbuGytrzc8d7dW9vJ5TGIgMCxII5B+X1ooqJ9GEko3sZ/gKEal8OJ5dX/wBL+1S3MLKcqPJWQqIzjtj0xxxWjY2eNN1W004x2bmaWGKUKz7SBtRm3NlioAxyB2GBxRRWcvikvMzhqrv+tjgDNcap4g8MeGL+YXAninku72VA0s+zKovsBhvUkHBNdjqepW7a3pfhu70+G4s9TsZriQsSNojk2KmB2wo9KKKue9v66mPM7fMr+NbkwaHphtILW3S01K2ggRIVxCpfadn93IJGRzyea6axto7iF7S+Vbm3kTEqOo2yLn7pHpRRUS0iv67G210jhPCcEXi601rUNYgt2mXVpYN0cKqzRxHMaM3UhenrjvXU6zpUDWd1HEXjN1B+8fOWwT0HoKKKqTaaX9bEwfuowNVu7XSdPtNGurFb201ZHsn3vt2AqSW6HJ/LHXNM0e/MGm39taxKsGm2ojgWU+ZnERClj/FjjjvjtRRWnKmrvr/maQW7OR16+v8AT7G08KaTePb2lvp8QeWVRM0vmMFIw3AX5icc9uRiu61exn1OBQ148em6zdWtubIIAlrbqnzRRbcbQ3l4HHAPQnmiinU91JozUV+D/Qz/AA7e3VlPP5tzNcxb47gRyEceducjOM8EYHOPasn4gX0+meJtLe22PFqwjtrmKcFwFfG4ocgqSFXpx37miinFLnKlsbemWEMXhKSXAWa9SS5EsahWgW4IkaJDzhRwp9cE8ZrnPDmvs1zoOiSWVqyX5nWacLtf93GSuMcdevt6daKKlaqX9dyp+7G68vzOh0/VpNS8P6dcXEa+ZcRBwQfucc89T0rE8Q2yS3vh9VeaKZpHuw6Pgb4kOMrjnJHt1I70UU0rSdvP9Sr+6dFoVtDdWFlqcyL52oR/aZkQYTcyEkAduc49K87vli0vVtb8OhZZIdBja/iuhKUuJJGAxucdhvAx7e/BRRB/vGjKbacf66M6LxnL9rt9E1Sdd0QZWe2/hZtobcCeh6/nXKtNJcX+oais04SC8ieOKRw5EQ+YwlwASmSCB0GBwTRRWtNe7/Xc15U7XOm0nSIdR1O5vX2rA2bg223IYu+VDN1YIV4B9eMUUUVz1JyUrJlxSZ//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph showing cohesive nests of epithelioid cells lacking keratinization or obvious intercellular bridges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14119=[""].join("\n");
var outline_f13_50_14119=null;
var title_f13_50_14120="Docetaxel: Pediatric drug information";
var content_f13_50_14120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Docetaxel: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"    see \"Docetaxel: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/15/12533?source=see_link\">",
"    see \"Docetaxel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Docefrez&trade;;",
"     </li>",
"     <li>",
"      Taxotere&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Docetaxel for Injection;",
"     </li>",
"     <li>",
"      Taxotere&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1009498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimicrotubular",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Natural Source (Plant) Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Taxane Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1009534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"      see \"Docetaxel: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion: Refer to individual protocols:",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with corticosteroids, beginning the day before docetaxel administration (administer corticosteroids for 1-3 days), to reduce the severity of hypersensitivity reactions and pulmonary/peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents: Sarcomas: 75-125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 21 days; administer on day 8 of treatment cycle if given in combination with other chemotherapy (Mora, 2009; Navid, 2008; Zwerdling, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Breast cancer:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Locally-advanced or metastatic: 60-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks as a single agent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Operable, node-positive (adjuvant treatment): 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks for 6 courses (in combination with doxorubicin and cyclophosphamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nonsmall cell lung cancer: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (as monotherapy or in combination with cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prostate cancer: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with prednisone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastric adenocarcinoma: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with cisplatin and fluorouracil)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Head and neck cancer: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with cisplatin and fluorouracil) for 3 or 4 cycles, followed by radiation therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for concomitant CYP3A4 inhibitors:",
"     </b>",
"     Avoid the concomitant use of strong CYP3A4 inhibitors with docetaxel. If concomitant use of a strong CYP3A4 inhibitor cannot be avoided, consider reducing the docetaxel dose by 50% (based on limited pharmacokinetic data).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for toxicity:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Toxicity includes febrile neutropenia, neutrophils &le;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;1 week, severe or cumulative cutaneous reactions; in nonsmall cell lung cancer, this may also include platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and other grade 3/4 nonhematologic toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Breast cancer (single agent): Patients dosed initially at 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     If the patient continues to experience these adverse reactions, the dosage should be reduced to 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or therapy should be discontinued; discontinue for peripheral neuropathy &ge;grade 3. Patients initiated at 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     who do not develop toxicity may tolerate higher doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Breast cancer, adjuvant treatment (combination chemotherapy): TAC regimen should be administered when neutrophils are &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients continuing to experience febrile neutropenia or patients experiencing severe/cumulative cutaneous reactions or moderate neurosensory effects (signs/symptoms) should receive a reduced dose (60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) of docetaxel. Patients who experience grade 3 or 4 stomatitis should also receive a reduced dose (60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) of docetaxel. Discontinue therapy in patients continuing to experience these reactions after dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nonsmall cell lung cancer:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Monotherapy: Patients dosed initially at 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     should have dose held until toxicity is resolved, then resume at 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; discontinue patients who develop &ge;grade 3 peripheral neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Combination therapy (with cisplatin): Patients dosed initially at 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     should have the docetaxel dosage reduced to 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subsequent cycles; if further adjustment is required, dosage may be reduced to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prostate cancer: Reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; discontinue therapy if adverse reactions persist at lower dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastric cancer, head and neck cancer:",
"     <b>",
"      Note:",
"     </b>",
"     Cisplatin may require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infection with neutropenia or neutropenia &gt;7 days should receive G-CSF in all subsequent cycles. For neutropenic complications despite G-CSF use, further reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Neutropenic complications in subsequent cycles should be further dose reduced to 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Patients who experience grade 4 thrombocytopenia should receive a dose reduction from 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .  Discontinue therapy for persistent toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal toxicity for docetaxel in combination with cisplatin and fluorouracil for treatment of gastric cancer or head and neck cancer:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Diarrhea, grade 3:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First episode: Reduce fluorouracil dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second episode: Reduce docetaxel dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Diarrhea, grade 4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First episode: Reduce fluorouracil and docetaxel doses by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second episode: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Stomatitis, grade 3:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First episode: Reduce fluorouracil dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second episode: Discontinue fluorouracil for all subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Third episode: Reduce docetaxel dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Stomatitis, grade 4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First episode: Discontinue fluorouracil for all subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second episode: Reduce docetaxel dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Renal excretion is minimal (&lt;5%); therefore, the need for dosage adjustments for renal dysfunction is unlikely (Li, 2007). Not removed by hemodialysis; may be administered before or after hemodialysis (Janus, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     The FDA-approved labeling recommends the following adjustments:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total bilirubin greater than the ULN, or AST/ALT &gt;1.5 times ULN concomitant with alkaline phosphatase &gt;2.5 times ULN: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic impairment dosing adjustment specific for gastric adenocarcinoma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST/ALT &gt;2.5 to &le;5 times ULN and alkaline phosphatase &le;2.5 times ULN: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST/ALT &gt;1.5 to &le;5 times ULN and alkaline phosphatase &gt;2.5 to &le;5 times ULN: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST/ALT &gt;5 times ULN and /or alkaline phosphatase &gt;5 times ULN: Discontinue docetaxel",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The following guidelines have been used by some clinicians (Floyd, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST/ALT 1.6-6 times ULN: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AST/ALT &gt;6 times ULN: Use clinical judgment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Docefrez&trade;: 20 mg, 80 mg [contains ethanol (in diluent), polysorbate 80 (in diluent); supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 20 mg/0.5 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Taxotere&reg;: 20 mg/mL [contains dehydrated ethanol 0.395 g/mL, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes  injection, powder for reconstitution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1009541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"     <b>",
"      Note: Multiple concentrations:",
"     </b>",
"     Docetaxel is available as a one-vial formulation at concentrations of 10 mg/mL (generic formulation) and 20 mg/mL (concentrate; Taxotere&reg;), and as a lyophilized powder (Docefrez&trade;), which is reconstituted (with provided diluent) to 20 mg/0.8 mL (20 mg vial) or 24 mg/mL (80 mg vial). Admixture errors have occurred due to the availability of various concentrations. Docetaxel was previously available as a two-vial formulation which included two vials (a concentrated docetaxel vial and a diluent vial), resulting in a reconstituted concentration of 10 mg/mL; the two-vial formulation has been discontinued by the manufacturer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     One-vial formulations: Product can be directly added to infusion solution. Further dilute for infusion in 250-500 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W in a non-DEHP container (eg, glass, polypropylene, polyolefin) to a final concentration of 0.3-0.74 mg/mL. Gently rotate to mix thoroughly.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Lyophilized powder:",
"     </b>",
"     Allow vials (and provided diluent) to stand at room temperature for 5 minutes prior to reconstitution. Dilute with the provided diluent (contains ethanol in polysorbate 80); add 1 mL to each 20 mg vial (resulting concentration is 20 mg/0.8 mL) and 4 mL to each 80 mg vial (resulting concentration is 24 mg/mL). Shake well to dissolve completely.  If air bubbles are present, allow to stand for a few minutes while air bubbles dissipate. Further dilute in 250 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W in a non-DEHP container (eg, glass, polypropylene, polyolefin) to a final concentration of 0.3-0.74 mg/mL (for doses &gt;200 mg, use a larger volume of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W, not to exceed a final concentration of 0.74 mg/mL). Mix thoroughly by manual agitation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administer as an I.V. infusion over 1 hour through nonsorbing polyethylene lined (non-DEHP) tubing; in-line filter is not necessary. Infusion should be completed within 4 hours of preparation.",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with corticosteroids for 3 days, beginning the day before docetaxel administration, is recommended to prevent hypersensitivity reactions and pulmonary/peripheral edema.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1009524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, cefazolin, cefepime, cefoperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, clindamycin, co-trimoxazole, dexamethasone sodium phosphate, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, enalaprilat, famotidine, fluconazole, furosemide, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, leucovorin, lorazepam, magnesium sulfate, mannitol, meperidine, meropenem, mesna, metoclopramide, metronidazole, minocycline, morphine, netilmicin, ofloxacin, ondansetron, piperacillin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, Ringer's injection (lactated), sodium bicarbonate, ticarcillin, ticarcillin/clavulanate, tobramycin, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, doxorubicin liposome, methylprednisolone sodium succinate, nalbuphine",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1009520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Docetaxel 10 mg/mL: Store intact vials at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from bright light. Freezing does not adversely affect the product. Multiuse vials (80 mg/8 mL and 160 mg/16 mL) are stable for up to 28 days after first entry when stored between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and protected from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Docetaxel (concentrate; Taxotere&reg;) 20 mg/mL: Store intact vials between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Protect from bright light. Freezing does not adversely affect the product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Docetaxel [lyophilized powder (Docefrez&trade;)]: Store intact vials between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Allow vials (and provided diluent) to stand at room temperature for 5 minutes prior to reconstitution. After reconstitution, may be stored refrigerated or at room temperature for up to 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solutions diluted for infusion should be used within 4 hours of preparation, including infusion time.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1009499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of breast cancer (locally advanced/metastatic or adjuvant treatment of operable node-positive); locally-advanced or metastatic nonsmall cell lung cancer (NSCLC); hormone refractory, metastatic prostate cancer; advanced gastric adenocarcinoma; locally-advanced squamous cell head and neck cancer (FDA approved in adults); has also been used in the treatment of bladder cancer (metastatic), ovarian cancer, cervical cancer (relapsed), esophageal cancer, small cell lung cancer (relapsed), and soft tissue sarcoma; Ewing&rsquo;s sarcoma, osteosarcoma, and unknown primary adenocarcinoma; sarcomas (Ewing&rsquo;s sarcoma, osteosarcoma and rhabdomyosarcoma) in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DOCEtaxel may be confused with cabazitaxel, PACLitaxel",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Taxotere&reg; may be confused with Taxol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Multiple concentrations: Docetaxel is available as a one-vial formulation at concentrations of 10 mg/mL (generic formulation) and 20 mg/mL (concentrate; Taxotere&reg;), and as a lyophilized powder (Docefrez&trade;) which is reconstituted (with provided diluent) to 20 mg/0.8 mL (20 mg vial) or 24 mg/mL (80 mg vial). Docetaxel was previously available as a two-vial formulation (a concentrated docetaxel solution vial and a diluent vial) resulting in a reconstituted concentration of 10 mg/mL. The two-vial formulation has been discontinued by the manufacturer. Admixture errors have occurred due to the availability of various docetaxel concentrations.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F162099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency of adverse effects may vary depending on diagnosis, dose, liver function, prior treatment, and premedication. The incidence of adverse events was usually higher in patients with elevated liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Fluid retention, hypotension, left ventricular ejection fraction decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, neuromotor/neurosensory events (including neuropathy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, cutaneous events, nail disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, stomatitis, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (dose dependent), febrile neutropenia (dose dependent),  leukopenia, neutropenia (nadir (median): 7 days, duration (severe neutropenia): 7 days; dose dependent), thrombocytopenia (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubin increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Infusion-site reactions (including hyperpigmentation, inflammation, redness, dryness, phlebitis, extravasation, swelling of the vein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Epiphora associated with canalicular stenosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary events",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (including with premedication), infection (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute myeloid leukemia (AML), acute respiratory distress syndrome (ARDS), anaphylactic shock, arrhythmia, ascites, atrial fibrillation, atrial flutter, AV block, bleeding episodes, bradycardia, bronchospasm, cardiac tamponade, chest pain, chest tightness, colitis, conjunctivitis, constipation, cutaneous lupus erythematosus, deep vein thrombosis, dehydration, disseminated intravascular coagulation (DIC), drug fever, duodenal ulcer, dyspnea, dysrhythmia, ECG abnormalities, erythema multiforme, esophagitis, gastrointestinal hemorrhage, gastrointestinal obstruction, gastrointestinal perforation, hand and foot syndrome, hearing loss, heart failure, hepatitis, hypertension, ileus, interstitial pneumonia, ischemic colitis, lacrimal duct obstruction, loss of consciousness (transient), MI, multiorgan failure, myelodysplastic syndrome, myocardial ischemia, neutropenic enterocolitis, neutropenic typhlitis, ototoxicity, pericardial effusion, pleural effusion, pruritus, pulmonary edema, pulmonary embolism, pulmonary fibrosis, radiation pneumonitis, radiation recall, renal failure, renal insufficiency, scleroderma-like changes, seizure, sepsis, sinus tachycardia, Stevens-Johnson syndrome, syncope, toxic epidermal necrolysis, tachycardia, thrombophlebitis, unstable angina, visual disturbances (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1009506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity to docetaxel or any component; prior severe hypersensitivity to other medications containing polysorbate 80; neutrophil count &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6094036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment-related acute myeloid leukemia or myelodysplasia occurred in patients receiving docetaxel in combination with anthracyclines and/or cyclophosphamide. Fatigue and weakness have been reported (incidence: 53% to 66%); may be severe in some cases (incidence: 13% to 18%); symptoms may last a few days up to several weeks; in patients with progressive disease, weakness may be associated with a decrease in performance status. Epiphora associated with canalicular stenosis has been reported; incidence with weekly administration was &le;77% and with every 3-week administration was &le;1%. Should be administered under the supervision of an experienced cancer chemotherapy physician. Avoid concomitant use with strong CYP3A4 inhibitors; although data are limited, a 50% dose reduction is suggested if concomitant therapy with a CYP3A4 inhibitor is required.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1009507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid use in patients with bilirubin exceeding upper limit of normal (ULN) or AST and/or ALT &gt;1.5 times ULN in conjunction with alkaline phosphatase &gt;2.5 times ULN",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients with abnormal liver function are at increased risk for the development of treatment-related adverse events, including grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fluid retention characterized by pleural effusion (requiring immediate drainage), ascites, peripheral edema (poorly tolerated), dyspnea at rest, cardiac tamponade, and weight gain (2-15 kg) has been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . The incidence (13% to 60%) and severity of the syndrome is dose-dependent and increases sharply at cumulative doses &ge;400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Patients should be premedicated with a corticosteroid (starting 1 day prior to administration) to prevent or reduce the severity of fluid retention.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension, bronchospasms, or anaphylaxis may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; do not administer to patients with a history of severe hypersensitivity to docetaxel; reported incidence is 1% to 21%; observe for hypersensitivity, especially with the first two infusions; discontinue for severe reactions; do not rechallenge if severe; minor reactions including flushing or localized skin reactions may also occur. Patients should be premedicated with a corticosteroid to prevent hypersensitivity reactions; severity is reduced with dexamethasone premedication starting 1 day prior to docetaxel administration; however, severe reactions may still occur (incidence: 15%). Patients should be observed closely for hypersensitivity reactions, especially during the first and second infusions. Contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The dose-limiting toxicity is neutropenia and frequent WBCs should be monitored. Patients with increased liver function tests experienced more episodes of neutropenia with a greater number of severe infections. Patients with an absolute neutrophil count &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     should not receive docetaxel",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Platelets should recover to &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     prior to treatment. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before platinum derivatives (carboplatin, cisplatin) to limit myelosuppression and to enhance efficacy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients with abnormal liver function, those receiving higher doses, and patients with nonsmall cell lung cancer and a history of prior treatment with platinum derivatives who receive single-agent docetaxel at a dose &gt;100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     are at higher risk for treatment-related mortality",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cutaneous reactions including erythema (with edema) and desquamation have been reported; may require dose reduction.  Dosage adjustment is recommended with severe neurosensory symptoms (paresthesia, dysesthesia, pain); persistent symptoms may require discontinuation; reversal of symptoms may be delayed after discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F162087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Taxane Derivatives may enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of DOCEtaxel. Management: Avoid this combination whenever possible.  If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May increase the serum concentration of DOCEtaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1009519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Avoid ethanol due to GI irritation. Avoid the herbal St John's wort as it may decrease docetaxel levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F162037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. An",
"     <i>",
"      ex vivo",
"     </i>",
"     human placenta perfusion model illustrated that docetaxel crossed the placenta at term. Placental transfer was low and affected by the presence of albumin; higher albumin concentrations resulted in lower docetaxel placental transfer (Berveiller,  2012). Women of childbearing potential should avoid becoming pregnant. A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1009544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver function tests, bilirubin, alkaline phosphatase, renal function; monitor for hypersensitivity reactions, neurosensory symptoms, gastrointestinal toxicity (eg, diarrhea, stomatitis), cutaneous reactions, fluid retention, epiphora, and canalicular stenosis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1009525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Docetaxel promotes the assembly of microtubules from  tubulin dimers and inhibits the depolymerization of tubulin which stabilizes microtubules in the cell. This results in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1009527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exhibits linear pharmacokinetics at the recommended dosage range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive extravascular distribution and/or tissue binding; V",
"     <sub>",
"      d",
"     </sub>",
"     : 80-90 L/m",
"     <sup>",
"      2",
"     </sup>",
"     , V",
"     <sub>",
"      dss",
"     </sub>",
"     : 113 L (mean steady state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~94% to 97%, primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein, albumin, and lipoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; oxidation via CYP3A4 to metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Terminal: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (75%, &lt;8% as unchanged drug); urine (6%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1009548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/15/12533?source=see_link\">",
"      see \"Docetaxel: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication can only be administered by infusion; report immediately any pain, burning, swelling, or redness at infusion site, difficulty breathing or swallowing, chest pain, or sudden chills. It is important to maintain adequate hydration (unless instructed to restrict fluid intake and adequate nutrition (small frequent meals may help). You will be more susceptible to infection (avoid crowds and exposure to infection and do not have any vaccinations without consulting prescriber). May cause nausea or vomiting (small frequent meals, frequent mouth care, sucking lozenges, or chewing gum may help); loss of hair (reversible); or diarrhea. Report immediately swelling of extremities, respiratory difficulty, unusual weight gain, abdominal distention, chest pain, palpitations, fever, chills, unusual bruising or bleeding, signs of infection, excessive fatigue, or rash.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1009550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Premedication with oral corticosteroids is recommended to decrease the incidence and severity of fluid retention and severity of hypersensitivity reactions. The manufacturer recommends dexamethasone 16 mg (8 mg twice daily) orally for 3 days. In one pediatric clinical trial, dexamethasone  3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     orally or I.V. every 6 hours for 2 doses, starting 12 hours before docetaxel administration has been described (Zwerdling, 2006).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Clarke SJ and Rivory LP, \"Clinical Pharmacokinetics of Docetaxel,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1999, 36(2):99-114.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/10092957/pubmed\" id=\"10092957\" target=\"_blank\">",
"        10092957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, \"Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li YF, Fu S, Hu W, et al, \"Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,\"",
"      <i>",
"       Int J Gynecol Cancer",
"      </i>",
"      , 2007, 17(4):739-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/17309673/pubmed\" id=\"17309673\" target=\"_blank\">",
"        17309673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mora J, Cruz CO, Parareda A, et al, \"Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2009, 31(10):723-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/19727011/pubmed\" id=\"19727011\" target=\"_blank\">",
"        19727011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navid F, Willert JR, McCarville MB, et al, \"Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(2):419-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/18484657/pubmed\" id=\"18484657\" target=\"_blank\">",
"        18484657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thiesen J and Kramer I, &ldquo;Physico-Chemical Stability of Docetaxel Premix Solution and Docetaxel Infusion Solutions in PVC Bags and Polyolefine Containers,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 1999, 21(3):137-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/10427584/pubmed\" id=\"10427584\" target=\"_blank\">",
"        10427584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zwerdling T, Krailo M, Monteleone P, et al, \"Phase II Investigation of Docetaxel in Pediatric Patients With Recurrent Solid Tumors: A Report From the Children's Oncology Group,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(8):1821-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/50/14120/abstract-text/16532433/pubmed\" id=\"16532433\" target=\"_blank\">",
"        16532433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13011 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14120=[""].join("\n");
var outline_f13_50_14120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708706\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162052\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162053\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009498\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009534\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162028\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162014\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009541\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009524\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009520\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009499\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162103\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162099\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009506\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6094036\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009507\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162087\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162022\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009519\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162024\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162037\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009544\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009525\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009527\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009548\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1009550\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13011\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13011|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=related_link\">",
"      Docetaxel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/15/12533?source=related_link\">",
"      Docetaxel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_50_14121="Clinical manifestations of paroxysmal nocturnal hemoglobinuria";
var content_f13_50_14121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/50/14121/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14121/contributors\">",
"     Wendell F Rosse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/50/14121/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14121/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/50/14121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14121/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/50/14121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder characterized by a defect in the GPI anchor due to an abnormality in the PIG-A gene. This leads to partial or complete absence of certain GPI-linked proteins, particularly CD59 (also called membrane inhibitor of reactive lysis, protectin, and membrane attack complex inhibitory factor) and CD55 (decay accelerating factor) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the spectrum of clinical manifestations that can result from these defects. The diagnosis and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one large series of patients with PNH, the median age at presentation was 33 years (range: 6 to 82 years), with 14 percent in the age range from 6 to 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The clinical manifestations of PNH are primarily related to abnormalities in hematopoietic function, including hemolytic anemia, a hypercoagulable state, bone marrow hypoplasia or aplasia, and progression to myelodysplastic syndrome or acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large retrospective study of 220 patients, published in 1996, found that the eight-year rates of the major complications of PNH (pancytopenia, thrombosis, and myelodysplastic syndrome) were 15, 28, and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/2\">",
"     2",
"    </a>",
"    ]. This report also demonstrated the considerable mortality associated with PNH. The median survival was 14.6 years, with Kaplan-Meier survival estimates of 78, 65, and 48 percent at 5, 10, and 15 years after diagnosis, respectively.",
"   </p>",
"   <p>",
"    A further publication from this group, published in 2008 and covering a total of 460 patients followed for a median duration of 6.8 years, indicated a longer median survival time of 22 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/3\">",
"     3",
"    </a>",
"    ]. Diagnoses made prior to 1986 and increasing age were associated with worse survival, as was development of thrombosis, bicytopenia, or pancytopenia.",
"   </p>",
"   <p>",
"    There has been an ongoing effort to correlate the clinical manifestations of the disorder with the biochemical defects that have been defined. This approach has been most successful for understanding the pathogenesis of hemolytic anemia, but has been less successful in understanding the hypercoagulable state and evolution into aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/1\">",
"     1",
"    </a>",
"    ]. The ability of free hemoglobin liberated during intravascular hemolysis to deplete nitric oxide has shed light on the mechanisms underlying esophageal spasm and sexual dysfunction seen in this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia of variable severity is a constant feature of PNH; its paroxysmal nature accounts for the name of this disorder. The hemolysis is mediated by complement activation. The sensitivity of red cells in PNH to the hemolytic action of complement is due to the partial or complete absence of two GPI-linked proteins: CD55 (decay accelerating factor); CD59; and possibly C8 binding protein. The absence of CD59 is clearly the most important.",
"   </p>",
"   <p>",
"    Different populations of red cells have been defined in PNH according to the status of GPI-linked proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PNH III cells &mdash; complete absence",
"     </li>",
"     <li>",
"      PNH II cells &mdash; partial absence",
"     </li>",
"     <li>",
"      PNH I cells &mdash; normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Determinants of hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is the complement-sensitive cells that are destroyed in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/4\">",
"     4",
"    </a>",
"    ]. PNH III cells are destroyed in a random fashion with a total life span of less than 20 days (normal: 110 to 120 days). PNH II cells have an intermediate life span of approximately 45 days that varies with their expression of CD59.",
"   </p>",
"   <p>",
"    The clinical hemolysis seen in PNH is related to three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of cells that are abnormal. Patients with fewer than 20 percent abnormal cells almost always have evidence of hemolysis and hemosiderinuria but rarely have hemoglobinuria. In contrast, many patients with more than 60 percent PNH III cells have frequent, often daily episodes of hemoglobinuria and crises. However, for reasons that are unclear, some patients do not have such episodes. Hemolysis can be precipitated by the administration of iron to an iron-deficient patient; in this setting, a large number of complement-sensitive cells are delivered to the circulation at one time [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The degree of abnormality of the cells. Patients with cells of intermediate abnormality (PNH II cells) have less hemolysis than patients with an equal number of PNH III cells. Partial restoration of CD55 to completely deficient cells increases their life span in the circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The degree to which complement is activated. Hemolysis is most pronounced when complement is activated by viral (particularly gastrointestinal viruses) or bacterial infections. Nocturnal hemolysis in PNH has been attributed to the intestinal absorption of lipopolysaccharide, a potent activator of complement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular hemolysis in PNH can lead to two forms of renal disease. First, a severe hemolytic episode of whatever cause (often in association with gastroenteritis), with massive hemoglobinuria can cause acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second, chronic hemolysis results in iron deposition in the kidneys in almost all patients. The excess iron can be detected by magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and, in some cases, by metal detectors at airports. Iron deposition can result in proximal tubular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]; in addition, chronic renal failure due to hemosiderosis and subsequent interstitial scarring can occur in patients with long-standing PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ]. Lesser degrees of chronic kidney disease in patients with PNH may be at least partially reversible following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other consequences of hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other symptoms appear to be directly related to hemolysis and the release into the circulation of the contents of red cells; the association of these symptoms with hemolysis has been made evident by their rapid and complete relief when hemolysis is abrogated by the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    . Most patients with PNH have a distressing degree of \"fatigue\" that is not directly related to the hemoglobin level, is made worse during a hemolytic episode, and is relieved by eculizumab well before a change in hemoglobin level is evident; the cause of this \"fatigue\" is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Eculizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several symptoms have been attributed to the sequestration of nitric oxide (NO) by the free hemoglobin released by intravascular hemolysis. NO relaxes smooth muscle and its absence results in excessive contraction of this type of muscle. In PNH, this apparently affects the smooth muscle of the gastrointestinal tract and of several arterial beds. In the GI tract, the most common manifestation is esophageal spasm. Many patients with PNH complain of pressure sensations in the chest and dysphagia concurrent with episodes of hemoglobinuria. When esophageal manometry is used to assess esophageal function, peristaltic waves of great intensity appear to be generated, thereby leading to symptoms. Similar symptoms have been noted in patients who have received injections of modified hemoglobin as \"substitute blood\" as well as in healthy volunteers receiving infusion of cell-free hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=see_link&amp;anchor=H19#H19\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\", section on 'Gastrointestinal side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients often complain of cramping abdominal pain of short duration, often in association with a hemolytic episode, which may be due to a similar mechanism affecting the intestinal musculature. This symptom, like the esophageal spasm, is relieved when intravascular hemolysis is stopped by therapy.",
"   </p>",
"   <p>",
"    Excessive arterial contraction may account for several symptoms. Many men complain of impotence and erectile dysfunction, particularly during hemoglobinuric episodes. Relaxation of the vessel walls is necessary for the engorgement of the corpora cavernosa, which may be impossible without NO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H2095400#H2095400\">",
"     \"Overview of male sexual dysfunction\", section on 'Role of blood flow and nitric oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A modest reduction in renal function and an element of pulmonary hypertension are frequently seen in patients with PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/19\">",
"     19",
"    </a>",
"    ]. Both of these are improved after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Eculizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNH is associated with a marked increase in venous thrombosis in the hepatic, other intra-abdominal, and peripheral veins. While this propensity to thrombosis is not well understood, activation of complement on the platelet surface stimulates removal of complement complexes by vesiculation; the resulting circulating microparticles are rich in phosphatidylserine and are highly thrombogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of thrombosis appears to be significantly related to the size of the PNH clone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/22\">",
"     22",
"    </a>",
"    ]. In two series almost all patients developing thrombosis had more than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/23\">",
"     23",
"    </a>",
"    ] or more than 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/22\">",
"     22",
"    </a>",
"    ] PNH granulocytes.",
"   </p>",
"   <p>",
"    This finding may help to explain the different incidences of thrombosis between reports from Asia (&lt;10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] and the United States and Europe (40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. In a comparative study, we found a significantly higher percentage of PNH granulocytes in patients seen at Duke compared with those seen in Japan (69 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once thrombosis has occurred in an organ, it usually tends to recur in the same site. This pattern may reflect residual endothelial proliferation from the initial episode [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/27\">",
"     27",
"    </a>",
"    ]. Asymptomatic patients who have had an episode of venous thrombosis often have evidence of continued activation of coagulation, as manifested by elevated levels of cross-linked fibrinogen and of D-dimer, a product of fibrin breakdown; these changes are not seen in patients without prior venous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hepatic vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thrombosis frequently occurs in the intraabdominal veins, particularly the hepatic veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The onset of hepatic vein thrombosis may be insidious or can occur suddenly, frequently in the setting of a hemolytic episode [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic vein thrombosis was, in the past, detected radiographically by venography. This approach has largely been replaced by MR imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]; CT scanning and ultrasonography also have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/31\">",
"     31",
"    </a>",
"    ]. However, even these very sensitive techniques may miss thrombosis of hepatic venous radicals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once it has occurred, hepatic vein thrombosis tends to recur, ultimately causing cirrhosis and rerouting of the blood from the portal drainage. The latter change is exaggerated by thrombosis of the portal vein, which often occurs in the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/11\">",
"     11",
"    </a>",
"    ]. The development of the Budd-Chiari syndrome is associated with a poor prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thrombosis of other intraabdominal veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis of other intraabdominal veins, particularly the portal vein, the splenic vein, and the inferior vena cava, is also common in PNH. This may result in splenomegaly of sufficient severity to produce hypersplenism requiring splenectomy or splenic rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microvascular thrombosis of splanchnic vessels can also occur in PNH. This can produce a number of clinical manifestations including bouts of severe abdominal pain and mucosal ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/33\">",
"     33",
"    </a>",
"    ]. Surgical removal of the ulcer may lead to resolution of the painful episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large vein thrombosis can be detected by MRI, CT scanning, or ultrasound with Doppler flow measurements. However, identification of thrombosis of smaller vessels is rarely accomplished.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Thrombosis of cerebral veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis of the cerebral veins occurs less frequently in PNH than involvement of the intraabdominal veins. Cerebral vein thrombosis can occur as a catastrophic event or with an insidious onset that may be confused with other causes of headache [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The major venous sinuses are most often involved, but thrombosis may be limited to the veins covering the cerebrum, particularly the parietal lobe. The diagnosis of cerebral vein thrombosis is often difficult to establish, even with modern imaging techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thrombosis of other veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombotic process can affect a variety of other veins including those of the extremities (common), epididymis (sometimes confused with orchitis), corpora cavernosa (causing priapism), kidneys, and skin. Dermal vein thrombosis can present as discrete areas of erythema, swelling, and pain or as a syndrome resembling purpura fulminans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the hematopoietic cells are abnormal in PNH, it has been assumed that these defects are somehow responsible for the occurrence of thrombosis. Preliminary data suggest that low grade in vivo activation of clotting is common in PNH, an abnormality that is enhanced with increased activation of complement and decreased when PNH is treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , a monoclonal antibody directed against complement factor C5 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/21\">",
"     21",
"    </a>",
"    ]. Membrane fragments from intravascular hemolysis, increased platelet aggregation, enhanced expression of tissue factor, and impaired fibrinolysis all may contribute to this process [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelets are able to isolate nascent membrane attack complexes (MACs) in patches that can then be removed by vesiculation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. The external faces of these vesicles become sites of assembly of the prothrombinase complex because of their ability to bind factor V of the coagulation system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In PNH, the formation of MAC complexes occurs at a much greater rate for a given amount of bound C5b-8 because CD59 is not present to prevent the conversion of C9; as a result, many more vesicles are budded from the platelets, resulting in a marked increase in prothrombinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/44\">",
"     44",
"    </a>",
"    ]. The thrombin that is generated is able to react with the thrombin receptor on the platelet, leading to platelet activation and aggregation and possibly the initiation of clot formation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The localization of the clot to the vessel wall may occur because complement activation and the generation of membrane attack complexes on the defective blood cells stimulate endothelial cells to express tissue factor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/46\">",
"     46",
"    </a>",
"    ]. Tissue factor provides the site on cells for activation of the so-called \"tissue activation pathway\" of coagulation. Such a site would provide a localizing area for aggregated platelets, particularly in areas where the flow of blood is sufficiently slow to allow stimulation of the endothelium to occur and aggregated platelets to adhere. Absence of the GPI-linked protein tissue factor pathway inhibitor is a likely contributor to abnormality of this procoagulant pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible contributing factor to venous thrombosis in PNH is delayed fibrinolysis. Fibrinolysis is promoted by the activation of plasminogen to plasmin, a reaction that is catalyzed by urokinase-like plasminogen activators. This reaction is localized at the cell surface by urokinase plasminogen activator receptor (UPAR), which is present on monocytes but not on platelets. Monocytes are thought to infiltrate thrombi and initiate fibrinolysis. UPAR is GPI-linked and is therefore deficient in PNH monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial thrombosis has been described in patients with PNH, but is much less common than venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIMINISHED HEMATOPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNH has been classified among the bone marrow failure syndromes. All patients have evidence of diminished hematopoiesis which can range from diminished colony growth in bone marrow culture to relative reticulocytopenia, granulocytopenia or thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In its most extreme form, PNH is manifest as aplastic anemia (AA). Approximately two-thirds exhibit granulocytopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia at some time during the course of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/54\">",
"     54",
"    </a>",
"    ]. These changes are presumably due to deficient production, since the survival of these cells in the circulation is usually normal in the absence of hypersplenism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who present with the clinical manifestations of PNH, including a large clone of abnormal cells, may progress to AA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The exact frequency with which this occurs is not known. One series of 220 patients found an 8 percent incidence of pancytopenia at eight years; the number with AA was not mentioned [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, patients who present with AA may develop PNH. Small numbers of GPI-deficient granulocytes and red cells can be found in up to 70 percent of patients with aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In a follow-up five years later, the number of GPI-deficient cells had increased in 17 percent, disappeared in 24 percent, and persisted in 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/61\">",
"     61",
"    </a>",
"    ]. Before the advent of immunosuppressive therapy for AA, approximately 5 percent of patients developed PNH while about 20 percent of those with PNH had antecedent AA. More recent studies have shown that between 15 and 33 percent of patients receiving antithymocyte serum for the treatment of AA recover with evidence of PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/62-67\">",
"     62-67",
"    </a>",
"    ]. This phenomenon has also been described after treatment of AA with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PNH arising in the setting of aplastic anemia may be a transient phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/70\">",
"     70",
"    </a>",
"    ]. The proportion of GPI-deficient PNH cells may remain small, with the predominant clinical manifestations being those of aplasia. In other cases, however, the abnormal clone of cells may increase and predominate the marrow, with the major clinical manifestations being those of PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/23,57\">",
"     23,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER HEMATOLOGIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because PNH is a disorder of the stem cell, it may have other manifestations of stem cell disorders, particularly myelodysplastic syndromes and acute leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Myelodysplastic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNH has been described in the setting of myelodysplastic (MDS) or myeloproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/71-74\">",
"     71-74",
"    </a>",
"    ], with an incidence ranging from 5 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/2,71\">",
"     2,71",
"    </a>",
"    ]. Small populations of GPI- granulocytes are found in all types of myelodysplasia (Explore study), particularly in those with refractory anemia (eg, refractory cytopenia with unilineage dysplasia). In this setting, their presence appears to predict an improved prognosis and response to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/75\">",
"     75",
"    </a>",
"    ]. In one patient the PNH cells and the cells characteristic of the dysplasia were derived from the same clone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/74\">",
"     74",
"    </a>",
"    ]. In a separate study of patients with PNH, cytogenetic abnormalities, and either aplastic anemia or MDS, the abnormal chromosomal patterns were found in the PNH clone in only one of the nine cases studied [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with PNH evolve to acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/73,77-84\">",
"     73,77-84",
"    </a>",
"    ]. Although an incidence as high as 5 percent has been reported, acute leukemia developed in only 2 to 300 cases (0.7 percent) in two series with long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. The most common form is acute myeloid leukemia, in some cases acute erythroleukemia (FAB M6) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/82-84\">",
"     82-84",
"    </a>",
"    ], although acute lymphoblastic TdT-positive (usually considered a marker for acute lymphocytic leukemia) and megakaryoblastic leukemia may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of leukemia after the diagnosis of PNH usually occurs at about five years, but the reported range is from a few months to 22 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/82,84\">",
"     82,84",
"    </a>",
"    ]. Acute leukemia has occurred in patients who had previously had refractory anemia with excess blasts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/77\">",
"     77",
"    </a>",
"    ], myelofibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/73\">",
"     73",
"    </a>",
"    ], or aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all cases thus far studied, the leukemic clone has evolved from the abnormal PNH clone, since the malignant cells lack GPI-linked proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/80,86,87\">",
"     80,86,87",
"    </a>",
"    ]. However, additional genomic abnormalities in these clones are most likely to be responsible for the malignant transformation. In one patient, for example, chromosomal abnormalities appeared to be present in the leukemic clone, which did not exist prior to the onset of leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/80\">",
"     80",
"    </a>",
"    ]. In another case, the PIG-A gene of the leukemic cells appeared to have two defects, but it is not known if these abnormalities were present prior to the onset of leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/88\">",
"     88",
"    </a>",
"    ]. These studies failed to demonstrate a difference between the PNH line and normal lines in the expression of proto-oncogenes or karyotypic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remarkably little evidence of immune deficiency as defined by a poor response to immunologic stimuli exists in PNH, despite the many abnormalities that can be demonstrated on lymphocytes. This finding may in part be due to the relatively small proportion of abnormal lymphocytes in most cases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to the onset of the abnormalities later in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\", section on 'Lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the granulocyte and monocyte abnormalities may result in some predisposition to infection. FcRIII, the low-affinity receptor for IgG, is normally GPI-linked in granulocytes. When this linkage is missing in PNH, the clearance of blood-borne infections should be compromised. However, most clinical reviews suggest that infections most frequently result from granulocytopenia, not from the absence of this receptor.",
"   </p>",
"   <p>",
"    The lack of effect of the loss of GPI-linked FcRIII may be due to one or both of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The higher affinity FcRII, present in small amounts on granulocytes, is able to compensate for the loss [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14121/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Monocytes and macrophages bear the more effective FcRI receptors which bound to the membrane by a transmembrane motif and are not missing in PNH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14812567\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder characterized by a defect in the glycosylphosphatidyl-inositol (GPI) anchor due to an abnormality in the PIG-A gene. This leads to partial or complete absence of certain GPI-linked proteins, particularly CD59 (also called membrane inhibitor of reactive lysis, protectin, and membrane attack complex inhibitory factor) and CD55 (decay accelerating factor). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of PNH are primarily related to abnormalities in hematopoietic function, including hemolytic anemia, a hypercoagulable state, bone marrow hypoplasia or aplasia, and progression to myelodysplastic syndrome or acute leukemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hemolysis",
"      </strong>",
"      : Intravascular hemolysis of variable severity is a constant feature of PNH, is mediated by complement activation, and is most pronounced following viral or bacterial infections. This hemolysis leads to a variety of symptoms (excessive fatigue, esophageal spasm, abdominal pain, erectile dysfunction) and to organ dysfunction and damage (renal dysfunction, pulmonary hypertension). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Determinants of hemolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypercoagulable state",
"      </strong>",
"      : PNH is associated with a marked increase in venous thrombosis in the hepatic, other intra-abdominal, and peripheral veins and, to a lesser extent, arterial thrombosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Venous thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Impaired hematopoiesis",
"      </strong>",
"      : All patients with PNH have evidence of diminished hematopoiesis which can range from diminished colony growth in bone marrow culture to relative reticulocytopenia, granulocytopenia or thrombocytopenia. In its most extreme form, PNH is manifest as aplastic anemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diminished hematopoiesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Stem cell disorders",
"      </strong>",
"      : PNH, a disorder of the stem cell, may evolve into one of the myelodysplastic syndromes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute leukemia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other hematologic disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/1\">",
"      Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997; 76:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/2\">",
"      Soci&eacute; G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/3\">",
"      de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008; 112:3099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/4\">",
"      Rosse WF. The life-span of complement-sensitive and -insensitive red cells in paroxysmal nocturnal hemoglobinuria. Blood 1971; 37:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/5\">",
"      Rosse WF, Gutterman LA. The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood 1970; 36:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/6\">",
"      Ninomiya H, Abe T, Fujita T. Prolongation of red-cell life-span by incorporation of decay-accelerating factor (DAF) into red cells of paroxysmal nocturnal haemoglobinuria (PNH). Br J Haematol 1989; 73:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/7\">",
"      Vellenga E, Mulder NH, Nieweg HO, de Vries-Hospers HG. Endotoxin in paroxysmal nocturnal haemoglobulinuria (PNH). Br J Haematol 1982; 50:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/8\">",
"      Jackson GH, Noble RS, Maung ZT, et al. Severe haemolysis and renal failure in a patient with paroxysmal nocturnal haemoglobinuria. J Clin Pathol 1992; 45:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/9\">",
"      Mooraki A, Boroumand B, Mohammad Zadeh F, et al. Acute reversible renal failure in a patient with paroxysmal nocturnal hemoglobinuria. Clin Nephrol 1998; 50:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/10\">",
"      Roubidoux MA. MR of the kidneys, liver, and spleen in paroxysmal nocturnal hemoglobinuria. Abdom Imaging 1994; 19:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/11\">",
"      Mathieu D, Rahmouni A, Villeneuve P, et al. Impact of magnetic resonance imaging on the diagnosis of abdominal complications of paroxysmal nocturnal hemoglobinuria. Blood 1995; 85:3283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/12\">",
"      Clark DA, Butler SA, Braren V, et al. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood 1981; 57:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/13\">",
"      Riley AL, Ryan LM, Roth DA. Renal proximal tubular dysfunction and paroxysmal nocturnal hemoglobinuria. Am J Med 1977; 62:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/14\">",
"      Hsiao PJ, Wang SC, Wen MC, et al. Fanconi syndrome and CKD in a patient with paroxysmal nocturnal hemoglobinuria and hemosiderosis. Am J Kidney Dis 2010; 55:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/15\">",
"      Zach&eacute;e P, Henckens M, Van Damme B, et al. Chronic renal failure due to renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria. Clin Nephrol 1993; 39:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/16\">",
"      Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010; 85:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/17\">",
"      Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/18\">",
"      Hill A, Rother RP, Hillmen P. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica 2005; 90:ECR40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/19\">",
"      Hill A, Sapsford RJ, Scally A, et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol 2012; 158:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/20\">",
"      Rosse WF. A new way to prevent thrombosis. Blood 2007; 110:3821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/21\">",
"      Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/22\">",
"      Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004; 126:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/23\">",
"      Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004; 83:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/24\">",
"      Dunn P, Shih LY, Liaw SJ. Paroxysmal nocturnal hemoglobinuria: analysis of 40 cases. J Formos Med Assoc 1991; 90:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/25\">",
"      Kruatrachue M, Wasi P, Na-Nakorn S. Paroxysmal nocturnal haemoglobinuria in Thailand with special reference to as association with aplastic anaemia. Br J Haematol 1978; 39:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/26\">",
"      Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/27\">",
"      Taylor SR, Hashida Y, Jaffe R. Venous thrombosis and endothelial proliferation in paroxysmal nocturnal hemoglobinuria. Pediatr Pathol 1989; 9:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/28\">",
"      Hartmann RC, Luther AB, Jenkins DE Jr, et al. Fulminant hepatic venous thrombosis (Budd-Chiari syndrome) in paroxysmal nocturnal hemoglobinuria: definition of a medical emergency. Johns Hopkins Med J 1980; 146:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/29\">",
"      Peytremann R, Rhodes RS, Hartmann RC. Thrombosis in paroxysmal nocturnal hemoglobinuria (PNH) with particular reference to progressive, diffuse hepatic venous thrombosis. Ser Haematol 1972; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/30\">",
"      Valla D, Dhumeaux D, Babany G, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology 1987; 93:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/31\">",
"      Birgens HS, Hancke S, Rosenklint A, Hansen NE. Ultrasonic demonstration of clinical and subclinical hepatic venous thrombosis in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1986; 64:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/32\">",
"      Zimmerman D, Bell WR. Venous thrombosis and splenic rupture in paroxysmal nocturnal hemoglobinuria. Am J Med 1980; 68:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/33\">",
"      Dunphy CH, Sotelo-Avila C, Luisiri A, Chu JY. Paroxysmal nocturnal hemoglobinuria associated with venous thrombosis and papillary endothelial hyperplasia presenting as ulcerated duodenal mass. Arch Pathol Lab Med 1994; 118:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/34\">",
"      Blum SF, Gardner FH. Intestinal infarction in paroxysmal nocturnal hemoglobinuria. N Engl J Med 1966; 274:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/35\">",
"      Donhowe SP, Lazaro RP. Dural sinus thrombosis in paroxysmal nocturnal hemoglobinuria. Clin Neurol Neurosurg 1984; 86:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/36\">",
"      Johnson RV, Kaplan SR, Blailock ZR. Cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria. Marchiafava-Micheli syndrome. Neurology 1970; 20:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/37\">",
"      Wozniak AJ, Kitchens CS. Prospective hemostatic studies in a patient having paroxysmal nocturnal hemoglobinuria, pregnancy, and cerebral venous thrombosis. Am J Obstet Gynecol 1982; 142:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/38\">",
"      Rietschel RL, Lewis CW, Simmons RA, Phyliky RL. Skin lesions in paroxysmal nocturnal hemoglobinuria. Arch Dermatol 1978; 114:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/39\">",
"      Kozuma Y, Sawahata Y, Takei Y, et al. Procoagulant properties of microparticles released from red blood cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2011; 152:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/40\">",
"      Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265:3809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/41\">",
"      Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263:18205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/42\">",
"      Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264:17049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/43\">",
"      Gilbert GE, Sims PJ, Wiedmer T, et al. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991; 266:17261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/44\">",
"      Wiedmer T, Hall SE, Ortel TL, et al. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/45\">",
"      Harmon JT, Jamieson GA. Activation of platelets by alpha-thrombin is a receptor-mediated event. D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone-thrombin, but not N alpha-tosyl-L-lysine chloromethyl ketone-thrombin, binds to the high affinity thrombin receptor. J Biol Chem 1986; 261:15928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/46\">",
"      Saadi S, Holzknecht RA, Patte CP, et al. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/47\">",
"      Maroney SA, Cunningham AC, Ferrel J, et al. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 2006; 4:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/48\">",
"      Ploug M, Plesner T, R&oslash;nne E, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992; 79:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/49\">",
"      Audebert HJ, Planck J, Eisenburg M, et al. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J Neurol 2005; 252:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/50\">",
"      Tejada J, Hern&aacute;ndez-Echebarr&iacute;a L, Sandoval V, Mostaza JL. [Cerebral ischemia as first manifestation of paroxysmal nocturnal hemoglobinuria]. Neurologia 2007; 22:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/51\">",
"      Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol 2008; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/52\">",
"      Parker CJ. Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria. Hematol Oncol Clin North Am 2009; 23:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/53\">",
"      Young NS, Maciejewski JP, Sloand E, et al. The relationship of aplastic anemia and PNH. Int J Hematol 2002; 76 Suppl 2:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/54\">",
"      DACIE JV. Paroxysmal nocturnal haemoglobinuria. Proc R Soc Med 1963; 56:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/55\">",
"      Brubaker LH, Essig LJ, Mengel CE. Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood 1977; 50:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/56\">",
"      Devine DV, Siegel RS, Rosse WF. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo. J Clin Invest 1987; 79:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/57\">",
"      Rosse WF. Paroxysmal nocturnal haemoglobinuria in aplastic anaemia. Clin Haematol 1978; 7:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/58\">",
"      Lewis SM, Dacie JV. The aplastic anaemia--paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol 1967; 13:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/59\">",
"      Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/60\">",
"      Nakao S, Sugimori C, Yamazaki H. Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure. Int J Hematol 2006; 84:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/61\">",
"      Sugimori C, Mochizuki K, Qi Z, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 2009; 147:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/62\">",
"      de Planque MM, Bacigalupo A, W&uuml;rsch A, et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol 1989; 73:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/63\">",
"      Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood 1995; 85:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/64\">",
"      Najean Y, Haguenauer O. Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias. Blood 1990; 76:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/65\">",
"      Nakakuma H, Nagakura S, Iwamoto N, et al. Paroxysmal nocturnal hemoglobinuria clone in bone marrow of patients with pancytopenia. Blood 1995; 85:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/66\">",
"      Schrezenmeier H, Hertenstein B, Wagner B, et al. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol 1995; 23:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/67\">",
"      Schubert J, Vogt HG, Zielinska-Skowronek M, et al. Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia. Blood 1994; 83:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/68\">",
"      Nakao S, Yamaguchi M, Takamatsu H, et al. Expansion of a paroxysmal nocturnal hemoglobinuria (PNH) clone after cyclosporine therapy for aplastic anemia/PNH syndrome. Blood 1992; 80:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/69\">",
"      Yamaguchi M, Nakao S, Takamatsu H, et al. Quality of hematologic recovery in patients with aplastic anemia following cyclosporine therapy. Exp Hematol 1995; 23:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/70\">",
"      Kruatrachue M, Na-Nakorn S. Transient paroxysmal nocturnal hemoglobinuria during the course of aplastic anemia. J Med Assoc Thai 1974; 57:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/71\">",
"      Graham DL, Gastineau DA. Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy. Am J Med 1992; 93:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/72\">",
"      Hansen NE, Killmann SA. Paroxysmal nocturnal hemoglobinuria in myelofibrosis. Blood 1970; 36:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/73\">",
"      Nakahata J, Takahashi M, Fuse I, et al. Paroxysmal nocturnal hemoglobinuria with myelofibrosis: progression to acute myeloblastic leukemia. Leuk Lymphoma 1993; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/74\">",
"      Longo L, Bessler M, Beris P, et al. Myelodysplasia in a patient with pre-existing paroxysmal nocturnal haemoglobinuria: a clonal disease originating from within a clonal disease. Br J Haematol 1994; 87:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/75\">",
"      Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100:3897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/76\">",
"      Sloand EM, Fuhrer M, Keyvanfar K, et al. Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive. Br J Haematol 2003; 123:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/77\">",
"      Aymard JP, Buisine J, Gr&eacute;goire MJ, et al. Refractory anaemia with excess of blasts as a terminal evolution of paroxysmal nocturnal haemoglobinuria. A case report with chromosomal analysis. Acta Haematol 1985; 74:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/78\">",
"      Hirsch VJ, Neubach PA, Parker DM, et al. Paroxysmal nocturnal hemoglobinuria. Termination in acute myelomonocytic leukemia and reappearance after leukemic remission. Arch Intern Med 1981; 141:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/79\">",
"      Katahira J, Aoyama M, Oshimi K, et al. Paroxysmal nocturnal hemoglobinuria terminating in TdT-positive acute leukemia. Am J Hematol 1983; 14:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/80\">",
"      Teyssier JR, Pigeon F, Behar C, et al. Chromosomal subclonal evolution in paroxysmal nocturnal hemoglobinuria evolving into acute megakaryoblastic leukemia. Cancer Genet Cytogenet 1987; 25:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/81\">",
"      Zittoun R, Bernadou A, James JM, et al. Acute myelo-monocytic leukaemia: a terminal complication of paroxysmal nocturnal haemolobinuria. Acta Haematol 1975; 53:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/82\">",
"      Carmel R, Coltman CA Jr, Yatteau RF, Costanzi JJ. Association of paroxysmal nocturnal hemoglobinuria with erythroleukemia. N Engl J Med 1970; 283:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/83\">",
"      Cowall DE, Pasquale DN, Dekker P. Paroxysmal nocturnal hemoglobinuria terminating as erythroleukemia. Cancer 1979; 43:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/84\">",
"      Shimano S, Omine M, Yashiro K, et al. A case of paroxysmal nocturnal hemoglobinuria terminating in erythroleukemia after 22 years' observation. Nihon Ketsueki Gakkai Zasshi 1983; 46:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/85\">",
"      Hiroshige Y, Matsumoto N, Harima K, et al. An autopsy case of aplastic anemia-PNH syndrome terminated in acute granulocytic leukemia. Nihon Ketsueki Gakkai Zasshi 1977; 40:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/86\">",
"      Devine DV, Gluck WL, Rosse WF, Weinberg JB. Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone. J Clin Invest 1987; 79:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/87\">",
"      Shichishima T, Terasawa T, Hashimoto C, et al. Discordant and heterogeneous expression of GPI-anchored membrane proteins on leukemic cells in a patient with paroxysmal nocturnal hemoglobinuria. Blood 1993; 81:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/88\">",
"      Stafford HA, Nagarajan S, Weinberg JB, Medof ME. PIG-A, DAF and proto-oncogene expression in paroxysmal nocturnal haemoglobinuria-associated acute myelogenous leukaemia blasts. Br J Haematol 1995; 89:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14121/abstract/89\">",
"      Hundt M, Schubert J, de Haas M, et al. The loss of Fc gamma RIIIb in paroxysmal nocturnal hemoglobinuria is functionally replaced by Fc gamma RII. Blood 1994; 83:3574.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7159 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-59BD6D52C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14121=[""].join("\n");
var outline_f13_50_14121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14812567\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Determinants of hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other consequences of hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VENOUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hepatic vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thrombosis of other intraabdominal veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Thrombosis of cerebral veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thrombosis of other veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIMINISHED HEMATOPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER HEMATOLOGIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Myelodysplastic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14812567\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=related_link\">",
"      Oxygen carriers as alternatives to red cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_50_14122="Treatment of the Ewing sarcoma family of tumors";
var content_f13_50_14122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of the Ewing sarcoma family of tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/50/14122/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14122/contributors\">",
"     David C Harmon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14122/contributors\">",
"     Mark C Gebhardt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/50/14122/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14122/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14122/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/50/14122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/50/14122/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/50/14122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ewing sarcoma (ES) is a rare malignancy that most often presents as an undifferentiated primary bone tumor; less commonly, it arises in soft tissue (extraosseous Ewing sarcoma, EES). Both are part of a spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), which also includes the more differentiated peripheral primitive neuroectodermal tumor (PNET, previously called peripheral neuroepithelioma, adult neuroblastoma, and Askin's tumor of the chest wall) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/1\">",
"     1",
"    </a>",
"    ]. PNET can also present either in bone or soft tissue. Because these tumors share similar histological and immunohistochemical characteristics and unique nonrandom chromosomal translocations, they are considered to have a common origin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H44#H44\">",
"     \"Diseases of the chest wall\", section on 'Malignant neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to their immunohistochemical and cytogenetic similarities, the EFT share important clinical features. These include a peak incidence between the age of 10 and 20 (70 percent of affected patients are under the age of 20), a tendency towards rapid spread to lungs, bone, and bone marrow, and responsiveness to the same treatments that include chemotherapy and radiotherapy. As with osteosarcoma (the other major sarcoma affecting bone), advances in multidisciplinary management over the past 30 years have resulted in a marked improvement in long-term survival. In data derived from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute, five-year survival rates for patients with Ewing sarcoma rose from 36 to 56 percent during the periods 1975 to 1984 and 1985 to 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Here we will discuss the management of the EFT. The epidemiology, pathology, molecular genetics, clinical presentation, and diagnosis of these tumors, surgical principles, indications for limb sparing surgery, indications for radiation therapy (RT), and treatment of central (supratentorial) PNET tumors are discussed elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that fewer than 25 percent of patients have overt metastases at the time of diagnosis, EFT is a systemic disease. Because of the high relapse rate (80 to 90 percent) in patients undergoing local therapy alone, it is surmised that the majority of patients have subclinical metastatic disease at the time of diagnosis, even in the absence of overt metastases.",
"   </p>",
"   <p>",
"    Chemotherapy can successfully eradicate these deposits, and modern treatment plans all include chemotherapy, usually administered prior to and following local treatment. For patients with localized disease, the addition of several months of intensive multiagent chemotherapy to local therapy has had a dramatic impact on survival, and reported five- and 10-year survival rates are now approximately 70 and 50 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/7-16\">",
"     7-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even patients with advanced disease may be cured by multimodality therapy, although the long-term survival rates are clearly lower than for localized disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/17\">",
"     17",
"    </a>",
"    ]. Approaching a child who has metastatic EFT with noncurative intent is rarely, if ever, appropriate, since it is not possible to predict a priori whose disease will be cured. Because of these issues, clinicians experienced in the treatment of Ewing sarcoma must direct the surgery and RT, and coordination with the medical oncologist is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adult patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 5 percent of cases of EFT arise in adults over the age of 40. There are no clinical trials that address treatment in adults; the vast majority of published studies have specifically excluded older individuals. The available information on treatment and prognosis is limited to six small single institution series of patients over the age of 15 who were treated for EFT (",
"    <a class=\"graphic graphic_table graphicRef81105 \" href=\"UTD.htm?22/21/22876\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/20-25\">",
"     20-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to conclude from these data whether treatment outcomes are different in adults as compared to children. Early studies suggested worse outcomes for patients &gt;15 years of age as compared to those 11 to 15 or under the age of 10 at the time of diagnosis (five-year relapse-free survival 43, 50, and 66 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/9\">",
"     9",
"    </a>",
"    ]. However, only nine of the 331 individuals in this retrospective report were over the age of 20 at the time of diagnosis.",
"   </p>",
"   <p>",
"    The interpretation of studies addressing outcomes in adults is further complicated by the fact that adults more often have pelvic or extraskeletal primaries, which are associated with a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/20,22,23,25\">",
"     20,22,23,25",
"    </a>",
"    ]. Despite this fact, adults who are treated with modern adjuvant and neoadjuvant chemotherapy for localized EFT may do as well as children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of adults with EFT should be guided by the same general principles as are used for younger individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT FOR LOCALIZED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most modern treatment plans utilize initial (induction or neoadjuvant) chemotherapy followed by local treatment and additional chemotherapy. Reduction of local tumor volume is accomplished in the majority of patients, and this can facilitate resection. This is particularly important with regard to limb-sparing procedures for extremity lesions. Since most treatment failures are attributable to systemic metastatic disease, local therapy considerations should never compromise the administration of effective systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with EES have been treated in the past on protocols for rhabdomyosarcoma and have a similar response to multimodality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/13\">",
"     13",
"    </a>",
"    ], both EES and PNET respond to the same chemotherapy regimens as osseous ES, and these EFT variants should be treated similarly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjuvant treatment has evolved, largely due to the efforts of several cooperative groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first Intergroup Ewing's Sarcoma Study (IESS-I), the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and actinomycin D (VDCA or VACA) was associated with a significantly better five-year relapse-free survival than vincristine, actinomycin D, and cyclophosphamide (VAC) alone or VAC plus adjuvant bilateral pulmonary irradiation (60 versus 24 versus 44 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increasing the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      dose intensity during the early months of therapy further improved response, and in the second intergroup study (IESS-II), the five-year relapse-free survival rates using intermittent high dose four drug therapy improved to 73 percent for non-pelvic lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/30\">",
"       30",
"      </a>",
"      ]. Because of concerns about limiting the dose intensity of doxorubicin in regimens containing actinomycin D [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/31\">",
"       31",
"      </a>",
"      ], actinomycin D was omitted from most trials thereafter, with no adverse impact on long-term outcome.",
"     </li>",
"     <li>",
"      Adding alternating cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      (I) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (E) to a VDC backbone provides further benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/14,32-34\">",
"       14,32-34",
"      </a>",
"      ]. In the randomized IESS-III study, the addition of",
"      <span class=\"nowrap\">",
"       I/E",
"      </span>",
"      to VDCA was associated with significantly better five-year relapse-free survival compared to VDCA alone (69 versus 54 percent, respectively) in patients with nonmetastatic, but not metastatic EFT or PNET [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/32\">",
"       32",
"      </a>",
"      ]. A similar outcome was shown with a slightly different",
"      <span class=\"nowrap\">",
"       IE/VDC",
"      </span>",
"      regimen at Memorial Sloan Kettering (four-year event-free survival 82 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/33\">",
"       33",
"      </a>",
"      ] and with ifosfamide plus VDCA by the Orthopedic Institute from Rizzoli (five-year event-free survival 79 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/14\">",
"       14",
"      </a>",
"      ]. Earlier trials from the Rizzoli group had suggested no additional benefit (five-year event-free survival rates 54 and 50 percent for VDCA plus",
"      <span class=\"nowrap\">",
"       I/E,",
"      </span>",
"      and for VDCA alone in two consecutive phase II trials) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these data, current standard chemotherapy for EFT in the United States includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    alternating with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    <span class=\"nowrap\">",
"     (VDC/IE)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef50917 \" href=\"UTD.htm?9/7/9340\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/32\">",
"     32",
"    </a>",
"    ]. Typically, four to six cycles of chemotherapy are given before local therapy. So long as there is any sign of response to preoperative chemotherapy, additional cycles of the same treatments are given post-operatively, and the total duration of therapy is approximately 48 weeks. Relief of pain, decrease in tumor size, fall in LDH level, radiologic improvement, or evidence of necrosis in the resected specimen all argue for continued chemotherapy for those who can tolerate its sometimes considerable side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dose intense chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of EFT to alkylating agents, which have a steep dose-response curve, has prompted the evaluation of dose intense regimens in patients with poor risk disease. The majority of patients in these studies have relapsed or metastatic disease. The benefit of dose-intensive therapy for patients with poor risk",
"    <strong>",
"     localized",
"    </strong>",
"    disease is unclear. Dose escalation did not improve outcomes in a COG trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, concerns for an increased risk of secondary malignancies in patients receiving dose-intense therapy have tempered enthusiasm for this approach.",
"   </p>",
"   <p>",
"    Another approach is &ldquo;dose-dense&rdquo; therapy as originally reported by Womer in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/37\">",
"     37",
"    </a>",
"    ]. A randomized trial by the Children&rsquo;s Oncology Group (COG) randomized patients with localized Ewing sarcoma family of tumors to receive",
"    <span class=\"nowrap\">",
"     VDC/IE",
"    </span>",
"    every 21 or 14 days, respectively. This trial demonstrated a significant event-free survival (EFS) benefit for interval-compressed",
"    <span class=\"nowrap\">",
"     VDC/IE",
"    </span>",
"    given every 14 days as compared to the same chemotherapy given at 21-day intervals (five-year EFS 73 versus 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/38\">",
"     38",
"    </a>",
"    ]. The toxicity of both regimens was similar. The results of this trial suggest that interval compressed therapy is preferred for front-line treatment of children with localized Ewing sarcoma family of tumors.",
"   </p>",
"   <p>",
"    Whether this approach is preferred in adults is unclear. In a preliminary report of this COG randomized trial presented at the 2007 meeting of the Connective Tissue Oncology Society, the benefit of interval compressed therapy seemed limited to patients aged 17 or younger [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/39\">",
"     39",
"    </a>",
"    ]. These data have not yet been reported in a peer-reviewed publication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Local treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local control for EFT can be achieved by surgery, radiation, or both. The choice of RT or surgery usually represents a tradeoff between functional result, and the risk of secondary radiation-induced malignancy. Patients who lack a function-preserving surgical option because of tumor location or extent may be recommended RT. However, surgery is preferred for potentially resectable lesions and for those arising in dispensable bones (eg, fibula, rib, small lesions of the hands or feet) for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It avoids the risk of secondary radiation-induced sarcomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link\">",
"       \"Radiation therapy for Ewing sarcoma family of tumors\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An analysis of the degree of necrosis in the excised tumor can permit refinements in the estimate of prognosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link&amp;anchor=H27#H27\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the skeletally immature child, resection may be associated with less morbidity than RT, which can retard bone growth and cause deformity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there are no randomized trials comparing surgery with RT for local control, multiple retrospective series suggest superior local control and survival for surgery compared to RT alone. However, selection bias may account for at least some of these results (ie, smaller, more favorably situated peripheral tumors are more likely to be resected while larger, axial lesions are radiated). Radiation dose and proper field planning are also important factors in local control. The role of RT in the local management of Ewing sarcoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical principles that apply to resection of the primary tumor and reconstruction are similar to those in patients with osteosarcoma and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .) However, there are three main differences between EFT and osteosarcoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EFT are radiosensitive while osteosarcoma is much less so.",
"     </li>",
"     <li>",
"      EFT tend to occur in a younger population, where skeletal immaturity and concern for radiation-induced growth inhibition must be considered.",
"     </li>",
"     <li>",
"      EFT tend to arise in different areas of the long bones than osteosarcoma (the diaphysis compared to epiphysis, (",
"      <a class=\"graphic graphic_figure graphicRef76662 \" href=\"UTD.htm?22/53/23391\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50795 \" href=\"UTD.htm?13/34/13864\">",
"       figure 2",
"      </a>",
"      )) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is an essential component of therapy for patients undergoing resection if the surgical margins are inadequate, although effective chemotherapy can also reduce the risk of local failure in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. RT is usually avoided in patients without residual disease, to avoid exposing them to the risk of a radiation-induced malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Adjuvant RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT FOR ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with overt metastatic disease at presentation have a significantly less favorable outcome than those with localized disease. However, aggressive multimodality therapy can relieve pain, prolong the progression-free interval, and cure some patients of their disease. In a review of 12 different series in which patients with metastatic EFT were predominantly treated with chemotherapy, five year event-free and overall survival rates averaged 25 (range 9 to 55) and 33 (range 14 to 61) percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/7,11,41-50\">",
"     7,11,41-50",
"    </a>",
"    ]. The small numbers of patients in each series and the heterogeneity in location and extent of metastatic disease probably accounts for these wide variations in outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Disease extent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In particular, the site of metastatic disease is an important variable. For patients with isolated lung and pleural metastases, cure rates up to 40 percent are reported with multimodality therapy; for metastases involving bone or bone marrow, cure rates fall to 20 to 25 percent and for combined sites, to less than 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/49\">",
"     49",
"    </a>",
"    ]. Because it can be difficult to predict which patients with metastatic disease will be long-term relapse-free survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/42\">",
"     42",
"    </a>",
"    ], treatment should be administered with curative intent. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General treatment principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several issues are pertinent to patients with metastatic EFT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the optimal initial chemotherapy regimen?",
"     </li>",
"     <li>",
"      Does dose escalation provide benefit in the initial treatment phase?",
"     </li>",
"     <li>",
"      Is there a role for dose-intense therapy as consolidation after initial therapy?",
"     </li>",
"     <li>",
"      Is RT to sites of metastatic involvement of any benefit?",
"     </li>",
"     <li>",
"      How should control of the primary site be approached?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with disseminated disease at diagnosis often respond well to the same type of systemic chemotherapy as that used for localized disease. Standard treatment options include conventional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , doxorubicin, and cyclophosphamide with or without actinomycin D (VDCA or VDC), alternating courses of VDC and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    <span class=\"nowrap\">",
"     (I/E),",
"    </span>",
"    regimens incorporating higher doses of alkylating agents, and more intensive multiagent combinations that generally require hematopoietic support. Unfortunately, there are few conclusions that can be garnered from the published literature as to the superiority of any of these regimens, because there are no randomized studies that directly compare different regimens. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Conventional dose",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      &ndash; The best results for doxorubicin and cyclophosphamide were obtained by investigators at St. Jude using both agents sequentially [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/43\">",
"       43",
"      </a>",
"      ]. Ten of 18 patients (55 percent) receiving oral cyclophosphamide (150",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      daily for seven days) followed by doxorubicin (35",
"      <span class=\"nowrap\">",
"       mg/m2)",
"      </span>",
"      who delayed surgery and delayed lower dose limited field radiation were alive and event-free at a median 47 months of follow-up. However, the same regimen administered every three weeks resulted in a five year EFS of only 21 and 23 percent in two subsequent trials by the Pediatric Oncology Group (POG) and the French Society of Pediatric Oncology [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/11,51\">",
"       11,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       VDCA",
"      </strong>",
"      &ndash; Results from two larger Intergroup Ewing's Sarcoma studies for patients with metastatic disease (IESS-MD-I and II) using VDCA seem superior to these results [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/50\">",
"       50",
"      </a>",
"      ]. In the first trial (IESS-MD-I), conducted from 1975 to 1977, 53 eligible patients received VDCA with concomitant RT to areas of gross disease, while in IESS-MD-II, conducted from 1980 to 1983, 69 eligible patients received 5-fluorouracil (5-FU) in addition to VDCA, and XRT was delayed until week 10 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/50\">",
"       50",
"      </a>",
"      ]. In both studies, the best response rate (complete and partial remissions combined) was similar (73 and 70 percent in IESS-MD-I and II, respectively), as was the response duration (approximately 30 percent of the patients on either study survived five years or more), leading the authors to conclude that 5-FU was not beneficial.",
"      <br/>",
"      <br/>",
"      Contrasting results were noted by others, using the same VDCA regimen and RT to the primary site with or without surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/46\">",
"       46",
"      </a>",
"      ]. Only 9 percent of patients with metastatic disease were relapse-free at five years; however, RT was not administered to sites of metastatic disease (pulmonary in 10 of 22 patients). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pulmonary metastases'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       VDC plus standard dose",
"       <span class=\"nowrap\">",
"        I/E",
"       </span>",
"      </strong>",
"      &ndash; In contrast to data for nonmetastatic disease, specific benefit for the addition of",
"      <span class=\"nowrap\">",
"       I/E",
"      </span>",
"      to the VDC backbone has not been shown for patients with metastatic disease at diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/32,34,44,45,52,53\">",
"       32,34,44,45,52,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher doses administered with conventional scheduling (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    6 to 9",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    or interval compression of standard dose",
"    <span class=\"nowrap\">",
"     VDC/IE",
"    </span>",
"    chemotherapy using every two as compared to every three week cycling in conjunction with hematopoietic growth factor support (as has been used for high-risk localized disease) has resulted in possibly better results, particularly in patients with isolated pulmonary metastases. Up to 40 percent of such patients are still alive and event-free at five years; results are less favorable in patients with nonpulmonary metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/37,41,45,49\">",
"     37,41,45,49",
"    </a>",
"    ]. Lung irradiation was used in the majority of patients in these trials. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Dose intense chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     High-dose chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the failure to cure the majority of patients with metastatic disease at diagnosis and the steep dose response curve that exists for alkylating agents, more intensive therapies incorporating high-dose chemotherapy with hematopoietic cell support (HDT) have been studied.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Induction phase",
"      </strong>",
"      &ndash; Initial treatment with very high doses of chemotherapy with or without total body irradiation and autologous hematopoietic stem cell support has been reported to improve survival in some small nonrandomized series [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/54-59\">",
"       54-59",
"      </a>",
"      ] but not others [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/60-65\">",
"       60-65",
"      </a>",
"      ]. Variability in the definition of high risk patients and in the regimens used makes it difficult to compare results and arrive at any firm conclusions regarding the benefit of this approach. Allogeneic stem-cell transplantation offers no advantage over autologous transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/60\">",
"       60",
"      </a>",
"      ] and has a higher complication rate. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Secondary malignancies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Consolidation phase",
"      </strong>",
"      &ndash; Another approach is to administer HDT as consolidation following standard dose chemotherapy and optimal local treatment. A number of small trials which include subsets of patients with EFT suggest benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/45,56,58,66-69\">",
"       45,56,58,66-69",
"      </a>",
"      ], but this is not universal. The following represents the range of findings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of the most favorable results were reported in a prospective study of 97 unselected patients with newly diagnosed metastatic",
"    <span class=\"nowrap\">",
"     EFT/PNET,",
"    </span>",
"    who underwent conventional chemotherapy; those with a complete or partial response (n = 75) went on to",
"    <span class=\"nowrap\">",
"     HDT/autologous",
"    </span>",
"    transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/70\">",
"     70",
"    </a>",
"    ]. The five-year event-free survival rate after HDT was 47 percent; for those with isolated pulmonary metastases it was 52 percent.",
"   </p>",
"   <p>",
"    On the other hand, disappointing results were shown for patients with metastatic EFT in a large prospective trial conducted by Children's Cancer Group, in which 32 patients with bone or marrow metastases received induction therapy (three cycles of VDC alternated with IE) and surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT for local control (and RT to sites of metastatic disease), followed by TBI over three days, high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and peripheral blood stem cell reinfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/71\">",
"     71",
"    </a>",
"    ]. The two-year event-free survival rate was only 16 percent, suggesting that this approach did not represent a therapeutic advance.",
"   </p>",
"   <p>",
"    Similar disappointing results (five-year survival 21 percent) were noted among patients with metastatic EFT reported by the European Bone Marrow Transplant Solid Tumor Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, given the mixed results seen to date in patients who present with advanced disease, high-dose chemotherapy with autologous stem cell transplantation remains an investigational approach and should be considered only in the context of a clinical trial. The ongoing EURO-EWING 99 trial is comparing high-dose chemotherapy versus standard approaches in a variety of clinical settings (including patients with metastatic disease at diagnosis and those with localized tumors and a poor initial histologic response to induction chemotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/73\">",
"     73",
"    </a>",
"    ]. It is hoped that the results will provide some insight as to which patients benefit from this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Secondary malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of EFT survivors have some late effects of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/74\">",
"     74",
"    </a>",
"    ], an additional detrimental impact of high dose chemotherapy regimens is the risk of secondary myelodysplasia (MDS) and leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/60,65,75,76\">",
"     60,65,75,76",
"    </a>",
"    ]. This was illustrated in a report from the Children's Oncology Group of 578 children with",
"    <span class=\"nowrap\">",
"     EFT/PNET",
"    </span>",
"    who were treated with three different regimens over a six-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/75\">",
"     75",
"    </a>",
"    ]. Overall, 11 children developed secondary",
"    <span class=\"nowrap\">",
"     MDS/AML,",
"    </span>",
"    and the cumulative risk was significantly higher among children treated with a regimen incorporating higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    as compared to those receiving standard dose VDCA with or without IE (11, 0.9, and 0.4 percent at five years, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgery and radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes are best when chemotherapy is combined with radiation and sometimes resection of sites of gross metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/50,61,77,78\">",
"     50,61,77,78",
"    </a>",
"    ]. This multimodality approach has been most successful for patients with limited pulmonary metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pulmonary metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a limited number of lung metastases do not share the same dismal prognosis of metastatic disease at other sites (ie, bone or bone marrow), because of the ability to accomplish wide resections both easily and repeatedly. In such patients, chemotherapy is a necessary component of therapy, and between 20 and 40 percent five-year survival can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/49,79,80\">",
"     49,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with more advanced pulmonary disease at diagnosis, supplemental radiation may provide benefit, even after a complete response to chemotherapy. Most of the available data supporting radiation in this setting are from nonrandomized series, and patient selection factors confound interpretation of the data. Nevertheless, low dose bilateral lung irradiation (15 to 20 Gy, in daily 1.5 to 2.0 Gy fractions) can control gross metastatic disease in the lungs without significant pulmonary toxicity and is usually recommended after chemotherapy, despite the paucity of data. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link&amp;anchor=H11#H11\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Pulmonary metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bone and soft tissue metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with solitary or circumscribed bone or soft tissue lesions can be irradiated at those sites, usually to doses of 45 to 56 Gy, in addition to irradiation of the primary tumor. However, the likelihood of long-term survival is considerably lower than for patients with isolated pulmonary metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link&amp;anchor=H12#H12\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Bone and soft tissue metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Local control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local control can pose major issues, even for patients with metastatic disease. The complete response rate to chemotherapy can be increased with subsequent radiation therapy or selected excision for all sites of evident disease; however, long-term relapse-free survival is still only achieved in the minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffuse metastatic disease can make it difficult to justify a large resection. In selected patients, resection may be reconsidered if chemotherapy results in significant volume reduction, particularly if areas of small volume metastatic disease are also amenable to surgical resection. On the other hand, radiation therapy, which is more often considered in patients with metastatic disease, will usually provide adequate local control with acceptable morbidity. If substantial amounts of bone marrow will need to be included in the radiation treatment volume, then radiating the primary tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastases may be delayed until the end of systemic therapy to avoid interfering with chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link&amp;anchor=H10#H10\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Management of the primary site'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24921961\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all EFT of bone or soft tissue, there are no prospective data that address the appropriate schedule or selection of tests for surveillance after initial treatment for localized disease. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) and from the Children's Oncology Group recommend physical examination, a complete blood count, chest imaging, and local imaging of the primary site every three months for two years, every four months for year three, every six months for years 4 and 5, and annually thereafter (",
"    <a class=\"graphic graphic_table graphicRef68393 \" href=\"UTD.htm?23/22/23917\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The appropriate duration of follow-up is unknown; however, the vast majority of recurrences are observed within 10 years.",
"   </p>",
"   <p>",
"    Physicians performing posttreatment surveillance must be cognizant of concerns for radiation exposure and the risk for secondary malignancies, particularly in younger individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of relapses occur within five years, but late relapse is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. In a report from the Childhood Cancer Survivor Study, the 20-year cumulative incidence of a late recurrence among five-year survivors of Ewing sarcoma was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/85\">",
"     85",
"    </a>",
"    ]. For this reason it is advisable that patients be followed for the potential of late relapse indefinitely. There are no definite protocols for this, but the authors suggest that an examination and chest radiograph be performed every two to five years for the life of the patient. Symptoms at the primary site or elsewhere should raise concern and be appropriately investigated. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications in long-term survivors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In general, survival after an early relapse is poor, with few survivors among those who relapse within two years of therapy. In contrast, up to 15 to 20 percent of those who relapse later may survive long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Other prognostic factors for death in patients with recurrent Ewing sarcoma include recurrence at combined local and distant sites, and an elevated lactate dehydrogenase (LDH) at initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a suspected recurrence should undergo evaluation of both the primary site and for the presence of metastatic disease before a treatment plan is formulated. The majority of patients with a local recurrence have either gross or microscopic metastatic disease.",
"   </p>",
"   <p>",
"    The documentation of a local recurrence can be difficult. The interpretation of irradiated areas on imaging studies can be challenging, and soft tissue masses may represent residual fibrosis rather than recurrent tumor. The evaluation of intraosseous sites is even more difficult, since the response to prior therapy and variability in reossification complicates the interpretation of radiographic studies. Progressive cortical destruction or increasing lytic areas suggest local recurrence, as do bone scans that demonstrate increased uptake. Bone biopsies are associated with local morbidity (ie, wound complications and bone fracture) and are subject to a high rate of sampling error.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the prognosis for patients with recurrent disease is poor, some patients can be successfully salvaged [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The sites of recurrence, prior treatment, and relapse-free interval affect remaining treatment choices. Management of a local recurrence usually includes surgery (and possibly an amputation if the local recurrence involves an irradiated extremity), radiotherapy, or both. Radiation therapy to bone lesions usually provides pain relief, while surgery can cure some cases with limited isolated lung metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of response to chemotherapy retreatment increases with longer duration of disease control. Late relapsers do better than those who progress during initial chemotherapy (primary refractory disease). In one report, 26 of 34 patients relapsing off treatment attained a second remission compared to none of 18 who had primary refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/90\">",
"     90",
"    </a>",
"    ]. Twelve of the 26 responders remained in second remission for periods up to 19 years. The role of intensive myeloablative regimens is unclear, although a few patients may be salvaged [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of chemotherapy regimen depends upon initial treatment and the duration of the relapse-free interval. Patients relapsing after a disease-free interval off chemotherapy may respond again to the same agents. Patients who have not previously received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    may respond to this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/91\">",
"     91",
"    </a>",
"    ]. At our center, the regimen used by the third Intergroup Ewing's Sarcoma Study is typically chosen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/32\">",
"     32",
"    </a>",
"    ], but doses are escalated as tolerated if there is not a prompt response. Most patients with relapsed disease will be treated at centers that have their own individualized approach.",
"   </p>",
"   <p>",
"    Clinical trials investigating new agents (eg, monoclonal antibodies and small molecule inhibitors targeting the insulin-like growth factor-I (IGF 1)-receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]) and new combinations (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/96\">",
"     96",
"    </a>",
"    ]) warrant consideration, since completion of these trials is crucial to improving outcomes. Although most of the available phase I or",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    studies do not specifically target advanced EFT and most phase III studies target early rather than advanced stage or recurrent disease, opportunities remain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/97\">",
"     97",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials\">",
"     National Cancer Institute clinical trials website",
"    </a>",
"    provides information about ongoing clinical trials",
"   </p>",
"   <p>",
"    Future therapies will probably emerge from the exploitation of the molecular targets accompanying the unique genetic alterations that are held responsible for these malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/17,98\">",
"     17,98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS IN LONG-TERM SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the survival of patients with Ewing sarcoma has improved steadily since the 1970, long-term survivors have considerable future health risks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/16,99-102\">",
"     16,99-102",
"    </a>",
"    ]. These include second malignancy, pathologic fractures, other radiation-associated complications (wound complications, pulmonary fibrosis, neuropathy, limb leg discrepancy, femoral head necrosis), and chemotherapy-related complications (renal insufficiency, bowel toxicity, neuropathy, and cardiomyopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The health status of long-term (&ge;5 years) survivors was addressed in a cohort study of 568 individuals who were diagnosed with Ewing sarcoma before age 21 from 1970 to 1986, including a subset of 403 patients who were participating in the Childhood Cancer Survivor study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/102\">",
"     102",
"    </a>",
"    ]. Cumulative mortality among all survivors was 25 percent at 25 years after diagnosis, and the cumulative incidence of secondary malignancy was 9 percent. Disease",
"    <span class=\"nowrap\">",
"     progression/recurrence",
"    </span>",
"    accounted for 60 percent of all deaths, while other causes included secondary neoplasms, cardiac disease, other medical causes, and pulmonary disease. The cumulative mortality attributed to subsequent malignant neoplasms and cardiopulmonary disease potentially attributed to treatment was 8.3 percent at 25 years. In addition, compared with their siblings, survivors had significantly higher rates of severe, disabling, or chronic health conditions, significantly lower fertility rates, and higher rates of self-reported moderate to extreme adverse health status.",
"   </p>",
"   <p>",
"    It is anticipated that the adoption of tailored radiation ports in the last 15 years (as opposed to whole bone ports used in the period 1960 to 1980) and use of lower and risk-adopted radiation therapy doses as well as an appreciation of the rise in radiation-induced second malignancy risk with doses above 60 Gy will reduce the risk of late effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link&amp;anchor=H23#H23\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Late effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, the relatively high complication rates seen with many of these earlier treatment approaches, the delayed nature of many of the complications, and the possibility that trends in chemotherapy intensification may alter the pattern of secondary malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/50/14122/abstract/100\">",
"     100",
"    </a>",
"    ] underscore the need for long-term follow-up.",
"   </p>",
"   <p>",
"    Long-term follow-up guidelines after treatment of childhood malignancy have been published by the Children's Oncology Group and are available at",
"    <span class=\"nowrap\">",
"     <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"      www.survivorshipguidelines.org",
"     </a>",
"     /.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31794?source=see_link\">",
"       \"Patient information: Ewing sarcoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with Ewing sarcoma or another of the Ewing sarcoma family of tumors (EFT) require referral to centers that have multidisciplinary teams of sarcoma specialists. With rare exception, systemic combination chemotherapy and definitive local therapy is required in all patients, and care should be coordinated among the medical oncologist, surgeon, and radiation therapist.",
"     </li>",
"     <li>",
"      In most cases, treatment will begin with chemotherapy. The primary tumor is then most often treated with surgical resection. Radiation, or a combination of radiation and surgery, is reserved for cases in which negative margins cannot be achieved while still preserving function. The choice between surgery and RT is dictated by the age of the patient, the location and size of the primary, and functional as well as long-term consequences of therapy (ie, radiation-induced growth inhibition or secondary malignancy). Following local treatment, chemotherapy is usually continued, typically for several months. Thus, the total duration of therapy ranges from 10 to 12 months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link\">",
"       \"Radiation therapy for Ewing sarcoma family of tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with clinically detectable metastatic disease at presentation, and those who relapse after initial therapy also require multimodality therapy. All patients with advanced disease should be approached with potentially curative treatment. Up to 40 percent of patients with limited pulmonary metastatic disease who undergo intensive chemotherapy and pulmonary resection with or without radiation therapy may be long-term survivors. The prognosis for other subsets of patients with advanced disease is less favorable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link&amp;anchor=H9#H9\">",
"       \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'RT for metastatic disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no conclusive evidence that high-dose therapy with or without hematopoietic stem cell infusion at any point during treatment is beneficial for patients with poor-risk localized and metastatic EFT. Most patients with advanced or recurrent disease need new approaches to improve outcomes, and participation in clinical trials should be encouraged. Long-term follow-up is needed following therapy because disease relapse, treatment-related complications, and second malignancies all occur beyond five years after treatment is initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link&amp;anchor=H23#H23\">",
"       \"Radiation therapy for Ewing sarcoma family of tumors\", section on 'Late effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/1\">",
"      Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 1997; 44:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/2\">",
"      Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991; 67:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/3\">",
"      Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/4\">",
"      Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest 1996; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/5\">",
"      Llombart-Bosch A, Carda C, Peydro-Olaya A, et al. Soft tissue Ewing's sarcoma. Characterization in established cultures and xenografts with evidence of a neuroectodermic phenotype. Cancer 1990; 66:2589.",
"     </a>",
"    </li>",
"    <li>",
"     Smith MA, Gurney JG, Ries LA. Cancer in adolescents 15 to 19 years old. In: Cancer incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, Ries, LA, Smith, MAS, Gurney, JG, et al (Eds). SEER program, National Cancer Institute, Bethesda MD, 1999. (Pub #99-4649).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/7\">",
"      Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998; 16:3628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/8\">",
"      Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/9\">",
"      Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/10\">",
"      Obata H, Ueda T, Kawai A, et al. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer 2007; 109:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/11\">",
"      Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/12\">",
"      Nilbert M, Saeter G, Elomaa I, et al. Ewing's sarcoma treatment in Scandinavia 1984-1990--ten-year results of the Scandinavian Sarcoma Group Protocol SSGIV. Acta Oncol 1998; 37:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/13\">",
"      Raney RB, Asmar L, Newton WA Jr, et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol 1997; 15:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/14\">",
"      Ferrari S, Mercuri M, Rosito P, et al. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. J Chemother 1998; 10:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/15\">",
"      Kinsella TJ, Miser JS, Waller B, et al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys 1991; 20:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/16\">",
"      Rodr&iacute;guez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007; 110:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/17\">",
"      Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010; 11:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/18\">",
"      Arai Y, Kun LE, Brooks MT, et al. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/19\">",
"      Dunst J, Sauer R, Burgers JM, et al. Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer 1991; 67:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/20\">",
"      Bacci G, Balladelli A, Forni C, et al. Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer 2007; 109:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/21\">",
"      Picci P, B&ouml;hling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol 1997; 15:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/22\">",
"      Siegel RD, Ryan LM, Antman KH. Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol 1988; 11:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/23\">",
"      Sinkovics JG, Plager C, Ayala AG, et al. Ewing sarcoma: its course and treatment in 50 adult patients. Oncology 1980; 37:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/24\">",
"      Klaassen R, Sastre-Garau X, Aurias A, et al. [Ewing's sarcoma of bone in adults: an anatomic-clinical study of 30 cases]. Bull Cancer 1992; 79:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/25\">",
"      Verrill MW, Judson IR, Wiltshaw E, et al. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol 1997; 8:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/26\">",
"      J&uuml;rgens H, Bier V, Harms D, et al. Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients. Cancer 1988; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/27\">",
"      Ahmad R, Mayol BR, Davis M, Rougraff BT. Extraskeletal Ewing's sarcoma. Cancer 1999; 85:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/28\">",
"      Gururangan S, Marina NM, Luo X, et al. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol 1998; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/29\">",
"      Castex MP, Rubie H, Stevens MC, et al. Extraosseous localized ewing tumors: improved outcome with anthracyclines--the French society of pediatric oncology and international society of pediatric oncology. J Clin Oncol 2007; 25:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/30\">",
"      Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990; 8:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/31\">",
"      Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/32\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/33\">",
"      Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003; 21:3423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/34\">",
"      Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996; 78:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/35\">",
"      Bacci G, Picci P, Ferrari S, et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies. Cancer 1998; 82:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/36\">",
"      Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 2009; 27:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/37\">",
"      Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000; 36:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/38\">",
"      Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:4148.",
"     </a>",
"    </li>",
"    <li>",
"     Womer RB, West DC, Krailo MD, et al. Chemotherapy intensification by interval compression in localized Ewing sarcoma family of tumors (ESFT) (abstract 855). Data presented at the 13th annual meeting of the Connective Tissue Oncology Society (CTOS), October 31-November 2, 2007, Seattle Washington. Abstract 855, available online at file://www.ctos.org/meeting/2007/program.asp (Accessed on December 11, 2012).",
"    </li>",
"    <li>",
"     Ginsberg JP, Woo SY, Hicks MJ, Horowitz ME. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Priniciples and Practice of Pediatric Oncology, 4th, Pizzo PA, Poplack DG (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/41\">",
"      Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995; 13:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/42\">",
"      Pinkerton CR, Bataillard A, Guillo S, et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 2001; 37:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/43\">",
"      Hayes FA, Thompson EI, Parvey L, et al. Metastatic Ewing's sarcoma: remission induction and survival. J Clin Oncol 1987; 5:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/44\">",
"      Sandoval C, Meyer WH, Parham DM, et al. Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children's Research Hospital experience, 1962 to 1992. Med Pediatr Oncol 1996; 26:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/45\">",
"      Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/46\">",
"      Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 1997; 33:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/47\">",
"      Dem&eacute;ocq F, Oberlin O, Benz-Lemoine E, et al. Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP). Cancer Chemother Pharmacol 1989; 24 Suppl 1:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/48\">",
"      Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 1999; 17:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/49\">",
"      Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/50\">",
"      Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/51\">",
"      Michon J, Oberlin O, Demeocq F, et al. Poor results in metastatic Ewing's sarcoma treated according to the wscheme of the St Jude 1978-1985 study: A study of the French Society of Pediatric Oncology. SIOP XXV Meeting. Med Pediatr Oncol 1993; 21:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/52\">",
"      Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004; 22:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/53\">",
"      Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26:4385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/54\">",
"      Czyzewski EA, Goldman S, Mundt AJ, et al. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study. Int J Radiat Oncol Biol Phys 1999; 44:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/55\">",
"      Perentesis J, Katsanis E, DeFor T, et al. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 1999; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/56\">",
"      Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/57\">",
"      Prete A, Rosito P, Alvisi P, et al. G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood. Bone Marrow Transplant 1998; 22 Suppl 5:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/58\">",
"      Laurence V, Pierga JY, Barthier S, et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol 2005; 28:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/59\">",
"      Burdach S, J&uuml;rgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/60\">",
"      Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at D&uuml;sseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000; 11:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/61\">",
"      Miser JS, Kinsella TJ, Triche TJ, et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J Clin Oncol 1988; 6:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/62\">",
"      Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/63\">",
"      Bader JL, Horowitz ME, Dewan R, et al. Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure. Radiother Oncol 1989; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/64\">",
"      Hawkins D, Barnett T, Bensinger W, et al. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000; 34:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/65\">",
"      Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001; 19:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/66\">",
"      Madero L, Mu&ntilde;oz A, S&aacute;nchez de Toledo J, et al. Megatherapy in children with high-risk Ewing's sarcoma in first complete remission. Bone Marrow Transplant 1998; 21:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/67\">",
"      Bertuzzi A, Castagna L, Nozza A, et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002; 20:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/68\">",
"      Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21:3072.",
"     </a>",
"    </li>",
"    <li>",
"     Ferrari S, Alvegard T, Luksch R, et al. Non-metastatic Ewing's family tumors: High dose chemotherapy withstem cell rescue in poor responder patients. Preliminary results of the Italian/Scandinavian ISG/SSG III protocol (abstract). J Clin Oncol 2007; 25:548s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/70\">",
"      Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Soci&eacute;t&eacute; Fran&ccedil;aise des Cancers de l'Enfant. J Clin Oncol 2006; 24:3997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/71\">",
"      Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19:2812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/72\">",
"      Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/73\">",
"      Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/74\">",
"      Novakovic B, Fears TR, Horowitz ME, et al. Late effects of therapy in survivors of Ewing's sarcoma family tumors. J Pediatr Hematol Oncol 1997; 19:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/75\">",
"      Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007; 109:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/76\">",
"      Rodriguez-Galindo C, Poquette CA, Marina NM, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol 2000; 22:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/77\">",
"      Pilepich MV, Vietti TJ, Nesbit ME, et al. Radiotherapy and combination chemotherapy in advanced Ewing's Sarcoma-Intergroup study. Cancer 1981; 47:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/78\">",
"      Haeusler J, Ranft A, Boelling T, et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/79\">",
"      Bacci G, Briccoli A, Picci P, Ferrari S. Metachronous pulmonary metastases resection in patients with Ewing's sarcoma initially treated with adjuvant or neoadjuvant chemotherapy. Eur J Cancer 1995; 31A:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/80\">",
"      Dunst J, Paulussen M, J&uuml;rgens H. Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. Strahlenther Onkol 1993; 169:621.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/82\">",
"      Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/83\">",
"      Weston CL, Douglas C, Craft AW, et al. Establishing long-term survival and cure in young patients with Ewing's sarcoma. Br J Cancer 2004; 91:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/84\">",
"      Bacci G, Balladelli A, Forni C, et al. Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Ann Oncol 2007; 18:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/85\">",
"      Wasilewski-Masker K, Liu Q, Yasui Y, et al. Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/86\">",
"      Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 51:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/87\">",
"      Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/88\">",
"      Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002; 94:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/89\">",
"      Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005; 23:4354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/90\">",
"      Hayes FA, Thompson EI, Kumar M, Hustu HO. Long-term survival in patients with Ewing's sarcoma relapsing after completing therapy. Med Pediatr Oncol 1987; 15:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/91\">",
"      Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5:1191.",
"     </a>",
"    </li>",
"    <li>",
"     Schoffski P, et al. Phase II trial of anti-IGF-IR antibody cixutumumab in patents with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors (abstract 10004). J clin Oncol 2011; 29:604s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=81273 (Accessed on June 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/93\">",
"      Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29:4534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/94\">",
"      Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011; 29:4541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/95\">",
"      Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012; 30:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/96\">",
"      Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009; 53:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/97\">",
"      Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19:3463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/98\">",
"      de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/99\">",
"      Fuchs B, Valenzuela RG, Inwards C, et al. Complications in long-term survivors of Ewing sarcoma. Cancer 2003; 98:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/100\">",
"      Navid F, Billups C, Liu T, et al. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer 2008; 44:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/101\">",
"      Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/50/14122/abstract/102\">",
"      Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010; 102:1272.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7740 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14122=[""].join("\n");
var outline_f13_50_14122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adult patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT FOR LOCALIZED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dose intense chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Local treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT FOR ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Conventional dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - High-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Secondary malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgery and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pulmonary metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bone and soft tissue metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Local control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24921961\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS IN LONG-TERM SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7740|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/53/23391\" title=\"figure 1\">",
"      Components of a long bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13864\" title=\"figure 2\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7740|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/21/22876\" title=\"table 1\">",
"      Rx Ewings sarcoma adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/7/9340\" title=\"table 2\">",
"      Ewings sarcoma chemo protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/22/23917\" title=\"table 3\">",
"      Imaging guidelines from COG for Ewing family of tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31794?source=related_link\">",
"      Patient information: Ewing sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=related_link\">",
"      Radiation therapy for Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_50_14123="Mayo model survival PSC";
var content_f13_50_14123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mayo model for predicted survival in primary sclerosing cholangitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        R = 0.03 (age [yrs]) + 0.54",
"        <sub>",
"         e",
"        </sub>",
"        (bilirubin [mg/dL]) + 0.54 log",
"        <sub>",
"         e",
"        </sub>",
"        (AST [IU/L]) + 1.24 (variceal bleeding [0=no/1=yes]) - 0.84 (albumin [g/dL]).]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Survival function coefficient [S",
"        <sub>",
"         0",
"        </sub>",
"        (t)]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 year = 0.963",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 years = 0.919",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 years = 0.873",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 years = 0.833",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Calculated patient survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probability of survival at time t years is calculated as S(t)= S",
"        <sub>",
"         0",
"        </sub>",
"        (t)",
"        <sup>",
"         exp(R-1.00)",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75:688. Calculator for this model available at: file://www.mayoclinic.org/gi-rst/mayomodel3.html (Accessed on September 11, 2007).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14123=[""].join("\n");
var outline_f13_50_14123=null;
var title_f13_50_14124="Diagnostic criteria HCM";
var content_f13_50_14124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for HCM in first-degree adult relatives",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Major criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Left ventricular wall thickness &ge;13 mm in the anterior",
"septum or posterior wall or &ge;15",
"mm in the posterior septum or free wall",
"        </p>",
"        <p>",
"         Severe systolic anterior motion of the",
"mitral valve",
"(septal-leaflet contact)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Left ventricular wall thickness of 12 mm in the anterior",
"septum or posterior wall, or of 14 mm in the posterior septum or free",
"wall",
"        </p>",
"        <p>",
"         Moderate systolic anterior motion of the mitral valve (no",
"leaflet-septal contact)",
"        </p>",
"        <p>",
"         Redundant",
"mitral valve",
"leaflets",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Electrocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         LVH + repolarisation changes (Romhilt",
"and Estes)",
"        </p>",
"        <p>",
"         T wave inversion in leads I and aVL (&ge;3 mm), with QRS-T wave",
"axis difference &ge;30",
"degrees, V3-V6 (&ge;3",
"mm) or II and III and aVF (&ge;5",
"mm)",
"        </p>",
"        <p>",
"         Abnormal Q (&gt;40 ms or &gt;25",
"percent R wave) in at",
"least two leads from II, III, aVF (in absence of left anterior",
"hemiblock), V1-V4; or I, aV1, V5-V6",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Complete bundle branch block or (minor) intraventricular",
"conduction defect (in LV leads)",
"        </p>",
"        <p>",
"         Minor repolarisation changes in left ventricular leads",
"        </p>",
"        <p>",
"         Deep S V2 (&gt;25 mm)",
"        </p>",
"        <p>",
"         Unexplained chest pain, dyspnea or syncope",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Proposed diagnostic criteria for establishing a diagnosis of hypertrophic cardiomyopathy (HCM) in first-degree adult relatives of affected individuals. In the absence of other causes of left ventricular hypertrophy (hypertension, obesity, athletic training), the diagnosis of HCM may be made by the presence of one major criterion, two minor echocardiographic criteria, or one minor echocardiographic and two minor electrocardiographic criteria. The proposed criteria cannot be used in children or adolescents since the disease may not be expressed until after completion of adolescent growth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from McKenna, WJ, Spirito, P, Desnos, M, et al, Heart 1997; 77:130.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14124=[""].join("\n");
var outline_f13_50_14124=null;
var title_f13_50_14125="ACEI delays moderately increased albuminuria";
var content_f13_50_14125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Captopril delays progression of moderately increased albuminuria (formerly called microalbuminuria) in diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of captopril or placebo in 225 patients with type 1 diabetes mellitus, normal blood pressure, and moderately increased albuminuria (formerly called microalbuminuria). At two years, captopril slowed the rate of progression to overt, dipstick-positive proteinuria and lowered the albumin excretion rate (AER) compared to placebo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Microalbuminuria Study Group, Diabetologia 1996; 39:587.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14125=[""].join("\n");
var outline_f13_50_14125=null;
var title_f13_50_14126="Bosentan in PAH";
var content_f13_50_14126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mean change (&plusmn;SE) in six-minute walking distance from baseline to week 16 in the placebo and bosentan groups",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    P&lt;0.01 for the comparison between the 125-mg dose of bosentan and placebo, and P&lt;0.001 for the comparison between the 250-mg dose and placebo by the Mann-Whitney U test. There was no significant difference between the two bosentan groups (P=0.18 by the Mann-Whitney U test).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rubin LJ, Badesch, DB, Barst, RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14126=[""].join("\n");
var outline_f13_50_14126=null;
var title_f13_50_14127="Hemostatic closure device";
var content_f13_50_14127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Insertion protocol for the hemostatic puncture closure device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hemostatic puncture closure device consists of an absorbable plug component and delivery system. The plug has a lactide and glycolide anchor attached to a 24- to 28-mg collagen sponge by an absorbable suture. The device is contained in a carrier tube. Delivery of the device is initiated by first exchanging the existing sheath over a wire for an 8 Fr sheath. Panels A and B: The carrier tube containing the plug is inserted through the sheath deploying the anchor within the arterial lumen. Panel C: The sheath and carrier tube assembly are then retracted, maintaining tension on the assembly while pushing down the tamper tube. Panel D: Through use of a tension spring, traction is maintained along the suture line, resulting in plugging of the anterior arterial wall puncture site by the anchor and collagen plug. After 20 minutes, the tension spring is removed and the suture is cut below skin level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ward SR, Lasale P, Raymond R, et al. Efficacy and safety of a hemostatic puncture closure device with early ambulation after coronary angiography. Angio-Seal Investigators. Am J Cardiol 1998; 81(5):569-72. Copyright 1998, with permission from Excerpta Medica, Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_50_14127=[""].join("\n");
var outline_f13_50_14127=null;
